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Abstract
The limited availability of autologous bone for grafting post-surgical defects in
patients with craniosynostosis, necessitates the use of alloplastic materials which are
prone to rejection or infection. The use of bio-composite materials consisting of alloplastic
bioabsorbable scaffolds and autologous osteoprogenitor cells to avoid rejection, could
provide a valuable approach to the repair of critical bone defects in the skull. However, in
patients with syndromic craniosynostosis, autologous osteoprogenitors carry the mutations
which cause premature ossification and consequent malformations requiring cranioplasty.
The aim of this study was to develop strategies for growing effectively mutated
osteoprogenitors with the view to developing autologous therapies for patients with
craniosynostosis.
To this purpose, the behaviour of mouse osteoprogenitor cell lines carrying either a
common human mutation (FGFR2-C278F) for syndromic craniosynostosis or the human
wild type FGFR2 (WT-FGFR2) was investigated. In particular the focus was on i) how the
mutation affected proliferation and osteogenisis; ii) the effect of exogenous fibroblast
growth factor (FGF) 18 on cell growth and morphology; iii) analysis of osteoprogenitor
attachment and growth on bioabsorbable scaffolds uncoated or coated with extracellular
matrix molecules (fibronectin, laminin).
RT-PCR analysis of cells carrying the FGFR2-C278F mutation and wild type FGFR2
cells, revealed differential expression of FGF18 and molecules important in the terminal
differentiation of mineralising osteoblasts: Osteocalcin was expressed at greater levels in
cells carrying the mutation compared to wild type cells at 1.8 fold (p < 0.01) and 1.4 fold
(p = 0.02) in pre-confluent and day 5 confluent cells respectively. Wild type cells expressed
alkaline phosphatase from day 5 compared to mutated cells which did not express until
day 30. Most striking was the greater expression of FGF18 in the mutated cells; 1.8 fold
(p < 0.01) at pre confluence, 1.3 fold (p = 0.01) at day 5 and 1.5 fold (p < 0.01) at day 30.
In the early phase of cell cultures, cells carrying the mutation demonstrated higher
mitotic activity than wild type cells as determined by p-H3 staining (18.6% +ve and 11.2%
+ve respectively; p < 0.01, day 2 post plating). However, mutated cells demonstrated
altered attachment behaviour, clustering forming early nodules and did not reach full
confluence. Subsequent treatment of mutated cells with FGF18 [10-9M] appeared to allow
cells to reach confluence and “rescue” the phenotype. A concentration dependent increase
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in cellular mitosis for all cell lines was observed. This was significantly greater at day 1 in
mutated cells compared to wild type cells (51% and 29% respectively; p <0.01 at FGF18
[10-9M], and 60% and 43% respectively; p < 0.01 at FGF18[10-8M]).
Attachment and growth of osteoblasts to a commercially available, clinically licensed
scaffold could be enhanced by modification of the surface with the extracellular matrix
(ECM) molecules, fibronectin and laminin. Both substrates significantly enhanced
attachment at all time points up to 48 hours post plating (e.g. C278F cells at 1 hour post
plating: 10,020 cells [-ve]; 37,600 [fibronectin]; 41,670 [laminin]; p < 0.01).
These findings indicated that the use of osteoprogenitor cells carrying mutations
could present a feasible strategy in bone tissue engineering, which warrants further
development towards the overall multidisciplinary approach in the management of these
complex clinical challenges.
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Chapter 1: Introduction
This thesis presents a study of osteoprogenitor cells carrying a mutation in the
human fibroblast growth factor receptor 2, coding for a syndromic form of
craniosynostosis. It further explores the potential use of cells carrying a mutation for bone
tissue engineering. The introduction will discuss the major themes of the study by giving
an overview of:
 Craniofacial development and craniosynostosis
 The surgical difficulties in managing craniosynostosis
 Fibroblast growth factor receptors (FGFRs) and fibroblast growth factors (FGFs)
 Biomaterials in bone tissue engineering
These themes will then be consolidated to form the hypothesis for this study.
1.1: Cranial Development and Ossification
1.1.1: Origin of the Craniofacial Skeleton
The mammalian craniofacial skeleton accommodates the expanding brain and
supports the structures and functions of existence such as feeding, breathing, seeing and
social interaction. It is a composite of neurocranium (calvaria/vault) which forms principally
in membranous bone and viscerocranium (skull base and facial skeleton) which forms by
endochondral ossification via a cartilaginous precursor (Fig. 1.1). The membranous bones
of the cranial vault are formed by ossification of mesenchymal condensations (Hall &
Miyake 1992), derived from early populations of cephalic neural crest which have migrated
from the closing neural folds (Noden 1975, 1983; Couly & LeDourian 1985; Tan & Morriss-
Kay 1985) and mesoderm (Morriss-Kay 2001; Jiang et al., 2002; Jeong et al., 2004). The
cranial bones lie between the dura mater which surrounds the brain and is derived from
neural crest (Yu et al., 1997) and by aponeurosis and skin originating in the ectoderm. The
sutures, which lie between the numerous bone plates of the skull vault and base, are
formed by neural crest-mesoderm boundaries (Jiang et al., 2002).
- 18 -
Viscerocranium
Neurocranium (skull base)
Neurocranium (skull vault)
A B
Frontal
Sphenoid
Ethmoid
Zygoma
Maxilla
Mandible Styloid
Middle ear bones
Temporal
Occipital
Parietal
Intramembranous
Endochondral
Figure 1.1: Development of the foetal cranium
A: Lateral view defining nomenclature boundaries.
B: Lateral view of foetal skull showing the principal bones and their mode of osteogenisis
(adapted from: www.hopkinsmedicine.org/craniofacial)
1.1.2: Skull Morphology Sutures and Fontanelles
Sutures form the interface zones between two bones of the cranial base or calvaria,
whilst fontanelles form where three or more bones meet. The principal sutures being the
coronal sutures (paired) between the frontal and parietal bones, the metopic suture
between the two hemi-frontal bones, the lambdoidal suture (paired) between the parietal
and occipital bone and the sagittal suture between the two parietal bones. The anterior
fontanelle exists at the confluence of the two parietal and frontal bones and the posterior
fontanelle, at the confluence of the two parietal bones and the occipital bone (Fig. 1.2).
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Parietal bone
Frontal bone
Metopic suture
Coronal suture
Anterior
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A B
Figure1.2: Illustration of principal sutures and fontanelles of the foetal cranium
A: Lateral view of the skull representing approximately 25 weeks gestation and showing
coronal, temporoparietal and lambdoidal sutures.
B: Antero-posterior view of the skull showing the occipital bone, paired parietal and frontal
bones with intervening lambdoidal, sagittal and parietal sutures, expanded by the
fontanelles. (Redrawn after Morriss-Kay & Wilkie 2005)
Sutures and fontanelles allow for a degree of compression of the skull during birth
and subsequent growth and remodelling, driven principally by the expanding brain.
Sutures are fundamental in allowing changes in form, size and orientation of the
craniofacial skeleton in response to normal or pathological growth of adjacent structures.
This occurs by a coordinated balance of bone deposition and resorption at the
bone/mesenchyme/periosteal/dural interface. (Fig. 1.3)
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Dura Mater
Mineralised bone
Unmineralised osteoid
differentiated osteoblasts
Undifferentiated
mesenchymal cells and
preosteoblasts of suture
Figure 1.3: Schematic illustration of cranial suture
Diagrammatic section through a patent cranial suture. In the adult human these are
normally obliterated in a temporal sequence (Table 1.1). In craniosynostosis, suture
obliteration occurs prematurely and often in-utero. (Redrawn after Marie 2003)
Patency of the sutures is maintained during growth of the brain, which initially keeps
the sutures widely separated (Cohen & McLean, 2000) and subsequently by signalling
mechanisms within the premineralised mesenchymal zone. Cells within the suture area
differentiate into osteogenic cells, and contribute towards the formation of new calvarial
bone, whilst others persist in an undifferentiated, proliferative state (Cohen, 1993).
Following birth, human sutures fuse in a site and time dependent manner which can be
highly variable (Sahni, 2004), although generally earlier in males than females and
commencing on the endocranial surface (Vu, 2001), consistent with findings in mice
(Opperman et al., 1997; Roth et al., 1997). Table 1.1 shows the normal sequence of
suture fusion. Whilst most of the calvarial sutures remain patent through adulthood, the
metopic suture closes within the first two years of life. This may be related to the finding
that the metopic is the only suture which forms solely within neural crest domain, the
others being formed at neural crest-mesodermal boundaries (Jieng et al., 2002).
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Table 1.1: Normal timing of human suture and fontanelle closure post-partum
(Created from data in: Perizonius, 1984; Vu et al., 2001; Sahni et al., 2004)
1.1.3: Dura mater
Sutures also require the proximity of the dura mater for sustained patency.
Opperman et al., (1993, 1995), demonstrated that the dura initially plays an inductive role,
then a permissive role in maintaining sutural patency through various signalling factors.
Embryonic mouse dura has been shown to regulate sutural patency (Kim et al., 1998) and
Levine et al., (1998), determined that the dura generates signals and that these signals
could be blocked by a silastic sheet interposed between the dura and the overlying suture.
Dura transplanted from under normally patent sutures to sites of sutural fusion in a
naturally occurring craniosynostotic rabbit model, successfully kept these sites from re-
obliterating following surgery (Mooney et al., 2001).
Fontanelle Timing of Closure
Posterior 0-4 months
Mastoid 6-12 months
Anterior 12-24 months
Suture Timing of Fusion
Metopic 3-48 months
Sagittal 20-45 years
Lambdoidal 25-45 years
Coronal 25-50 years
Spheno-temporo-parietal 30-60 years
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1.1.4: Mechanical forces
Mechanical forces may also play a role in maintaining sutural patency or premature
fusion. It is a striking observation that skull size and form, matches brain size, in both
children with normal brains and in those with hydrocephalus or microcephaly, a condition
in which there has been an “appropriate” premature suture fusion. In this situation, a
primary failure of the brain to grow is interpreted by poorly understood biofeedback
mechanisms within the sutures, which then go on to fuse.
Fusion of the right coronal suture is twice as common as on the left, possibly
reflecting the 3:1 right laterality bias of cephalic presentation births (Ververs et al., 1994).
The application of tensile forces across rat sutures has been shown to cause an increase
in the production of Insulin like growth factor receptors in osteoblast-like cells, resulting in
cellular proliferation at the suture (Hirukawa et al., 2004).
Sutures thus allow the growth of the craniofacial skeleton, usually symmetrically and
principally in response to the growing brain. However, if individual or multiple sutures fuse
prematurely, the remaining patent sutures can respond by compensatory growth, often
leading to asymmetry (Jane & Persing, 1986). Where sutures have fused prematurely, this
is known as craniosynostosis and shall be discussed in further detail.
1.2: Craniosynostosis
1.2.1: Description of Craniosynostosis
Craniosynostosis is a defect which effects the normal temporo-spatial development
of the sutures of the cranial vault and/or skull base. It follows failure of the signalling
mechanisms that govern the processes of growth and differentiation at the suture margins.
This results in the premature fusion of one or more of the cranial sutures. Fused sutures
may be found in isolation (non-syndromic craniosynostosis), as part of a syndrome
(syndromic or complex craniosynostosis), or as a secondary consequence of a primary
disease process such as one of the metabolic disorders. The combined incidence of these
disorders is approximately 1 in 2500 live births (Cohen & McLean, 2000).
Premature fusion of sutures prevents further bone apposition and hence growth of
the bone perpendicular to the line of the suture. Continued and compensatory bone growth
in those sutures which have remained patent, results in the development of an abnormal
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skull shape (Fig. 1.4), the form of which depends upon the sequence and site of
premature fusion. Traditionally, craniosynostosis is classified according to the sutures
involved, the resulting dysmorphology of the head, the presence or absence of an
identified craniofacial syndrome, and the degree of progression of the anomaly. Whilst the
multi-suture and syndromic craniosynostosis do not lend themselves so readily to
descriptive classification, specific head shapes are recognised most obviously in single
suture craniosynostosis and a descriptive classification based on head shape exists
(Table 1.2).
Diagramatic
Form
Pointed
forehead
Symmetric
loss of
forehead
contour
Commonly
associated
with a
syndromic
form
(Seathre-
Chotzen)
Asymmetric
flattening of
forehead
Raised
supraorbital
rim on
affected side
Antero-
posterior
elongation of
the head
Narrowing
across
temples
Flattened
occiput
Asymmetric
ear position,
Tilted head
position
Clinical
Features
TrigonocephalyBrachycephalyPlagiocephalyScaphocephalyPosterior
plagiocephaly
Clinical
Classification
MetopicBicoronalUni-coronalSagittalLambdoidAffected
Suture
Table 1.2: Clinical classification of single suture craniosynostosis
Adapted from Posnick (1999)
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Figure 1.4: 3-Dimensional
computer tomograms(CT) of
craniosynostosis
A: Lateral view of a six month old
child with bicoronal synstosis
associated with Muenke
syndrome. Arrow “a” denotes the
location of the fused (absent)
coronal suture.
B: Axial view of a 1 year old child
with metopic synostosis. Arrow “b”
denotes the location of the fused
metopic suture.
C: Lateral view of a two year old
child with sagittal synostosis. The
fused suture is not visible in this
view which demonstrates the
typical antero-posterior elongation
of the skull
B
a
A
b
(Great Ormond Street Hospital)
C
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1.2.2: Aetiology of Craniosynostosis
The causes of craniosynostosis are numerous and involve a wide spectrum of
conditions. The majority are not syndromic, but sporadic, isolated, single suture
synostoses, where no molecular abnormality can be identified, and where it is likely that
their aetiology is not of genetic origin (Cohen & McLean, 2000). Craniosynostosis can
occur secondary to pathogenesis such as metabolic diseases e.g. hyperthyroidism,
haematological disease, such as thalassaemia, glycogen storage disorders such as
Hurler syndrome, and foetal teratogenesis induced by drugs such as retinoic acid and
phenytoin (Gorlin et al., 2001; Thompson et al., 1994). Over 100 forms of causally related
craniosynostosis have been described (Cohen & McLean, 2000). However, in up to 15% of
cases of craniosynostosis there is evidence of Mendelian inheritance (Reardon & Winter,
1995). For historical reasons, these have been named eponymously by those first given
credit for describing the clinical features of the syndrome. The most common
craniosynostoses or syndromes with a defined molecular basis are, Seathre-Chotzen
syndrome (1 in 20,000 live births) Crouzon syndrome (1 in 25,000), Jackson-Weiss
syndrome (1 in 26,000), Apert syndrome (1 in 100,000), Pfeiffer syndrome (1 in 200,000)
(Gorlin et al., 2001). In addition, the recently described Muenke syndrome which presents
as a highly variable, atypical syndrome which is not easily categorised on clinical grounds
(Muenke et al., 1997), accounts for between 17% and 31% of apparently non-syndromic
coronal or bicoronal synostosis (Moloney et al., 1997; Lajeunie et al., 1999). The molecular
mechanisms underlying these genetically based syndromes will be explored more fully
later in this chapter.
1.2.3: Clinical Manifestations of syndromic craniosynosis
A number of presenting features are shared between the syndromes, these are
summarised for the commonest syndromes in Table 1.3. These features are used to
distinguish one syndromic case from another in clinical terms.
An abnormal skull shape [turricephally (tall flattened forehead), acrocephally (cone
shaped) or “klebblatschadel” (clover-Leaf), widely spaced orbits (hypertelorism)], proptosis
and an underdeveloped midface with apparent prognathism are characteristic features of
these disorders. Hand and foot anomalies are observed in some, but not all
craniosynostosis syndromes. The severest digital anomalies are found in Aperts syndrome
and involve variable but significant degrees of syndactely (fusion of the digits) which
usually require surgery to improve function (Upton, 1991), Children with Saethre-Chotzen
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syndrome have variable and often subtle degrees of sydactely of the 2nd 3rd or 4th web
spaces, whilst children with Pfeiffer syndrome have broad thumbs and broad big toes
which are deviated towards the midline. They may also demonstrate mild levels of
webbing between the digits of the hands and feet. Jackson-Weiss syndrome demonstrates
foot abnormalities very similar to Pfeiffer syndrome, but interestingly the digits of the hand
are unaffected. (Cohen & McLean, 2000)
Phenotype AS PS CS SCS JWS
Craniosynostosis + + + + +
Midface hyposplasia + + + - +
Hand anomalies + + - + -
Foot anomalies + + - + +
Table 1.3: Phenotypes in craniosynostosis syndromes.
AS: Apert syndrome, PS: Pfeiffer syndrome CS: Crouzon syndrome, SCS: Saethre-
Chotzen syndrome, JW: Jackson-Weiss syndrome,(Muenke syndrome has been omitted
as the clinical phenotype is less severe). Adapted from Muenke and Schell, (1995)
The clinical phenotype is not limited to premature fusion of the cranial sutures and
defective limb development. Individuals may present with additional cutaneous (Orlow,
1992; Hall 1992), dental (Berkowitz 1971; Sidhu 1989), ophthalmic (Matthews, 1979),
aural (Bergstrom et al., 1972), cardiac (Hunter & Rudd, 1977), respiratory (Gonzalez et al.,
1997) and CNS abnormalities (Davidson & Young, 1981; Thompson et al., 1997). As a
result of this spectrum of potential clinical manifestations, children with craniosynostosis
suffer from a variety of often serious functional complications. These include airway
obstruction, due to midface hypoplasia (Lauritzen et al., 1986; Gonzalez et al., 1996),
hydrocephalus (Murtagh & Baird, 1961; Noetzal et al., 1985), intracranial venous
hypertension (Sainte-Rose, 1984; Thompson et al., 1995), raised intracranial pressure
(Lundar and Hornes, 1991; Gault et al., 1992; Hayward et al., 1992; Gosain et al., 1995,
Murovic et al.,1993; Thompson et al., 1995), palatal clefting (Cohen et al., 1971) and
occlusal anomalies (Kreiborg & Cohen, 1992), visual problems such as proptosis,
keratopathy and papilloedema (Miller 1984; Newman 1991), speech and language delay
(Shipster et al., 2003) and developmental delay (Patton et al., 1988; Renier & Marchac
1988). In addition, psychosocial problems are increasingly recognised (Pertzchuk &
Whitaker, 1987; Endriga & Kapp-Simon, 1999).
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Raised intracranial pressure (ICP) represents one of the most serious consequences
of syndromic craniosynostosis. Raised ICP can cause impaired cerebral perfusion and
retinal damage, leading to blindness (Stavrou et al., 1997), impairment of intellectual
development (Renier et al., 1982; Bellew et al., 2005), seizures, and can occasionally lead
to premature sudden death in this group of individuals (Gosain et al., 1995). The incidence
of raised ICP in individuals with syndromic craniosynostosis is at least twice as high as in
non-syndromic cases. In addition to raised intracranial pressure, high-pressure
hydrocephalus is prevalent amongst individuals with syndromic craniosynostosis. Hayward
and Gonzales, (2005), have concluded that cerebral perfusion, raised intracranial pressure
and respiratory obstruction interact in a viscious cycle to exacerbate neurodevelopmental
damage. These studies confirm that raised intracranial pressure is a significant feature of
syndromic craniosynostosis. The causes of raised intracranial pressure in these individuals
remain highly contentious. However, vault constriction through premature sutural fusion is
thought to play a fundamental role (Renier et al., 1982).
1.2.4: Surgical Options for Craniosynostosis
Therapeutic intervention for craniosynostosis involves surgery as the mainstay and
surgical procedures are performed for a number of indications. The timing, extent and type
of procedure is determined on the basis of the severity and location of the cranial
deformity. Early surgery would undoubtedly be desirable in order to correct deformity and
prevent functional problems as previously described. However, continued abnormal growth
and ossification would in a high proportion of cases lead to relapse and further, possibly
earlier episodes of surgery (Hayward et al., 2004). The planning of surgery tends to fall
into two categories: Those procedures carried out electively for psychosocial wellbeing
and elective functional problems such as severe malocclusion and those which can be
considered as being performed on a “crisis intervention” basis to alleviate or prevent
progressing functional deficits. Concerns over increased intracranial pressure strongly
influence the timing and staging of surgical intervention. This latter group is for the vast
majority associated with syndromic cases with multiple suture involvement or
pansynostosis, although raised intracranial pressure and its sequelae, can occur in single
suture craniosynostosis (Renier et al., 1982; Gault et al., 1992).
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1.2.4.1: Vault Expansion Procedures
The purpose of early calvarial surgery in syndromic craniosynostosis is two-fold;
firstly lowering of raised intracranial pressure and venous hypertension by immediate
expansion of the intracranial volume and secondly, removal or release of fused sutures to
allow further unconstrained growth of the brain. Furthermore, combined fronto-facial
advancement procedures (Ortiz-Monesatrio, 1978) may be required at an early stage to
produce an increase in intracranial volume, simultaneous with an advancement of the
facial skeleton for protection of exposed cornea and improvement in respiratory function,
by opening of the nasopharyngeal airway (Polley et al., 1995; Britto et al., 1999).
Surgical procedures for individuals with complex craniosynostosis include cranial
vault expansion or fronto-facial advances. Vault expansion can be accomplished either as
a staged procedure or in a single stage. There are proponents of each technique and no
individual approach has been proven superior in a validated way. However, most authors
favour a two stage procedure with either primary anterior or posterior vault decompression,
followed by counterpole vault expansion (Marchac et al., 1995; McCarthey et al., 1995;
Hayward et al., 2004). Others, less commonly, advocate a complete single stage calvarial
vault expansion (Persing et al., 1981; Zuccaro et al., 1996).
Recently the technique of distraction osteogenisis has been added to the
armamentarium of the craniofacial surgeon (McCarthey, 1992; Cohen et al., 1999;
McCarthey et al., 2001). This has allowed larger and more stable advances of the
craniofacial skeleton to be achieved with concomitantly fewer serious side effects such as
life threatening infection (Cohen et al., 1999; Shin et al., 2003). However, while this
technique has significant advantages, this has also led to the simultaneous creation of
large bony defects overlying the brain (Bradley et al., 2006 and personal observations),
which are filled with a thin fibrous scar joining the dural surface to pericranium or galeal
aponeurosis (Dahlin et al., 1991; Ripamonti, 1992) (Fig 1.5). However, there is also a
period of soft tissue interposition prior to successful regeneration of long bones through
distraction osteogenisis. Why bone does not regenerate as completely in distracted cranial
bones as it does in long bone is not fully understood. There is evidence that distraction
osteogenisis in long bones proceeds when cells are stressed (Kanno et al., 2005; Cho et
al., 2007) which in evolutionary terms, links to the fact that long bones are undergoing
significant stresses during normal function, whereas the cranium is a protective vault
compiled of normally unstressed bony plates.
Of further importance may be the fact that cranial bone is derived from
neuroectodermal origin and forms in membrane without going through a cartilaginous
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precursor. The recent work by Leucht et al., (2008), who have highlighted the potential
clinical importance of fundamental differences in expression of genes such as the Hox
patterning genes between mesenchyme derived and neuroectoderm derived
osteoprogenitors, may provide vital clues to direct the future manipulations aimed at
resolving the problem of cranial bone regeneration.
Figure 1.5: Post fronto-facial advance for child with Crouzon syndrome
A: Lateral skull view of 3-D CT scan showing a two year old boy with Crouzon syndrome
one month before surgery. This demonstrates the relative mandibular prognathism which
is a result of poor forward and downward growth of the orbito-maxillary complex due to
suture fusions of the neuro and viscerocranium.
B: Similar view 2 months post surgery. Monobloc osteotomies were performed followed by
a one week period to allow callus formation and soft tissue healing before daily distraction
of the fronto-facial skeleton by 1mm for 25 days. A further four week period of
consolidation is necessary before frame removal. Arrow b* points to bony regeneration
which has occurred in the vicinity of the skull base and mid-facial bones. Arrow b
demonstrates the absence of bone regeneration of the cranial vault. Minimal further
regeneration of bone would be anticipated in the vault regions in a child of this age or
older. (Great Ormond Street Hospital for Children)
b
b*
A B
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1.2.5: The surgical problem.
The precedent and to a lesser extent the subsequent review, has been carried out
with the focus on reconstruction of the craniofacial skeleton, as it relates to the conditions
and surgical challenges encountered by the craniofacial surgeon. However, scenarios
involving replacement of bone are also a frequent and sometimes everyday occurrence for
orthopaedic surgeons, neurosurgeons, otolaryngologists and oral surgeons. The review
therefore has relevance to all of the surgical specialties involved in bony reconstruction.
This is manifest in the broad source of the review material, drawn from all of the above
specialties and the basic scientific literature.
By the very nature and geometry of vault expansion, what all surgical approaches
have in common is that defects will be created between the cut edges of the expanded
bone. Moreover, spaces may be created between the dura and the dural surface of the
calvarial bone (Wolfe et al., 1993). These spaces may eventually be obliterated by the
expanding brain. However, this remains a potential cause of poor bone repair, as the
dural-bone interface has been shown in animal studies to be the source of greatest bone
regeneration (Hobar et al., 1993; Gosain et al., 2003). These studies also demonstrated
that regeneration is significantly poorer in mature animals. This is consistent with findings
in humans, where the capacity of children over the age of 2 to regenerate calvarium is very
limited (Sirola, 1960; Bradley et al., 2006). This may be linked to the findings that
immature dural cells are capable of producing greater amounts of growth factors
compared with mature cells. (Greenwald et al., 2000).
The knowledge that calvarial defects do not heal in all but the youngest children, has
necessitated the repair of defects with a number of alternatives. This is required for a)
protecting individuals from the risk of cerebral injury, b) stabilisation and prevention of
relapse in the “craniotomised” bony fragments and c) optomising aesthetic outcome by
restoration of contour defects.
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1.2.6: Current techniques for calvarial defect reconstruction
Historically, autologous bone grafts, allografts, and a variety of alloplastic
biomaterials have been used for the repair of cranial defects (Koenig et al., 1995; Gosain
et al., 1999). However, problems related to graft availability, donor site morbidity,
unpredictable graft resorption (Fig.1.6), long term growth, long-term biocompatibility,
immunogenicity, and biomechanical integrity, have all limited the success and
applicability of these methods (Gosain & Persing, 1999; Pou, 2003), Moreover, because
alloplastic materials remain as permanent foreign bodies, their use in pediatric patients is
limited by concerns about their influence on the growing craniofacial skeleton, including
the possibilitiy of non degradable materials being translocated to the endocranial surface
(Fearon et al., 1995).
1.2.6.1: Autologous Bone Graft
Several techniques and material options for the reconstruction of calvarial defects
exist. The choice made should take into account many factors including surgical site, risk
of infection, previous surgeries, indication for surgery and patient age, to account for the
need for future growth (Moreira-Gonzales et al., 2003). The most commonly used
technique available for reconstruction of calvarial defects is the autologous free bone graft.
Autologous grafting for craniofacial defects was first reported by Muller in 1890 to restore a
skull defect by harvesting bone from the cranium (van Wyck, 1989). Since then and
despite drawbacks, autologous grafts have remained popular and are considered by most
specialists to be the gold standard in the absence of the “ideal” bone substitute (Citardi &
Friedman, 1994; Kirschner et al., 2002). The most commonly utilised donor areas include
cranium, rib, and iliac crest grafts (Guyuron et al., 1988; Prolo & Oklund, 1991). They have
the advantage of bringing potentially osteogenic tissue to the defect and in-growth of
adjacent fibro-vascular tissue (Gladstone et al., 1995; Jackson et al., 1987). However,
they are not vascularised tissues in themselves and the degree to which they are
incorporated is variable. Cranial bone grafts have the advantage of being situated at the
site of primary surgery, thereby avoiding the need for a further donor site. Often large
amounts of bone can be harvested by splitting of the calvarial graft into an inner and outer
cortex. However, this technique is dependent on there being a well developed, age related
diploe between cortices to allow feasible splitting (Koenig et al., 1995). Unfortunately, this
is seldom the case in individuals with craniosynostosis who need surgery at an early age.
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Bone grafts from all donor sites are prone to unpredictable but significant levels of
resorption (Moreira-Gonzales et al., 2003), although cranial bone grafts are accepted as
being the most reliable (Whitaker et al., 1979; Tessier 1982; Jackson et al., 1986;
D’Adonna and Nowzari, 2000). The reliability of cranially derived graft may be linked to the
recent findings of Leucht et al., (2008), who have shown in mice that mandibular defects
regenerate more effectively when grafted with bone from a neuroectodermal origin.
Suggesting that skeletal stem cells have ‘positional memory’, which influences how the
cells behave when grafted into ectopic locations.
In addition to resorption or loss due to infection, complications associated with graft
harvest can involve persistent cerebro-spinal fluid leak, epidural or subdural haematoma,
contour deformities of the cranial vault, and permanent neurologic impairment (Kline &
Wolfe 1995; Zins et al., 1995). Iliac crest grafts are readily available, but they have been
associated with persistent postoperative pain, herniation of abdominal contents,
haematomas, and neuropathy of the lateral femoral cutaneous nerve (Fowler et al., 1995;
Russell & Block, 2000). Split rib grafts provide bone which is malleable to a degree and
which complies well with skull form and in keeping with other autologous donor sites, it
seldom fails due to infection. However, harvest involves a secondary donor site which can
cause severe post operative pain or pneumothorax (Munro & Guyuron, 1981). In common
with iliac grafts, rib grafts have been reported as undergoing a greater degree of resorption
than cranial grafts (Zins & Whitaker, 1983; Hardesty & Marsh, 1990; Donovan et al., 1993),
although recent studies in rabbits have found no difference in resorption volume between
endochondral (iliac crest) and membranous (mandible) sources, when cortical bone was
utilised, concluding that bone architecture dictates resorption and not embryological origin
(Ozaki & Buckman, 1998).
1.2.6.2: Bone-Fibrin Composite
Where small defects are to be filled or where extensive surgery has produced
significant quantities of bone dust or small bone fragments which can be morselised,
defects can be filled by a bone pate, created by mixing the residual bone with
commercially available fibrin glue (Anderl et al., 1987; Matsumoto et al., 1998). While this
utilises bone which might otherwise be wasted, there are no studies confirming the long
term outcome of a morselised bone composite, although a high resolution CT scan study,
has confirmed the complete resorption of bone dust replaced during cranioplasty in all
patients (O’broin et al., 1997)
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1.2.6.3: Bone Allografts
Allogenic bone is non-vital bone taken from one individual and transferred to another
individual of the same species. Bone allografts exist in three main forms; a) fresh frozen,
b) freeze dried and c) demineralised bone matrix (DBM). Due to concerns regarding
transmission of viral and PRION infection, only DBM continues to have a significant role to
play in the clinical setting. Demineralised bone matrix is produced by demineralisation of
freeze dried bone, a process which not only removes any inherent structural strength but
also renders the material incapable of transmitting infection (Mellonig et al., 1992). Urist
(1965), demonstrated in the 1960s that DBM induced the formation of bone in non-
osseous tissue such as muscle. This ability to induce osteogenisis in cells, not of the
osteogenic lineage is termed osteoinduction. It has subsequently been shown that this
osteoinductive ability is due to the availability of bone morphogenic proteins (BMPs)
following the demineralisation process (Urist et al., 1984; Wozney et al., 1988). DBM has
been shown to provide complete bone healing of critical-sized defects in rabbits (Lindholm
et al., 1993) and dogs (Oklund et al., 1986). Despite the fact that commercial formulations
of DBM have been available since 1991, recent studies have reported great variability and
inconsistency with the levels of BMPs present and ability of the material to heal bony
defects (Maddox et al., 2000; Russell et al., 2000). DBM is used widely for a number of
dental (Callan 2000, Babbush 2003) otolaryngological (Leatherman & Dornhoffer, 2004)
and orthopaedic indications, particularly spinal scenarios (Ludwig & Boden, 1999; Vaccaro
et al., 2002; Price et al., 2003). However, the take-up in craniofacial practice appears
limited, although Chen & Wang (2002), have reported favourable results in 10 consecutive
patients with an average 33 months follow-up.
1.2.6.4: Polymethylmethacrylate
Polymethylmethacrylate (PMM) or PMM hybrid cements are widely used and
considered to be one of the most consistently accepted options for reconstruction in the
fully grown skull (Blum et al., 1997; Lara et al., 1998). They are however, not resorbed,
incorporated or replaced by bone and do not adapt with the growing skull. They are difficult
to model during polymerisation which involves a highly exothermic reaction (peak temps of
81oC), potentially causing thermal necrosis to the underlying tissues (Stelnicki &
Ousterhout, 1996). Giant cell foreign body reactions have been described (Constantino et
al., 1992) and may cause loosening and fragmentation, necessitating removal. Removal
due to infection is not common unless associated with the sinuses or multiple procedures
(Manson et al., 1986).
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1.2.6.5: Titanium
While autologous bone remains the preferred method of reconstruction for cranial defects,
the reconstruction of large defects becomes more difficult owing to the availability of
appropriate bone stock. In these circumstances defects can be reconstructed with
prefabricated titanium plates (Fig. 1.6) or mesh (Simpson, 1965). Until the early 1990s this
technique had the disadvantage of requiring a two stage procedure in order to construct an
accurately fitting prosthesis, the first stage allowing an accurate impression of the defect to
be obtained. This problem has since been overcome by the ability to model the titanium
prosthesis from 3-Dimensionally reformatted CT scans and stereolithographic models
(Joffe et al., 1992, 1999). Titanium is inert and does not produce a significant foreign body
reaction and reports of removal due to displacement or infection are few (Joffe et al., 1999;
Kamyszek et al., 2001). They are however not suitable for use in the growing skull.
A B C
Figure 1.6: Bone resorption and prefabricated titanium plate reconstruction
A: A 17 year old with Apert syndrome underwent recontouring of the frontal region with split
calvarial grafts.
B: Six months following surgery and associated with a chronic staphylococcal infection of the
bone, the majority of grafted bone has resorbed, creating a further significant contour defect
and resulting in only soft tissue protection for the brain. C: Lateral view (patient supine) of
exposed skull. The brain is protected and contour defect reconstructed using a prefabricated
titanium plate due to risk of further resorption and further graft availability. (Great Ormond
Street Hospital for Children)
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1.2.6.6: Calcium salt compounds
In the search for bioinert, osteoactive, easily applied and adaptable alloplastic
materials, ceramic forming, calcium salt compounds, used separately or in combinations,
have gained popularity (Burstein et al., 1999; Gosain et al., 2002; Durham et al., 2003;
Eppley, 2003). Commercially produced hydroxyapatite [Ca10(PO4)6OH2] is chemically
similar to the mineral component which accounts for 70% of the mineralised tissue in
mammals. Furthermore, it is naturally occurring, tissue compatible, radiolucent and readily
available.
Biologically, hydroxyapatite and other ceramic compounds are meant to substitute for
the mineral phase of bone and are purely osteoconductive, although they can be
combined with autologous cancellous bone to provide osteogenic potential (Ohgushi et al.,
1989; LeGeros 2002). Their ability to support osteoconduction seems to be dependent
upon porosity, which appears to be important in allowing diffusion of nutrients, cellular
attachment and tissue ingrowth (LeGeros, 2002). Typically, these bioceramics degrade by
a combination of mechanisms; a) simple physicochemical dissolution and b) osteoclastic,
resorption (LeGeros, 1993; Pietrzak & Ronk, 2000). Tay et al., (1999), recommend that the
use of these materials should be limited to the filling of bony defects in which the
surrounding host environment is conducive to bony healing.
Comparison of studies reporting the use of these compounds is difficult, as they
relate to a large number of different formulations, studied within different species,
observing differently sized defects. Of the many studies which exist, reports have been
mixed. Animal experiments have reported generally favourable findings (Kirschner et al.,
2002). Moreira-Gonzales et al., (2003), reported good results with the use of
hydroxyapatite granules for augmentation in the maxillary-mandibular region. The same
authors reported that hydroxyapatite paste for reconstruction of human calvarial defects
produced an immunoguided delayed inflammatory reaction that leads to thinning of the
skin and exposure of the material, making secondary repair difficult. High levels of
loosening, fracture, infection and extrusion have also been reported. (Matic & Manson,
2004),
The most challenging surgical cases in terms of bony reconstruction are those with
syndromic craniosynostosis. Since the aetiology which underlies the majority of these
conditions is abnormal signalling via the fibroblast growth factor receptor (FGFR) group of
receptors and their ligands the fibroblast growth factors (FGFs), it follows that any attempts
at cell based tissue engineering strategies, are likely to be influenced by these mutations
and interactions also.
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1.3: Fibroblast growth factors and receptors
1.3.1: Fibroblast growth factors
The fibroblast growth factors (FGFs) are a family of ligands which bind and activate
fibroblast growth factor receptors. The FGF family consists of structurally related low
molecular weight polypeptides of which 22 have been identified in mammals (Ornitz & Itoh,
2001). Features of FGFs include a homologous central core of 140 amino acid residues
which form a compact -barrel, similar in structure to interleukins 1 and 1 (Smallwood et
al., 1996), with a strong affinity for heparin and heparan sulphate proteoglycan molecules
(Schlessinger et al., 1995). Most FGFs are readily secreted from cells. However, the most
ubiquitous factors, FGF1 and FGF2 lack a secretory amino acid signal sequence and are
not secreted, but enter the extracellular matrix and cellular surfaces by a mechanism
independent of the endoplasmic reticulum-Golgi pathway (Mignatti et al., 1992).
Fibroblast growth factors are capable of inducing a wide variety of effects, such as
angiogenesis, chemotaxis, cell survival, proliferation and differentiation in
neuroectodermal, epithelial and mesodermal cell types (Basilico & Moscatelli, 1992;
Szebenyi & Fallon, 1999). Studies together with analyses of the role played by FGFs in
specific developmental systems and the analyses of the expression patterns of FGFs in
different tissues and cells, demonstrate that FGFs play critical roles during most stages of
mouse development and organogenesis (Ornitz & Itoh, 2001). Their pattern of expression
is highly variable ranging from the widely expressed FGF2 (Bikfalvi et al., 1997) to the
highly restricted expression of FGF4 (Niswander & Martin, 1992). However, we know that
the expression of FGFs and their receprtors, is temporally and spatially regulated which is
of importance during craniofacial ossification (Delezoide et al., 1998).
1.3.2: Fibroblast growth factor receptors
Fibroblast growth factor receptors (FGFRs) are members of the Immunoglobulin (Ig)
superfamily of receptors that have been shown to play a key role in developmental
processes including proliferation, migration and differentiation of tissues as well as being
expressed at high levels during embryogenesis (Peters et al., 1994).
First discovered in the mid 1980s (Olwin et al., 1986), four FGF receptors (FGFR1-4)
have been characterised. The general structure of FGFRs is illustrated in Fig. 1.7. The
extracellular (ligand-binding) domain of FGFR is composed of three immunoglobulin (Ig)
like domains, designated IgI, IgII and IgIII, stabilised by disulphide bridges. These
intramolecular disulphide bridges result from an interaction between two highly conserved
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cysteine residues, which stabilise the loop conformation. Situated between IgI and IgII is a
region of 4-8 acidic amino acid residues, called the ‘acid box’ and a positively charged
region in IgII that serves as a binding site for heparin. Also in this region is the ‘cell
adhesion molecule’ (CAM) homology domain which is a stretch of 20 amino acids that
shares sequence homology with NCAM and N-Cadherin. FGFRs have a single
transmembrane domain (TMD) (Jaye et al., 1992) and, with the exception of the as yet
uncharacterised FGFR5 (Kim et al., 2001), a ‘split’ intracellular tyrosine kinase domain
separated into two parts by a 14 amino acid insert.
1.3.3: FGFR isoforms
An important feature of the FGFR family of receptors is that a variety of FGFR
isoforms are generated by alternative splicing of FGFR transcripts. The different FGFR
isoforms include FGFRs with an extracellular domain composed of either two or three Ig-
like domains, soluble secreted FGFR forms, as well as alternative splicing in the third Ig-
like domain (IgIII) that profoundly alters ligand-binding specificity (Miki et al., 1992). The
alternative splicing in IgIII exists in FGFR1, 2 and 3, but not in FGFR4. It has been shown
that exon 7 of FGFR2 gene encodes for the N-terminal half of IgIII (designated ‘a’), while
exons 8 and 9 alternatively encode for the C-terminal half of IgIII. and are thus designated
as ‘b’ and ‘c’ forms of FGFR, respectively (Fig. 1.7). Splice variants alter receptor function,
and in several cases, lead to different ligand-binding specificities. Structural and functional
diversity amongst FGFR isoforms, combined with numerous receptor ligands of which
fibroblast growth factors (FGFs) are the most important, results in the potential for
extremely complex and diverse FGFR-ligand interactions (Ornitz & Itoh, 2001). It has been
shown that the FGFR2b isoform is exclusively expressed in epithelial cells and that the
FGFR2c is expressed exclusively in mesenchymal cells (Orr-Urtreger et al., 1993). The
lineage-specific expression of the IIIb and IIIc isoforms of FGFRs enables interaction
between the epithelial and mesenchymal layers during development in response to
different ligands.
1.3.4: FGFR / ligand specificity
The extracellular regions of FGFRs are involved in ligand binding. Loops II and III
and the interlinker region between them are required for conferring specificity upon the
interaction between the receptor and FGF (Plotnikov et al., 1999). Ornitz et al., in 1996,
showed that mitogenic responses to FGF signalling were highly specific, and dependent
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Figure 1.7: General structure and isoforms of FGFRs
FGFR isoforms generated by alternative splicing of FGFR transcripts. The two forms of
FGFR are generated by alternative splicing of exons 8 and 9. The C-terminal half of IgIII is
encoded by exon 8 to generate the FGFR-IIIb isoform while the C-terminal half of IgIII
when encoded by exon 9 generates the FGFR-IIIc isoform. TKD= tyrosine kinase domain,
TMD= transmenbrane domain (Adapted from Morriss-Kay & Wilkie 2005)
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upon the combination of ligand and FGFR isoform. Table 1.4 shows the specificities of
FGFRs and FGFs based principally on this study.
Upon ligand binding, receptor dimerisation brings the cytoplasmic domains of the
receptors in close vicinity of each other providing the opportunity for receptor trans-
autophosphorylation, subsequent tyrosine kinase activation and initiation of downstream
signalling pathways (Yarden and Ullrich, 1988).
The binding of FGFs to their receptors and subsequent dimerisation is dependent
upon the low affinity, co-binding of heparan sulphate containing proteoglycans (Ornitz et
al., 1992; Spivak-Kroizman et al., 1994).
FGFR Isoform Ligand Specificity
1b FGF1,2,3,10
1c FGF1,2,4,5,6
2b FGF1,3,7,10,22
2c FGF1,2,4,6,9,17,18
3b FGF1 and 9
3c FGF1,2,4,8,9,17,18,23
4 FGF1,2,4,6,8,9,16,17,18,19
Table 1.4: Ligand specificities of FGFR isoforms
FGF ligand binding specificity determined by thymidine incorporation. Adapted from Ornitz
et al., (1996); Xu et al., (2000) ; Yamashita et al., (2002) ; Umemori et al., (2004)
1.3.5: FGFR expression
In the earliest stages of the normal human developing skull and before ossification,
FGFR1 expression is present in the entire head mesenchyme. FGFR2 is expressed in the
epidermis and preosteogenic mesenchymal condensation and low levels of FGFR3 are
found in basal head mesenchyme and epidermis. Approximately half way through
gestation, sutures appear at the periphery of osteogenic centres and FGFR1 and FGFR2
are expressed at high levels in the osteogenic fronts of the sutures where only low levels
of FGFR3 are found, (Delezoide et al., 1998). Studies in mice by Rice et al., (2003), found
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mRNA for FGFR1c was detected weakly in osteoblastic cells in the developing calvarial
bones. FGFR2c transcripts were detected at high levels in differentiating osteoblasts at the
sutural osteogenic fronts of the calvarial bones. FGFR2b transcripts were detected in the
cranial base where FGFR3b and FGFR3c were also localised. FGFR4, which has not
been found to be a source of mutations for craniosynostosis, was detected minimally in
calvarial cartilage. These distribution patterns are important in explaining the link between
FGFR mutations and phenotype expression of individual craniofacial syndromes (Britto et
al., 2001).
1.3.6: Mutations in syndromic craniosynostosis
As previously described in this chapter, the severest forms of craniosynostosis are
associated with abnormalities of the molecular genetics which are summarised in
Table1.5. The recent discoveries of mutated genes that cause syndromic
craniosynostosis, and the subsequent molecular investigations into these mutations, have
greatly enhanced our understanding of the biological events that underlie them.
In 1993 a breakthrough came when the first mutation to be associated with
craniosynostosis was found in the MSX2 gene (Jabs et al., 1993). Subsequently,
mutations in various locations of the FGFR2 gene were found in children with a clinical
diagnosis of Crouzon syndrome (Reardon et al., 1994). Since then Crouzon, Apert,
Pfeiffer, Jackson Weiss and Beare-Stevenson syndromes have all been shown to arise as
a result of mutations in FGFR2 (Jabs et al., 1994; Muenke et al., 1994; Wilkie et al.,
1995,). Mutations in FGFR1 and FGFR3 can also occur in rarer forms of Pfeiffer syndrome
and Crouzon patients respectively (Muenke et al., 1994; Schell et al., 1995; Pryzlepa et al.,
1996). Muenke syndrome, the commonest and the mildest of the syndromic
craniosynostoses is caused by a mutation of FGFR3 which is more commonly the site of
mutations causing achondroplasia. To date, no causal mutations have been reported in
FGFR4 (Gaudenz et al., 1998) or in FGFR5 (Kim et al., 2001). The similarity in clinical
phenotype of cases with Apert syndrome, reflects its restricted genotype compared to that
of the other syndromes including Crouzon, Jackson-Weiss and Pfeiffer which exhibit an
overlapping clinical phenotype. It is noteworthy that Apert syndrome is associated with
increasing paternal age (Moloney et al., 1996) and implicates the involvement of
spermatogenesis in mutagenesis.
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Mutations in TWIST, a basic helix-loop-helix transcription factor have been identified
in individuals with Saethre-Chotzen syndrome (Howard et al., 1997; El Ghouzzi et al.,
1997). The mechanism for mutated TWIST activity is not clearly understood, although
most of the mutations result in a non-functional protein and are likely to result in
haploinsufficiency (Wilkie, 1997). Yousfi et al., (2001), found that this produced altered
osteoblast function in cultured human calvarial cells which may be linked to alteration of
FGFR expression (Rice et al., 2000; Funato et al., 2001). This has been confirmed by
Guenou et al., (2005), who have demonstrated that TWIST haploinsufficiency
downregulates Fgfr2 mRNA expression, which in turn reduces Runx2 and downstream
osteoblast-specific genes in human calvarial osteoblasts. Thus, providing evidence for a
role of FGFR2 in the altered osteoblast phenotype induced by TWIST mutations in
Saethre-Chotzen syndrome. More recently, Connemey et al., (2008), have shown that
TWIST happloinsufficiency alters the TWIST heterodimers/homodimer ratio, effecting
sutural patency by altering suture responsiveness to FGF signalling. In contrast to the
majority of mutations in the TWIST gene, all FGFR mutations are in-frame mutations which
code for functional proteins and are due to missense mutations, deletions, insertions or
splice events. Although many mutations have been reported, there is marked clustering of
mutations at particular locations in the FGFR genes. Namely, at the interlinker region
between IgII and IgIII, the membrane end of the 3rd immunoglobulin domain and the
transmembrane domain (Wilkie, 1997). Homologous mutations have been identified at
equivalent positions in more than one FGFR. For example, in the interlinker region
between IgII and IgIII, Pro252Arg substitution of FGFR1 causes Pfeiffer syndrome,
Pro253Arg substitution in FGFR2 causes Apert syndrome, and Pro250Arg substitution in
FGFR3 causes Muenke craniosynostosis (Muenke et al., 1994; Wilkie et al.,, 1995; and
Bellus et al., 1996). Interestingly, it has also been identified that single mutations such as
the C278F missence mutation of the FGFR2, can manifest as either Crouzon, Pfeiffer or
Jackson-Weiss syndrome (Meyers et al., 1996; Passos-Bueno et al., 1997). Moreover, the
same syndrome can be caused by mutations in different genes as exemplified by
mutations in both FGFR1 and FGFR2 causing Pfeiffer syndrome. The mechanism by
which the same genotypes cause different phenotypes is still uncertain. It may be due to
unidentified polymorphisms within FGFRs or a complex temporal interaction between
receptor regulation and ligand availability within different domains (Wilkie et al., 2006).
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Table 1.5: Craniofacial syndromes associated with mutations in FGFRs
Abbreviations: Ig: Immunoglobulin, a.n.: acanthosis nigricans. (Adapted from Wilkie, 2005)
There is evidence that mutations cause constitutive activation of receptors (Neilson &
Friesel, 1995; Galvin et al., 1996; Mangasarian et al., 1997; Robertson et al., 1998). This
activation is brought about by a number of effects including a) alteration in the number of
cysteine residues allowing covalent cross linking with another mutant receptor and
receptor dimerisation in the absence of FGF (Kannan and Givol, 2000), b) destabilisation
of the disulphide bridge leading to alternative intermolecular bonds (Burke et al., 1998),
c) formation of transmembrane hydrogen bonds leading to conformational change and
dimerisation (Webster and Donoghue, 1996) or d) increased ligand affinity of reduced
ligand dissociation, leading to prolonged receptor signalling (Anderson et al., 1998).
(Fig. 1.8)
Gene Syndrome Typical mutation sites/regions
FGFR1 Pfeiffer IgII - IgIII interlinker
FGFR2 Crouzon
Pfeiffer
Apert
Jackson-Weiss
Beare Stevenson
Ig III – mainly the creation of unpaired
cysteine residues
As for Crouzon, sometimes the mutations are
identical (e.g. C278F)
IgII-IgIII interlinker
As for Crouzon
Creation of new cysteine residues
FGFR3 Muenke syndrome
Achondroplasia
Crouzon (with a.n.)
Thanotophoric dysplasia I
Thanatophoric dysplasia II
IgII-IgIII interlinker (P250R)
Transmembrane
Transmembrane
Creation of cysteine residue
Tyrosine kinase domain
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Figure 1.8: Schematic representation of FGFR mutations
A. General structure of FGFR showing mutation foci
B. Effects of mutations in syndromic craniosynostosis. a) normal FGFR activation, b)
intermolecular disulphide bridge formation secondary to unpaired cysteines. c) hydrogen
bond formation in transmenbrane domains d) mutations leading to increased affinity or
reduced dissociation of FGF ligand. (Adapted from Anderson et al., 1998; Burke et al.,
1998; Green et al., 1996; Kannan & Givol, 2000; Webster & Donohue, 1996)
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1.3.7: FGF/FGFR interactions and osteogenisis
Bone development is dependent on the expression of members of the FGF family
expressed locally during bone formation. FGF2, FGF4, FGF9, FGF18 and FGF20
transcripts are found in cranial and sutural mesenchymal cells and osteoblasts (Gonzalez
et al., 1996; Kim et al., 1998; Britto et al., 1998; Rice et al., 2000; Ohbayashi et al., 2002;
Hajihosseini and Heath, 2002), suggesting that they may be involved in regulating calvarial
osteogenisis. Recent data indicates that FGF18 is becoming recognised as an important
coordinator of osteogenisis via FGFR2 and FGFR3 and will be reviewed separately. FGF
expression is also dependent on the temporo-spatial expression pattern of FGFRs
(Powers et al., 2000). FGFR1 and FGFR2 are expressed in mesenchymal cells during
condensation prior to deposition of bone matrix, at early stages of long bone development
(Orr-Urtreger et al., 1991) and are also expressed in the cranial suture (Delezoide et al.,
1998). Later in development and postnatally, FGFR1 and FGFR2 are found in pre-
osteoblasts and osteoblasts together with FGFR3 (Iseki et al., 1997; Delezoide et al.,
1998; Kim et al., 1998). The coordinate actions of FGFs on gene expression in osteoblasts
is not only dependent on FGFR expression, but also on the affinity and specificity of FGF
binding to the various alternative splice forms of FGFRs (Ornitz et al., 1996). FGFR2IIIc is
expressed in early mesenchymal condensates and later in sites of endochondral and
intramembranous ossification where it was recently found that in mice, the recessive
phenotype of Fgfr2IIIc(−/−) is characterised initially by decreased expression of bone
transcription factor RunX2 (previously Cbfa) and retarded long bone ossification,
suggesting that Fgfr2IIIc is a positive regulator of ossification (Eswarakumar et al., 2002).
Furthermore, FGFs bind cell surface heparan sulfate proteoglycans acting as low-affinity
co-receptors that interact with FGF binding and signalling (Ornitz, 2000; Schlessinger,
2000). Some of these proteoglycans, including syndecans are expressed in bone (Solursh
et al., 1990) and may affect the osteoblast response to FGF during osteogenisis (Molténi
et al., 1999). Given this mix of interacting molecules, it is likely that subtle changes
occurring in the expression or localisation of any number of them, may induce variable
functional effects on FGF signalling and osteoblast gene expression in vivo. Moore et al.,
(2002), have shown that there is a gradient of FGF2 expression, which is greatest at the
suture, lessening in the surrounding mesenchyme, suggesting FGF2 may be driving
proliferation at the sutures to keep them patent.
This group further found that blocking FGF2 activity prevents osteogenisis in a
concentration dependent manner, consistent with previous findings that over-expression of
FGF2 in mice induces abnormal bone formation (Coffin et al., 1995), whereas FGF2
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perturbation inhibits it (Montero et al., 2000; Greenwald et al., 2001). There is also good
evidence that at the osteoblast level, the effect of FGFs is dependent on the stage of
cellular maturation: and this will be discussed more fully in chapter 5.
1.3.8: FGF18 in osteogenisis
FGF18 is a recently investigated member of the FGFs, having been isolated in the
rat and mouse in 1998 (Ohbayashi et al., 1998; Hu et al., 1998). The human FGF18 gene
has been localized to chromosome 5q34 (Whitmore et al., 2000). It is highly conserved
with a 99% identity match with the amino acid sequence, while the nucleotide sequence is
90% conserved between humans and mice. It is involved in specification of left-right
asymmetry (Ohuchi et al., 2000) and in the development of the intestinal tract (Hu et al.,
1998), brain (Ohuchi et al., 2000) and lung (Whitsett et al., 2002). A role in endochondral
and intramembranous bone formation has been demonstrated in rodents and chicks
(Ellsworth et al., 2002; Liu et al., 2002; Ohbayashi et al., 2002). Hajihosseini et al., (2002),
found that FGF18 is strongly expressed in mouse coronal sutures, dorsal rims of the
parietal bones and in the cranial base and that these regions directly abut with zones of
osteopontin expression. It is interesting that of the FGFs so far targeted in mice, only those
lacking FGF18 have demonstrated a phenotype affecting calvarial development:
Ohbayashi et al., (2002) demonstrated FGF18 expression in differentiating osteoblasts
and osteogenic mesenchyme, between the osteogenic fronts in calvarial bones and in the
perichondrium of developing long bones. FGF18-/- mice illustrated delayed ossification
characterised by widened metopic, coronal and sagittal sutures, delayed suture closure
and decreased calvarial mineralisation. Proliferation within the calvarial osteogenic
mesenchyme was also decreased.
FGF18 shows strong binding affinity for FGFR3c and FGFR2c, as well as strong
mitogenic activity for FGFR3c, modest for FGFR2c and not at all for FGFR1, FGFR4 or
any of the b spliced variants (Xu et al., 2000). Both FGF18-/- and FGFR3-/- mice display a
similar although not identical long bone phenotype suggesting that while FGF18 signalling
through FGFR3 is important in chondrogenisis, FGF18 must also signal through other
FGFRs (Liu et al., 2002). More recently Liu et al., (2007), have emphasised the role of
FGF18 in the control of mesenchymal vascularisation around centres of endochondral
osteogenisis. Since FGFR1 and FGFR2 are the predominant FGFRs expressed in the
calvarial bones (Iseki et al., 1999; Rice et al., 2000), it is likely that these FGFRs are the
target for FGF18 in calvarial osteogenisis.
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The MC3T3-E1 murine cell line treated with FGF18 show a dose dependent increase
in proliferation through ERK activation and inhibition of matrix synthesis and differentiation.
These effects were comparable to the effects produced by FGF2 and it has been
postulated that it might compensate for FGF2 in skeletal development (Shimoaka et al.,
2002).
1.3.9: FGF/FGFRs and osteoblast gene expression
The number of ligands and receptors acting on osteoblast are many and complex.
However, FGF/FGFR interactions play an important part in modifying the expression of
multiple genes that characterise the osteoblast phenotype. In osteoblastic cell cultures, as
is the case for many other proteins, the effects of FGF signalling on osteocalcin (OC)
expression are complex and depend on the cell type. Indeed, FGF1 inhibits OC gene
expression in rat calvarial cells (Tang et al., 1996), but enhances its expression in bovine
bone cells (Schedlich et al., 1994). Direct regulation has been reported in mouse calvarial
cells, where FGF2 effects OC expression by acting on specific elements in the OC gene
(Schedlich et al., 1994, Newberry et al., 1996), FGF2, FGF4 and FGF8, or transfection
with a vector expressing a mutant FGFR2 that is constitutively activated in the presence of
FGF ligand, was found to stimulate Runx2 expression in osteoblasts (Zhang et al., 2002;
Kim et al., 2003). FGF signalling effects the expression of proteins involved in cellular
communication and adhesion including the connexins and cadherins which will be
discussed in more detail later in the chapter. FGFs interact with other growth factor
signalling pathways and may thereby regulate osteoblast function. For example, FGF2
up-regulates TGFβ expression in osteoblasts in vitro (Noda & Vogel 1989). Conversely,
TGFβ regulates FGF2 and FGFR expression in osteoblastic cells (Sobue et al., 2002).
Additionally, FGF2 increases insulin-like growth factor-I (IGF-I) gene expression in vitro
(Zhang et al., 2002) and in vivo (Power et al., 2002). Recent data indicate that FGF2 and
FGFR2 inhibit the expression of the bone morphogenic protein (BMP) antagonist noggin in
the patent cranial suture, resulting in premature suture fusion (Warren et al., 2003), thus
indicating that FGF signling can control cranial suture fusion indirectly through BMP
signalling. It is therefore likely that the biological activities of FGFs in bone depend not only
on the balance between FGF and FGFR expression, but also on the presence of other
signalling molecules. In addition, FGFs regulate genes that are involved in matrix
resorption by increasing the expression of extracellular collagenase (Hurley et al., 1996,
Varghese et al., 2000). These studies suggest that FGFs may modulate bone matrix
breakdown by regulating collagenase expression and activity. Taken together, activation of
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FGF/FGFR signalling seems to regulate genes involved in most of the steps of
osteogenesis. These finding would also suggest that genes may participate in regulating
cell progression from osteoprogenitor cell to osteoblast death
1.4: Cellular bone biology
1.4.1: Bone Cells
Bone is a constantly changing tissue which necessitates the presence of cells both
for deposition and resorption. Calvarial bones ossify by the direct secretion of extracellular
matrix, by osteoblasts, into mesenchymal condensations, forming centres of ossification.
Osteoblasts are the predominant cell of bone deposition and are derived from
mesenchymal cells which become preosteoblast prior to becoming functioning osteoblasts.
Osteoclasts, which are derived from the monocyte/macropghe lineage, play an equally
important role in bone growth and remodelling by their function of resorption (Sommerfeldt
& Rubin 2001). They are regulated by the acidified microenvironment in addition to being
under hormonal control by numerous factors, both pro-resorbative such as vitamin D3 and
corticosteroid and anti-resorbative such as oestrogen and calcitonin (Boyle et al., 2003).
Osteocytes are found, throughout mature bone enclosed within lacunae. They are the
most common cell type in bone, forming an intercommunicating, syncitial network. Their
role in osteogenisis and skeletal health has until recently been unclear. However, it is now
appreciated that osteocytes are highly responsive to circulating hormone levels and
cytokine (Bringhurst, 2002), and there is now growing evidence to support the hypothesis
that the osteocyte is the bones mechanoreceptor (Noble et al., 2003).
1.4.2: Osteoblast differentiation and function
Osteoblasts are channelled through a path of commitment from mesenchyme to
become mature osteoblasts. This journey from pluripotent mesenchymal cell to fully
differentiated and functioning osteoblast is a process which involves a variety of
hormones, cytokines and growth factors (Roelen, 2004). Osteoblasts are principally
responsible for the deposition and regulation of extracellular matrix proteins and the
expression of genes required for mineralisation and interaction with osteocytes and
osteoclasts to regulate bone turnover. Molecules important for development of the
osteoblastic phenotype include, Runx2 a transcription factor required for osteoblast
differentiation and bone formation (Ducy et al., 1997). Absence of Runx2 in knock-out
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mice causes a complete absence of osteoblasts and osteogenisis (Komori et al., 1997,
Otto et al., 1997). In humans, mutations within the Runx2 gene cause cleidocranial
dysplasia (Lee at al 1997; Mundlos et al., 1997), characterised by short stature, widely
patent inter-parietal and metopic regions and dental anomalies.
Osterix (Osx) is a recently identified zinc-finger containing transcription factor, that is
expressed in all developing bones and appears necessary for osteogenisis. Osx null mice,
do not deposit bone matrix and membranous mesenchymal cells cannot differentiate into
osteoblasts. These cells do, however, express Runx2. In contrast, Osx is not expressed in
Runx2 null mice, suggesting that Osx acts downstream of Runx2 (Nakashima et al., 2002).
Mature osteoblasts are morphologically indistinguishable. However recent in-situ
studies in rat calvaria show that they are not a homogeneous class of cells, but are instead
a molecularly diverse group of subpopulations based on the expression patterns of specific
markers. These can be divided into two categories; those that are expressed by all
osteoblasts, irrespective of their position in the calvaria, including, alkaline phosphatase
and those such as the matrix proteins osteopontin, osteocalcin and bone sialoprotein
which are differentially expressed only in subpopulations of osteoblasts (Candeliere et al.,
2001). This work complements previous, similar findings of osteoblast subpopulations
within bone nodules of cultured rat osteoblasts (Malaval et al., 1994). The mRNA
expression of some of the important markers of osteogenisis will be studied in this work.
1.4.2.1: Type 1 Collagen
Synthesised by fibroblasts and odontoblasts, type 1 collagen is principally the
product of osteoblasts during the laying down of bone matrix and is the most abundant
protein in bone, accounting for approximately 90% of bone matrix (Bilezikian et al., 1996).
It is a trimeric molecule composed of two α1 chains and a α2 chain, which are in
themselves made from polypeptide sequence repeats. These allow the formation of a triple
helix which gives rise to a highly ordered fibrillar structure, important for tensile strength
within mineralised tissues. Mutations within the genes coding for collagen I α chains lead
to osteogenisis imperfecta, characterised by fragility and deformities of bone and dentine
(Penttinen et al., 1975). Ascorbic acid is required for normal fibrillar crosslinking, which in
turn is necessary for expression of the osteoblast phenotype and expression of alkaline
phosphatase, osteocalcin (Franceschi et al., 1994; Wenstrup, 1996; Xiao et al., 2002) and
for optimal cell adhesion and migration (Masi et al., 1992). Studies indicate that interaction
of type I collagen with alpha2 integrin, is a crucial signal for the induction of osteoblastic
differentiation and matrix mineralisation (Xiao et al., 1998; Reyes et al., 2004)
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Pathologically increased secretion of type 1 collagen by calvarial osteoblasts has
been demonstrated in craniosynostosis associated with mutations of FGFRs (Bodo et al.,
1996; Lomri et al., 1998; Baroni et al., 2002).
1.4.2.2: Alkaline Phosophatase
Alkaline phosphatase (ALP) is a glycoprotein phosphohydrolase which exists in four
isomeric forms encoded by different genes. The ALP associated with bone metabolism is
tissue non-specific. This is found as a membrane bound enzyme in many tissues including
some preosteoblasts and all osteoblasts (Candeliere et al., 2001). The function of ALP in
bone formation is not entirely clear. However, it is thought to play a role in mineral
maturation, as humans carrying mutations for ALP suffer from variable degrees of
hypophosphatasia, a condition characterised by poor bone mineralisation (Weiss et al.,
1988). ALP is an early marker of the osteoblast (Whyte et al., 1994) phenotype, with
expression which is inversely related to cellular proliferation increasing as cellular
maturation progresses (Fedarko et al., 1990; Cowls et al., 1998).
Alkaline phosphatase activity requires normal type 1 collagen secretion (Wenstrup et
al., 1996) and decreased levels of ALP have been demonstrated in the calvarial
osteoblasts of patients with craniosynostosis associated with Crouzon syndrome
(Ratisoontorn, 2003).
1.4.2.3: Osteocalcin
Osteocalcin is a highly conserved, noncollagenous matrix protein found in bone, and
other mineralised tissues (Ulrich et al., 1987) and is amongst the most abundant of the
bone matrix proteins. (Gerstenfeld et al., 1987). The functions of osteocalcin, suggested by
an analysis of genetically engineered osteocalcin-deficient (“knockout”) mice includes,
bone mineral maturation and inhibition of bone formation. Osteocalcin knockout mice have
an accelerated rate of bone formation without changes in osteoblast or osteoclast number
(Ducy et al., 1996). It is highly expressed by mature osteoblasts, usually as a late marker
of osteoblast differentiation and is commonly examined in studies of osteogenisis. Raised
OC levels have been demonstrated in craniosynostosis associated with mutations in the
FGFRs (Lemmonier et al., 2001; Tanomoto et al., 2004) whilst decreased levels have
been expressed in other craniosynostoses, associated with mutations in the TWIST gene
(Yousfi et al., 2001).
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1.4.3: Coordinate expression profile of osteodifferentiation markers
Osteoblastic cell cultures, both primary and cell line, demonstrate a coordinate
pattern of gene expression for molecules associated with the osteoblast lineage. The
pattern of expression is dependent on the cells progressing through recognised stages
from proliferation to terminal differentiation usually leading to mineralisation. Generally, the
differentiation sequence is defined by an increase in collagen synthesis, acquisition and
increase in alkaline phosphatase activity, followed by expression of several non-
collagenous bone matrix proteins, such as osteopontin, bone sialoprotein and finally
osteocalcin as the latest marker of the mature osteoblast (Quarles et al., 1992; Heersche
et al., 1992; Choi et al., 1996). However, discrepancies in this expression profile have been
reported and it should be borne in mind that whilst the general pattern exists across
species, expression patterns are species specific; for example osteocalcin is expressed at
a later stage of differentiation than ALP in the rat calvaria, whereas it parallels expression
of ALP in chick calvaria (Stein & Lian 1993; Gersternfeld et al., 1987). Within osteoblast
lines, expression of different levels of the same marker are even observed (Heersche et
al., 1992; Malaval et al., 1994; Smith et al., 2000), indicating considerable plasticity and
functional heterogeneity of the osteoblast phenotype; for example within the MC3T3-E1
osteoblast line which shall be examined more fully later, subclones of cells were identified
in which expression of ALP was highly variable (Wang et al., 1999).
1.4.4: Cell adhesion and communication
As well as regulating the expression of genes characterising the osteoblast
phenotype, FGF/FGFR signalling controls osteogenisis indirectly, via the expression of
genes involved in osteoblast function, including, amongst others, those of cell adhesion
and communication channel proteins. These are required for cell-cell and cell-matrix
interaction, communication and adhesion (Francheschi, 1999).
1.4.4.1: N-Cadherin
Cell-cell adhesions are mediated by adherens junctions containing cadherins. These
are transmembrane glycoproteins acting with intracellular partners known as catenins
which in turn interact with intracellular proteins (Yamada & Geiger, 1997). The cadherin
family is composed of several calcium dependent molecules of which N-cadherin is one.
Human osteoblasts were first shown to express N-cadherin by Cheng et al., (1998), who
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demonstrated that cadherins were critical for the expression of Bone Morphogenic Protein
(BMP)2.
During the early stages of intramembranous bone formation, cadherins play an
important role in the condensation of mesenchymal cells prior to ossification (Hall &
Miyake, 2000). Osteoblasts in human and mouse cranial sutures and preosteoblasts and
osteoblasts in the foetal human cranial sutures are known to express N-cadherin
(Tsutsumimoto et al., 1999; Lemmonier et al., 2000). In human calvarial osteoblasts,
N-cadherin neutralising antibodies have been shown to down-regulate the expression of
alkaline phosphatase, type I collagen and osteocalcin (Hey et al., 2000). Lemmonier et al.,
(2001) and Lomri et al., (2001), have demonstrated over-expression of N-cadherin,
mediated by Protein Kinase C, in osteoblasts from the coronal suture of fetuses with Apert
syndrome carrying an activating mutation for FGFR2. This resulted in increased cell-cell
adhesion and over-expression of osteodifferentiation markers in days 0-7 of confluent
primary cell cultures.
1.4.4.2: Connexin 43
Intercellular communication is a fundamental requirement of skeletal tissue and is
thought to control several physiological functions of bone cells, including, the coordination of
tissue responses to mechanical stimulations (Duncan & Turner, 1995), sensitivity to
hormones and growth factors (van der Molen et al., 1996) and the progression of
differentiation (Lecanda et al., 1998). This communication is mediated by the transfer of
small molecules and ions through transmembrane channels called gap junctions which are
abundant in bone cells (Stanka, 1975; Doty, 1981) and have been demonstrated in cultured
osteoblasts including MC3T3-E1 cells (Yamaguchi et al., 1994).The principal functional
components of gap junctions are the connexins. These comprise a closely related
group of hexameric proteins that associate to form cell-cell adhesion channels which
assemble in gap junctions (Makowski et al., 1977; Beyer et al., 1990). When the
connexin of one cell is in contact with a similar structure on a neighbouring cell, a
transcellular channel is formed (Civitelli, 1995). The most abundant connexin in human
and MC3T3-E1 osteoblasts is connexin 43(Cx43) (Civatelli et al., 1993; Yamaguchi et
al., 1994). The gene is located on human chromosome 6q22. Mutations within the gene
cause Oculo-digital-dental dysplasia, characterised by ocular, nasal, limb and dental
deformities (Paznekas et al., 2003). The expression of Cx43 is associated with elevated
levels of metabolic coupling (Jorgensen et al., 1997) and with a high degree of cellular
differentiation (Schiller et al., 1997; Li et al., 1999). Over-expression of Cx43 has resulted in
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increased expression of osteocalcin in MC3T3-E1 cells (Lecanda et al., 1998), whilst Cx43-
null mice display globally delayed ossification, osteoblast dysfunction and craniofacial
abnormalities characterised by poor membranous bone ossification (Lecanda et al., 2000).
Cx43 has also been implicated in altered cell motility and adhesion; Xu et al., (2001), have
reported that neural crest cells deficient in Cx43 displayed poor motility and delayed neural
crest migration has been observed by Huang et al., (1998). Gramsch et al., (2001),
reported enhanced proliferation, bone nodule formation and mineralisation of the UMR
osteosarcoma cell line overexpressing Cx43. FGF2 treatment has been shown to down-
regulate Cx43 dependent cellular communication in astroglial cells (Reuss et al., 1998)
and in MC3T3-E1 cells (Shiokawa-Sawada et al., 1997).
1.5: Bone engineering
1.5.1: The “Ideal” biomaterial
There is a strong need for bone substitution materials in craniofacial reconstruction
and surgery in general. Currently, standard autologous bone grafting remains the default
“best option” for bony reconstruction of the craniofacial region, although frequently this is
not feasible and several allograft options, along with their potential problems, do exist.
However, primary bone grafting fails in up to 20% of cases for a number of reasons
(Younger & Chapman, 1989) and harvesting requires a donor area often at a secondary
site. Thus, in addition to potentially increasing the operative time, this also increases the
potential complications as reviewed in section 1.2.6.1. It would be desirable therefore, to
try and eliminate these associated problems by creation of a bone graft substitute. An
engineered bone substitute that can mimic the native structure and replace the mechanical
and biological functions of the natural tissue being replaced would be ideal. This “ideal”
would be a mechanically appropriate, biocompatible, bioresorbable scaffold, capable of
supporting sufficient numbers of functioning cells (Langer & Vacanti, 1993), capable of
regenerating bone.
The search for this ideal synthetic bone substitute has been long and has
generated numerous and ongoing studies (Rose & Oreffo, 2002). Initial attempts to
produce materials with this aim, had as their main objective, the provision of implants
which were physically suitable and which did not involve unacceptable host toxicity. This
principally meant materials which were inert and did not produce a foreign body reaction.
This resulted in more than 50 prosthestic implants being introduced into clinical use in the
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1960s-70s. None of which however, attempted to allow or induce bone regeneration
(Hench, 1980).
More recently, work has focused on the two material properties which seem
fundamental to creation of the “ideal”. Firstly, the creation of biodegradable materials and
secondly the creation of materials which either permit bone regeneration by supporting
osteoblast growth (osteoconductive), or actively stimulate bone regeneration by inducing
cells to differentiate down the osteoblast lineage to form bone (osteoinductive). The
classic example of the latter being the induction of ectopic bone within muscle following
the intramuscular injection of demineralised bone matrix (DBM) (Urist, 1965).
Biodegradable materials offer several physical advantages over metals and other
non-degradable materials currently in use as orthopaedic or craniomaxillofacial implants.
These are best described in terms of avoiding the reported disadvantages inherent to non
degradable materials such as titanium. These include growth disturbance (Resnick et al.,
1990; Lin et al., 1991; Eppley et al., 1993), plate migration (Fearon et al., 1995), the need
for subsequent removal (Beals & Munro, 1987; Schmidt & Perrot, 1998) compatibility with
future imaging needs, long-term palpability and thermal sensitivity (Orringer et al., 1998).
Numerous naturally occurring, biodegradable compounds have been studied in an
attempt to create scaffolds including collagen (Mizuno et al., 1997), chitosan (Lee et al.,
2000), alginate (Shang et al., 2001), agarose (Mauck et al., 2003) and fibrin (Karp et al.,
2004). While these are degradable and biologically derived, their utility has been
questioned on the basis that they provide poor mechanical strength and degradation rates
can prove inconsistent (Gombotz et al., 1993). Synthetic alternatives which provide
mechanical strength have therefore been studied and developed, including
polycarbonates, polyesters, polyorthoesters, polyanhydrides, polyurethanes and
polyphophosphazenes (Gunatillake & Adhikari, 2003). As a result of these developments,
several have been licensed for clinical use.
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1.5.2 Biomaterial options
1.5.2.1 Polyesters
One of the most extensively studied biodegradable, polymeric materials, are the
group known as the polyesters, of which polylactic acid (PLA) and polyglycolic acid (PGA)
are the two most commonly encountered. They have been used for a number of clinical
applications including resorbable sutures, drug delivery systems and fixation devices such
as rods, pins screws and plates (Ashammakhi & Rokkanen, 1997, Middleton & Tipton,
2000). They have also been studied for tissue engineering applications (Hollinger, 1983;
Wong & Mooney, 1997), particularly bone engineering (Ishaug-Riley et al., 1998; Burg et
al., 2000).
1.5.2.2 Polylactic acid (PLA, L-PLA)
Polylactic acid is a naturally occurring compound produced from readily renewable
recourses such as corn and sugarbeet, which when polymerised to form polylactic acid is
used in a wide range of industrial applications where natural degradation is a requirement
(Drumright et al., 2000). Polylactic acid exists as two optical isomers, a poly-L-lactide and
a poly-D-lactide. The poly-L isomer is a semicrystalline polymer with a high melting point
(178oC) and glass transition temperature (65oC). These properties impart high tensile
strength and a prolonged degradation time (3-5 years) to materials constructed from it.
There are few reports of the use of L-PLA, although successful outcomes have
been reported in craniomaxillofacial surgery (Bos et al., 1987, Waris et al., 1994). However
the long degradation time has been associated with chronic foreign body tissue reactions
to PLA crystal remnants (Bergsma et al., 1993). Thus the long degradation time appears to
have negated the advantages of a resorbable material. However, polymerisation of a poly-
D, poly-L isomer blend (PLA), gives rise to an amorphous lower melting point (60oC),
weaker compound with a correspondingly shorter degradation time (12-16months) (Gilding
& Reed, 1979). This blend gives rise to a degradation profile which theoretically should be
less likely to cause chronic reactions. Haers & Sailer, (1998) and Turvey et al., (2002),
have reported 10 and 55 cases respectively with good mandibular and maxillary fixation
with minimal complications following osteotomies. Serlo et al., (2001), have used PLA
plates and screws in 15 children undergoing cranioplasties and reported good clinical
results with no complications at 8 year follow-up.
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1.5.2.3 Polyglycolic acid (PGA)
Like PLA, polyglycolic acid is formed by polymerisation of glycolic acid to produce a
semicrystalline structure with a melting point reported to be in the range of 225-230°C and
a glass transition temperature between 35-40°C. There are no isomeric forms (Gilding &
Reed, 1979). PGA has the greatest flexural strength of the polyesters but undergoes the
most rapid degradation with the majority of its strength lost by 6 weeks and complete
volume loss by approximately 9 months (Imola et al., 2001). A major medical application of
PGA came in 1970 with its introduction as a braided, resorbable suture known as Dexon
(American Cynamide Company), (Bender & Brouwer, 1975), which is still in current use,
testifying to its long term safety and biocompatibility. However, given the relatively rapid
degradation of PGA, its clinical use as a single constituent for the manufacture of rigid or
semi-rigid fixation devices has not been reported, although their successful use as a
“membrane” for supporting orbital contents in orbital floor repairs, where minimal
mechanical loading is involved, has been reported (McVicar et al., 1995).
1.5.2.4 Polylactic-co-glycolic acid copolymers (PLGA)
Copolymerisation of PLA and PGA disrupts the crystallinity of these monomers,
leading to an amorphous network with a degradation rate dictated by the monomer ratio.
The ratio of monomers used in the copolymerisation process allows the physical properties
of the polymer to be manipulated, which in turn alters the degradation properties of the
polymer (Gopferich, 1996). The first commercial use of this copolymer range was in 1971
with the resorbable suture material Vicryl (Ethicon inc.) composed of 8% PLA and 92%
PGA (Aston & Rees, 1976).
Commercially available fixation devices blend approximatelly 80% PLA with 20%
PGA, to reflect the combination of degradation and structural strength required. The
copolymer is largely amorphous and has a degradation profile between PLA and PGA
Clinically, It has been reported as providing successful rigid bony fixation, retaining 70% of
its initial strength for 6-8 weeks and has disappeared between 12-16 months after
implantation (Tatum et al., 1997; Peltoniemi et al., 2002). Eppley et al., (2004),
retrospectivelly reviewed a multicenter experience of 1883 cases of craniosynostosis in
which PLGA plates/screws were used. Significant infectious complications occurred in 0.2
percent, device instability primarily resulting from postoperative trauma occurred in 0.3
percent, and self-limiting local foreign-body reactions occurred in 0.7 percent of the treated
patients. The overall re-operation rate attributable to identifiable device-related problems
was 0.3 percent. A further retrospective multicentre study of 165 cases (Ashammakhi et
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al., 2004) stated that PLGA plates were safe and effective although noted an overall
complication rate of 7.2% not all of which were directly attributable to the fixation device.
The degradation process takes place in two steps during which the polymer or
copolymer is converted back to its monomer acids. Firstly tissue fluid diffuses into (non-
crystalline) regions of the polymer matrix, cleaving the ester bonds; the second step starts
after the amorphous regions have been eroded, leaving the crystalline portion of the
polymer susceptible to hydrolytic attack by random hydrolysis and tissue esterases. The
degradation product, glycolic acid, is non toxic and this then excreted directly in urine or
enters the citric acid cycle after which it is excreted as water and carbon dioxide.
(Drumright et al., 2000).
1.5.3 Bioactive glasses
The bioactive glasses are a group of biodegradable and biocompatible materials,
originally developed by Hench in the 1960s (Hench et al., 1971). The structure which is
manufactured in several formulations, depending on the percentage of SiO2, consists of
silica, calcium, sodium and phosphate. This develops a hydroxyapatite layer when
exposed to tissue fluids, which has been shown to be osteoconductive (Hench et al.,
1971). More recently, Yuan et al., (2001), have demonstrated the limited osteoinduction of
ectopic bone in the muscle of dogs implanted with bioactive glass.
Bioactive glasses have been shown in microarray analysis of primary human
osteoblasts to activate genes associated with bone formation within a few hours of
exposure to bioactive glass dissolution products in a concentration dependant manner
(Xynos et al., 2001). Bielby et al., (2004), have shown that murine embryonal stem cells
cultured in the presence of bioactive glass dissolution products will develop down the
osteoblast lineage to express markers of bone differentiation and form mineralised bone
nodules.
Although glasses demonstrate good compressive strength, they are very brittle and
have poor tensile strength. This makes them unsuitable for fixation purposes but has
shown them to be effective in clinical applications where tensile forces are absent or
minimal including grafting of periodontonal bone defects (Larmas et al., 1995), filling of
frontal sinuses (Peltola et al., 1998), reconstruction of orbital floor fractures (Aitasalo et al.,
2001) and maxillary sinus augmentation (Turunen et al., 2004).
In an attempt to utilse a strengthened formulation of bioactive glass for bone tissue
engineering, work in our laboratory has shown that a composite scaffold consisting of
bioactive glass and PLGA co-polymer, supports growth and progression of bone
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differentiation of cell lines and primary osteoblasts carrying mutations for craniosynostosis.
(Santos-Ruiz et al., 2007).
1.5.4 Bio-material composites
The ability of materials to induce significant regeneration of new bone appears from
the literature to be limited. Hence the hypothesis that cells on polymer scaffolds could give
rise to organised tissue was developed from the observations of Vacanti, (1988) that;
a) all tissues undergo constant remodelling, b) dissociated mature cells can reorganise
themselves into their native histological structure when placed in appropriate culture
conditions, c) this reorganisation is limited by lack of a template to guide restructuring and
d) the volume of tissue that can be implanted is restricted by gas and nutrient
requirements.
Material scaffolds have to date principally acted as carriers and support structures
on which osteoblasts must be able to survive and produce bone, although as will be
discussed later, strategies are being developed to enhance this interaction. In this bio-
composite approach, a scaffold is seeded with osteogenic cells. The interaction which
ensues and subsequent success of the approach, will be dependent upon the chemical
and surface properties of the material, the cell type, and the implant environment.
1.5.5 Surface and chemical properties
The primary interaction between cell and material, involving attachment and
spreading is likely to be highly influential in further proliferation and differentiation and is
therefore of great importance. The initial short term adhesion will involve physical forces
such as ionic and van der Walls forces, followed by longer term molecular interactions
including the material surface, ECM proteins and cytoskeleton proteins (Anselme et al.,
2000) which are likely to act in concert to induce signal transduction to ultimately regulate
gene expression. Initial interaction and subsequent cellular growth is affected by levels of
surface free energy of different materials (Schakenraad et al., 1986) and also by differing
ionic charges between cell types which affects the ability of cells to attach and spread on
solid substrata (Schakenraad et al., 1988). In addition, cells do not interact with bare
materials either in-vivo or in-vitro, and surface energy and charge effects the adsorption
and structural arrangement of tissue fluid proteins on a material (Chesmel et al., 1995;
Boyan et al., 1996; Shelton et al., 1998). The cellular adhesion properties of fibronrctin
(FN) were altered by the surface properties of materials, affecting the ability of endothelial
cells and fibroblasts to spread and adhere (Iuliano et al., 1993; Altankov et al., 1997).
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El-Amin et al., (2003), have demonstrated that PLGA surfaces are more hydrophilic
than a PLA surface and that human osteoblast adhesion to PLGA was significantly higher
than on PLA surfaces. However, this difference became less marked as incubation time
increased post-plating, concluding that cellular adhesion was also dependent on either the
chemical composition that differs between PLGA and PLA, or the accumulation of
degradation products including lactic acid. These authors also found that cells grown on
PLGA produced higher levels of ECM molecules and cytoskeletal organisation than seen
on PLA or tissue culture plastic. It is possible to surmise from these findings that the
different formulations produce varying concentrations of breakdown products which may
differentially effect cellular function.
The surface roughness of materials also causes cells to react differently. Osteoblasts
have been shown to spread and form continuous layers more readily on smooth surfaces
(Naji & Harmand, 1990; Anselme et al., 2000). A smooth surface also appears to benefit
proliferation of osteoblasts with appropriately decreased levels of OC and ALP when
grown on hydroxyapatite or titanium surfaces (DeSantis et al., 1996)
1.5.6 Scaffold modification
Each biomaterial has its own characteristic advantages and disadvantages. For this
reason and in an attempt to optimise physical and regenerative capabilities, workers in the
field have sought to combine properties by producing composite materials. Indeed, natural
bone matrix is an organic-inorganic composite of collagen, matrix proteins and apatites
and it could be postulated that composite materials are the obvious choice for bone
engineering. For example, in an attempt to make glasses structurally more suitable for
bone engineering, material composites of bioactive glasses or apatites and polyesters
have been developed (Kikuchi et al., 1997; Marcolongo et al., 1998; Kellomaki et al.,
2000). Moreover, it has been discovered that the alkaline dissolution products of glasses
and the acidic degradation products of polyesters, can neutralise each other to create a
physiological environment for optimised cell survival (Lu et al., 2003)
The three dimensional (3-D) structure of scaffolds has been considered to be an
important part of scaffold design for bone engineering (Yamamoto et al., 1997; Griffith
2002; Hutmacher, 2000). The scaffold should have a high porosity and interpore
connectivity, to allow a large number of cells to penetrate the scaffold and to allow the
efficient diffusion of nutrients and metabolites to and from the cells (Vacanti et al., 1988).
This has led to the development of numerous scaffold forming techniques including solvent
casting and particulate leaching (Lu & Mikos 1994; Ma & Choi, 2001), gas foaming (Harris
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et al., 1998), freeze-drying (Whang et al., 1995) electro-spinning (Renejer & Chun, 1996;
Boland et al., 2001; Yoshimoto et al., 2003), phase-separation (Nam & Park, 1999) and
rapid-prototyping (Landers et al., 2002).
Further innovative methods of formulating and producing scaffolds with variable
physical characteristics have been described, which can for example successfully trap and
release osteogenic enhancers, principally recombinant proteins, such as BMP-2 and TGF-
ß1 (Tielinen et al., 1999; Oldham et al., 2000). Recently, pre-osteoblasts have been grown
on scaffolds which have incorporated DNA plasmids on PLA based, electrospun nano-
fibers, promising a flexible, biodegradable carrier capable of transfecting adjacent cells
(Shea et al., 1999). Materials incorporating antibiotics have been reported (Overbeck et
al., 1995; Zhang & Zhang, 2002); of particular potential benefit, carriers of antibiotics
against Staphylococcal aureus species, the species having the greatest infective risk for
implanted materials (Kim et al., 2004). However, difficulties have been reported when
incorporating pharmaceuticals or co-materials. These stem from alterations to the material
properties of the carrier, including weakening of constructs upon addition of antibiotics and
the addition of bioactive glasses to polyesters (Tianen et al., 2002, Leinonen et al., 2002).
The surface nature of a material can directly affect cellular attachment, proliferation
and phenotype, which ultimately will affect the ability of a system to regenerate new bone
(Yamamoto et al., 1997). For example, polyesters are poorly hydrophilic, which greatly
effects cell adhesion onto the surface and penetration into the scaffolds (Mikos et al.,
1994). Furthermore, there are no cell recognition sites on the
surfaces of most tissue scaffolds which leads to poor cell affinity and potentially failed
tissue engineering. (Liu et al., 2004). In recognition of this, surface modification is an area
which has received considerable attention in the quest to optimise osteogenisis. This can
be achieved by physico-chemical modification of the material surface or coating of the
material.
1.5.7 Substrates adhesion
Cell-protein-surface interactions are critical to the development of biotechnological
applications including biomaterials and tissue engineering. In many of these applications,
cells interact with proteins synthesised and secreted by cells or adsorbed from
physiological tissue fluid. Cellular interaction with ECM constituents provides signals that
control cell survival, proliferation and phenotypic expression (Werb et al., 1989; Adams &
Watt, 1990). Therefore, extracellular matrix components are likely to be important in
regulating the survival and function of osteoblasts (Meredith & Schwartz, 1997), (Fig 1.9).
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Osteoblast differentiation is partially dependent on adhesion to bone matrix proteins
such as type1 collagen, laminin and fibronectin (Damsky, 1999; Franceschi, 1999;
Zimmerman, 2000). These interactions between matrix proteins and osteoblasts are
mediated in part by a group of transmembrane glycoproteins known as integrins (Plow et
al., 2000) and more specifically the ß1 integrin subunits (Gronthos et al., 2001), which
have been shown to mediate early osteoblast differentiation (Moursi et al., 1997) and
which represent the primary mechanism of cell-ECM interaction across all cell types.
(Hynes, 1992). Many bone ECM proteins including FN and laminin have chemotactic or
adhesive properties, notably because they contain an Arg–Gly–Asp (RGD) sequence
which is specific to the fixation of cell membrane receptors such as integrins which contain
RGD recognition domains (Takada, 1997). Modification of PLA films by attaching RGD
peptide to the surface has led to improved cellular attachment and spreading (Cook et al.,
1997; Quirk et al., 2001).
1.5.7.1 Fibronectin
Fibronectin is widely expressed by multiple cell types and is critically important in
vertebrate development, as demonstrated by the early embryonic lethality of mice with
targeted inactivation of the FN gene (George et al., 1993). Although FN molecules are the
product of a single gene on chromosome 2, the resulting protein can exist in multiple forms
that arise from alternative splicing of a single pre-mRNA that can generate as many as 20
variants in humans (Kosmehl et al., 1996) which are tissue and function dependent (Xia &
Culp, 1994; Sinkin et al., 1995; Price et al., 1998). It is a large dimeric ECM glycoprotein
which has been shown to regulate adhesion, migration and differentiation of an array of
mesenchymal cells (Yamada et al., 1992).
The FN molecule is a dimer of similar or identical subunits crosslinked by a pair of
carboxyl-terminal disulphide bonds. Fibronectin interacts with cell surface receptors and
other ECM components via well defined domains. The amino-terminal domain of FN binds
to collagen, while the carboxy-terminal domains and central cell binding domains which
include the Arg–Gly–Asp (RGD) sequence, have sites for interaction with cell surface
receptors, including selectins, cadherins, immunolgobulins and integrins (Ruhoslahti &
Pierschbacher, 1987, Damsky & Werb 1992; Hynes, 1992).
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Figure 1.9: Interaction of extracellular matrix protein with intracellular signalling and
cell functions via membrane receptors.
This diagram schematically represents the role of ECM protein binding and the influence of
downstream effects via multiple signalling pathways (adapted from van der Flier and
Sonnenberg 2001, Lee & Juliano, 2004)
Fibronectin is a main ligand for integrins and specifically the α5ß1 subunit which only
binds FN (Werhle-Haller & Imhof, 2003). Varner et al., (1995), demonstrated that human
colonic cells overexpressing integrin α5ß1 showed growth arrest which could be reversed
by ligation of this receptor with fibronectin. Activation of the intracellular FAK and ERK2
signalling pathways in CHO cells is directly proportional to the level of FN-integrin binding
(Asthagiri et al., l999). This has been confirmed by Carvalho et al., (2003), who
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demonstrated that enhanced adherence of chicken calvarial osteoblasts to FN, stimulated
FAK translocation from the nucleus to the cytoplasm, with a concomitant increase in
expression of osteopontin. Moursi et al., (1996), showed that the addition of anti-
fibronectin antibodies to cultures of osteoblasts from fetal rat calvaria at confluence
reduced subsequent formation of mineralised nodules to less than 10% of control values
and suppressed the expression of osteocalcin and alkaline phosphatase. The same
authors subsequently showed that this effect was mediated through a decrease in
fibronectin-integrin interaction (Moursi et al., 1997). Yang et al., (2001), demonstrated
increased attachment, spreading and differentiation of osteoprogenitors derived from
human bone marrow cultured on PLGA scaffolds and PLA membranes treated with FN
and the RGD peptide. The attachment and proliferation of MC3T3-E1 osteoblasts onto
polystyrene (Stephansson et al., 2002) and dimethylsiloxane, a synthetic polymer (Toworfe
et al., 2004) has been enhanced by FN coating. Moreover, it has been shown that
disrupting the osteoblast-fibronectin interaction can induce massive apoptosis in
differentiated osteoblasts (Globus et al., 1998). It is therefore apparent that FN is crucial
for expression of the osteoblast phenotype and that cellular attachment, proliferation and
differentiation might be the subject of FN manipulation.
1.5.7.2 Laminin
Laminins are a family of glycoproteins that make up an integral part of the structural
scaffolding of basement membranes in almost every animal tissue. Each laminin is a
heterotrimer of which twelve exist in mammals, assembled from α, ß and γ chain subunits, 
which are secreted and incorporated into cell-associated extracellular matrix (Sasaki et al.,
1988). Like fibronectin, the subunit chains can be alteranively spliced to produce multiple
isoforms (Colognato & Yurchenco, 2000). Laminins bind to other matrix macromolecules,
and have unique and shared cell interactions mediated by integrins, and other receptors
(Henry et al., 2001). Through these interactions, laminins critically contribute to cell
differentiation, cell shape and movement, maintenance of tissue phenotypes, and
promotion of tissue survival. Targeted disruption of laminins causes a wide spectrum of
developmental faults depending on subunit specificity, from early embryonic lethality with
defects in placental vessels, anterior neural tube closure, kidney and limb development
(Miner & Campbell, 2002) to central and peripheral nerve defects, muscular dystrophies
(Sunada et al., 1995) and epidermolysis bullosa (Christiano & Uitto, 1996).
Lundgren et al., (1985), found that after 2 weeks of culture, myocytes seeded on
dishes coated with laminin formed a denser monolayer than those cultured on uncoated
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plastic dishes. These also exhibited spontaneous contraction. Carvalho et al., (2003),
demonstrated enhanced adherence and osteopontin expression of chicken calvarial
osteoblasts cultured on laminin coated polystyrene. They also concluded that of several
substrate coatings studied, laminin was the most efficient enhancer of osteoblast
attachment. Roessler et al., (2001), found that bonding of MC3T3-E1 cells to titanium
dental implants was enhanced by a linear adhesion peptide developed from the laminin
sequence. Interestingly, microarray gene expression studies of MC3T3-E1 cells by Beck et
al., (2001), identified high levels of expression of laminin receptor 1. These reports
suggested that laminin could be a further potential modifier of the osteoblast phenotype.
1.5.8 Cell Strategies
The bio-material composite model for tissue engineering requires a source of cells
with which to seed material scaffolds. Just as the ideal material should possess certain
characteristics, so an ideal profile for any cell type utilised, exists. They should be non-
immunogenic, easily and rapidly expandable in culture and accessible with minimal donor
morbidity and risk (Warren et al., 2004). Cells used may be drawn from a range of
sources, including primary tissues or cell lines such as the murine, calvaria derived
MC3T3-E1 osteoblast like cell line. This line which will be discussed more fully in chapter 4
has been well characterised in terms of its temporal expression of osteoblast related
proteins and has been widely used in studies of osteogenisis.
Primary tissues may be autologous (from the same individual), syngenic (from a
genetically identical individual), allogenic (from a different individual of the same species)
or xenogenic (from a different species). However, the use of xenogenic or allogenic cells is
limited by the need for host immunosupression, although techniques to render cells
immunologically “invisible” may make them a clinical reality for the future.
An area of research which is rapidly developing, involves the potential use of
embryonal stem cells, although ethical issues and ongoing medico-political debate
regarding the further development and implementation of this source, renders them
currently inaccessible (Zoloth, 2002; Walters, 2004). Therefore, cells derived from bone
marrow aspirates are the most likely therapeutic candidates for host derived cells. They
are capable of developing cell lineages producing adipose, muscular and cartilaginous
tissues as well as bone (Prockop, 1997). Shen et al., (2002), has used systemically
administered bone marrow derived cells to enhance healing of long bone fractures in mice.
The remarkable potential to use cells from liposuction of fat, a readily available source, has
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also been reported when Zuk et al., (2001), demonstrated the multi-lineage potential of
human derived adipose cells.
A further potential source of cells in patients would be those derived from the site of
surgery. This would require subsequent enzymatic digestion and culture expansion of
osteogenic cells in much the same fashion that cells are currently derived for research.
This approach however, would only be feasible on ethical grounds, for individuals having
planned multi-staged procedures.
1.6 Hypothesis and study strategy
The need for reconstruction of bony defects following surgery in children with
syndromic craniosynostosis has been established. Very little is known about the
behaviour, interactions and ability of osteoprogenitors carrying FGFR mutations to produce
viable bioscaffolds, which would appropriately regenerate bony defects.
The working hypothesis for the study was that:
Osteoprogenitors carrying mutations for craniosynostosis could be grown on bioresorbable
scaffolds to regenerate bony calvarial defects.
The ultimate long term goal of regenerating critical size cranial bone defects, of which this
study would be an initial part, would require several steps.
In the first instance, the study involved working exclusively with the MC3T3-E1 cell
line. An important first step was to further characterise the osteogenic phenotype of this
line, transfected with the FGFR2-C278F mutation for craniosynostosis and wild type
human FGFR2. This would help clarify whether this model was a suitable one in which to
progress the further work required toward the long term clinical aim.
To accomplish this, the examination of mRNA expression of matrix proteins
produced by the osteoblast phenotype was undertaken using RT-PCR. Subsequently
genes which may have been significantly regulated by the mutation, given the observed
behaviour and morphological appearance of the mutated line were studied. An indirect
immunohistochemistry technique was utilised to assess proliferation of the cell lines.
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Having observed and further characterised the effect that the mutation was having on
the phenotype, these findings directed the attempt at pharmacological manipulation of the
mutated cells, in order to revert or rescue them towards the wild-type (Chapter5). It was
then appropriate to study the growth of these cells on a bioabsorbable scaffold, whilst
exploring potential substrates to enhance osteogenisis. (Chapter 6)
A novel, composite material incorporating an expanded formulation of
polylactide-co-polyglycolide combined with a bioactive glass had been pledged at the
beginning of the project. Unfortunately as the study reached the stage where it was
feasible to proceed to investigate cellular behaviour on the scaffold, it was not made
available. Therefore, following discussion with study supervisors, it was elected to
substitute this novel material with PLGA plates (80:20, PLA:PGA) (Bionx, Tempere,
Finland), which were already being used for craniofacial reconstruction/fixation in our
institution and which were therefore readily available.
Towards the end of the study, the first formulation of this novel material became
available and only initial pilot studies of cellular growth on this material were possible.
The research questions which were to be answered in an attempt to fulfil those first
steps were therefore:
 Did the stably transfected FGFR2-C278F cell line proliferate then differentiate to
express markers appropriate to an osteoblastic phenotype and subsequently
mineralise.
 Could this cell line attach, proliferate and mineralise on a bioabsorbable membrane
in an attempt to assess its usefulness as a model for future study of bio-composite
bone engineering in craniosynostosis.
 Could the attachment, growth and differentiation of these mutated osteoprogenitor
cells on bioresorbable scaffolds be optimised for osteogenisis.
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Chapter 2: Materials
The manufacturers of all materials used are detailed below. The region and country
of the manufacturer is given with the product description. Where the same manufacturer
has supplied multiple items, the region and country will be shown once. Subsequent
references to the same manufacturer will show only the country of manufacture.
2.1: Murine cell lines
MC3T3-E1 pre-osteoblasts and MC3T3-E1 cell lines stably expressing either Human
Fibroblast Growth Factor Receptor 2 (referred to subsequently as “wild-type”- WT) and a
mutated form of the receptor (referred to subsequently as “C278F”) coding for the C278F
missense mutation (Oldridge et al., 1995), were used. Transfection had been carried out in
pcDNA3 plasmid (Invitrogen, Carslbad, California) by electrocorporation and selected
using 200µg/ml of Zeomycin to establish stable cell lines (Santos-Ruiz et al., 2007). All
lines were stored in liquid nitrogen and thawed as required.
2.2: Tissue culture media and equipment
Alpha modification of Eagle’s minimal essential medium with ribosides and
deoxyribonucleosides (-MEM) and Dulbecco’s calcium, magnesium and sodium
bicarbonate-free phosphate buffered saline (DPBS), L-Glutamine, Penicillin/streptomycin
solution (100,000 units per ml), and foetal calf serum (FCS) were all supplied by Gibco
BRL (Paisley, UK). Bovine or calf serum (FBS and FCS, respectively) are the most widely
used growth supplements for cell culture, primarily because of their high levels of growth
stimulatory factors and low levels of growth inhibitory factors. Maintaining successful and
consistent cell fermentations can be difficult, as FBS and FCS are complex natural
products and may vary from lot to lot even from a single manufacturer. Moreover, the
quality and concentration of both bulk and specific proteins can affect cell growth.
Therefore, batches of FCS were tested at the start of the project and a single batch
ordered and used throughout, in all cultures.
Dexamethasone, b-glycerophosphate and ascorbic acid were purchased from Sigma-
Aldrich (Gillingham, UK).
Trypsin –EDTA for cellular dissociation was purchased from Sigma-Aldrich (UK).
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Tissue culture grade Petri-dishes, multiple well plates and other plastics were
supplied by Philip Harris (Stoke, Staffordshire, UK), Nunc Inc (Roskilde, Denmark) and
Helena Bioscience (Sunderland, UK).
2.3: Substrate coating agents
Laminin (L2020), and fibronectin (F2006) for coating of surgical plates and culture
dishes were obtained from Sigma-Aldrich (UK).
2.4: Growth factors
Human recombinant FGF18 (F7301) was purchased from Sigma-Aldrich (UK)
2.5: Bioabsorbable membranes
Surgical grade polyglactide plates used for craniofacial fixation were purchased
from Bionx Implants Ltd (Tempere, Finland). Two formulations of Bioglass/PLGA80
composite membrane were a gift from Bionx Implants Ltd.
2.6: Primary antibody
Anti-phospho-Histone H3 (mitosis marker) rabbit polyclonal IgG was obtained from
Upstate Biotechnology (Buckingham, UK). In all experiments, the antibody was used at a
dilution of 1 in 400. The immunogen used for the antibody production was a KLH-
conjugated peptide corresponding to amino acids 7-20 of the human histone H3, which
recognises the phosphorylated form of histone H3 in vertebrate species
2.7: Secondary antibody
Goat anti-rabbit immunoglobulin was obtained from DAKO Ltd (UK). In all
experiments, the antibody was used at a dilution of 1 in 100.
2.8: Sera as blocking agent
Goat serum was obtained from DAKO Ltd (UK).
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2.9: Other immunohistochemical detection reagents
StreptavadinABComplex/HRP (ABC duet kit), used for the labeling and signal
amplification of secondary antibodies used in H3 staining was purchased from DAKO Ltd
(UK). Diaminobenzidine tetrahydrochlorodihydrate (DAB) tablets, Triton X100 and
paraformaldehyde(PFA) were obtained from Sigma-Aldrich (UK). Alkaline phosphatase
activity was detected by NBT/BCIP purchased from Roche, (Basel, Switzerland). The
combination of BCIP (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt) and NBT
(Nitro-Blue Tetrazolium Chloride) yields an intense, insoluble black-purple precipitate when
BCIP is hydrolyzed by alkaline phosphatase to form an intermediate that undergoes
dimerisation to produce an indigo dye.
2.10: Microscopy and image capture
Cultured cells were observed under a Zeiss SV11 inverted microscope, using
objective lenses of 2.5x, 10x and 32x and photographed using a Yashika 108 multi
program 35mm single lens reflex camera and Kodak TMax 160 colour reversal film or
Fujichrome T64 colour reversal film. Brightfield microscopy was performed on a Zeiss
Axiovert135 microscope (Carl Zeiss, Germany) using objective lenses of 2.5x, 10x, and
20x . Digital images were captured electronically using a Hamamatsu digital camera
(C4742-95, Hamamatsu Photonics KK, Japan), and opened into Openlab software version
3.05 (Improvision, Coventry, UK). Images were saved in formats compatible with Adobe
Photoshop version 6.0 (Adobe Systems Europe, Edinburgh, UK). Images taken on colour
reversal film were scanned digitally using an Epson Film Scan 200 slide scanner and the
associated Twain 32 software (Epson, Hemel Hempstead, UK). Images were processed
using Adobe Photoshop version 6.0 where necessary (Adobe Systems Europe, UK) and
saved to a Macintosh G3 computer.
2.11: Cell Tracker probes
5-Chloromethylfluorescein diacetate (CMFDA) vital cell-tracking dye was obtained
from Molecular Probes (Invitrogen, USA).
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2.12: Mineral detection
Alizarin red, Silver nitrate and sodium thiosulphate were purchased from Sigma-
Aldrich (UK).
2.13: General laboratory reagents
The general reagents used for experimental procedures were Analar grade
supplied by BDH Ltd (UK) unless otherwise stated. Sigma-Aldrich (UK) supplied
diethylpyrocarbonate (DEPC), ethidium bromide, orange G, paraformaldehyde (PFA), citric
acid and hydrogen peroxide. Phosphate buffered saline (PBS) tablets were purchased
from Oxoid (Hampshire, UK).
2.14: Gel electrophoresis and molecular size markers
Agarose powder was supplied by Gibco BRL (UK). Agarose gels were run in the
Horizon horizontal gel electrophoresis system (Gibco BRL, UK). 1Kb ladders for RNA
analyses were either from Gibco BRL (UK), or Bioline (London, UK). Trisma base, glacial
acetic acid and EDTA (used to make Tris acetate EDTA electrophoresis buffer-TAE) were
purchased from Sigma Aldrich (UK). Gel images were captured using AlphaImager1200
computer software (Alpha Innotech Corporation, San Leonardo, Ca., USA).
2.15: Reagents and equipment for RT PCR
Reverse transcriptase, random hexamer primers, deoxynucleoside triphosphates
(dNTPs), RNA inhibitor, magnesium chloride and 10x buffer set, and Taq polymerase were
purchased from Promega (Southampton, UK). Thermostable PCR tubes were purchased
from Elkay Laboratory Supplies Ltd. (Hampshire, UK). PTC-1000 thermal cycler machine
was from MJ Research Inc. (Boston MA, USA).
2.16: Restriction Enzyme
Following a restriction site search using the Promega search resource at:
www.promega.com/guides/re_guide/research.asp?search=seq, the restriction enzyme
BbsI was purchased from New England Biolabs (Hertfordshire, UK) to confirm the
presence of the C278F mutation.
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2.17: Oligonucleotides
Oligonucleotides were custom synthesised by Genosys (Cambridge, UK). The
oligonucleotides presented in Table 2.1 were each designed from published records of
cDNA using the Pubmed nucleotide enquiry facility on:
www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090
The appropriate sequence was then used to design the oligonucleotide forward and
reverse primers with the aid of PRIMER3 software, based centrally at Massachusetts
Institute of Technology on: http://fokker.wi.mit.edu/primer3/input-030.htm
2.18: Centrifuges
Samples were centrifuged in a Heraeus Biofuge 13R (Heraeus instruments, UK) or
a Sigma 113 microfuge (Sigma, Osterode, Germany).
- 71 -
Table 2.1 : Oligonucleotide sequences of primers used for reverse transcriptase
polymerase chain reaction (RT-PCR)
The accession number is underlined. Bold characters indicate the expected product size in
base pairs. Italics indicate the position of the primer sequence relative to the position of the
corresponding base pairs in the cDNA sequence. Primer annealing temperatures used are
shown to the right of the base pair number. All primers are murine cDNA sequence derived
other than hFGF
AlkP AF285233 403bp 56°C
Forward 192-211 5’ ATGGGCGTCTCCACAGTAAC 3’
Reverse 595-576 5’ TTATCCGAGTACCAGTCCCG 3’
Col1 U08020 283bp 56°C
Forward 293-212 5’ GCTTCAGTGGTTTGGATGGT 3’
Reverse 576-557 5’ AGAGCCTCTAGCTCCTTGGG 3’
Cx43 M61896 468bp 56°C
Forward 143-162 5’ GGGTGATGAACAGTCTGCCT 3’
Reverse 602-621 5’ GAGAGGAAGCAGTCCACCTG 3’
FGF18 NM8005 267bp 56°C
Forward 190-209 5’ CCTGCACTTGCCTGTGTTTA 3’
Reverse 457-438 5’ AGCCCACATACCAACCAGAG 3’
GapDH L26492 396 bp 55°C
Forward 151-170 5’ ACTCCACTCACGGCAAATTC 3’
Reverse 547-528 5’ GTCATGAGCCCTTCCACAAT 3’
hFGFR2 Z 71929 630bp 56°C
Forward 413-432 5’ ATGGTGCGGAAGATTTTGTC 3’
Reverse 1042-1023 5’ TAGAATTACCCGCCAAGCAC 3’
NCad M31131 306bp 56°C
Forward 634-653 5’ CGGTTTCACTTGAGAGCACA 3’
Reverse 939-920 5’ CACAGTGATGATGTCCCCAG 3’
OC L24431 214bp 60°C
Forward 51-70 5’ TGAGGACCCTCTCTCTGCTC 3’
Reverse 264-245 5’ GCGTCTGTAGGCGGTCTTTA 3’
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Chapter 3: Methods
3.1: Cell Culture
3.1.1: Sterile technique and culturing
All tissue culture plates, bioabsorbable membranes, dishes, pipettes, containers and
solutions used were sterile. All aliquotting and preparation of plates was performed under
a laminar flow tissue culture hood which had been switched on at least 30 minutes prior to
use, and cleaned with 70% industrial methylated spirit (IMS)/dH20. Clean nitrile gloves
were used during all procedures, and these were regularly sprayed with 70% IMS and
changed periodically. Instruments were flamed in 100% IMS, under the laminar flow hood,
and allowed to cool before use. Manipulation and washing of Bionx plates was carried out
under sterile conditions throughout.
All media and additives prepared and aliquotted into Falcon tubes and dishes were
kept under the laminar flow hood prior to seeding, splitting or feeding of cultures. Cells
were harvested for passage or RNA extraction as follows: Medium was removal from
flasks, adherent cells were washed twice with warmed phosphate buffered saline (PBS)
and released with 0.5% trypsin-EDTA. Cultures were maintained in a humidified incubator
in a mixture of 95% air and 5%CO2 at 37oC. Unless stated otherwise, cells grown for 30
day osteodifferentiation cultures were grown in T-25 flasks, seeded at 12,000 cells/cm2.
Cells grown for pre-confluent studies were seeded at 5000 cells/cm2 in T-75 flasks to
maximise biomass for RNA extraction. Unless otherwise stated, all cells for preconfluent
studies were cultured in standard medium to maximise proliferation (αMEM, 10%FBS,
2mM L-glutamine, 100U/ml penicillin, 50µg/ml streptomycin) Cultures for differentiation
studies were supplemented with 50µg/ml ascorbate and 10mM ß-glycerol-phosphate when
cells became fully confluent.
3.1.2: Freezing and Thawing
Freezing cells involved harvesting them as described above, suspending them at a
concentration of 106/ml in freezing medium containing 10% dimethylsulphoxide (DMSO)
and 20% FBS, aliquoting 1 ml of cell suspension into cryotubes, slow freezing in a -20oC
freezer, transferring and storing the cryotubes overnight at -80 °C and transferring them to
a liquid nitrogen container the next day.
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To thaw frozen cells, vials were removed from liquid nitrogen storage and
immediately placed in a 37°C water bath. The cell suspension was transferred by pipette
to a 15-ml falcon tube and 5 ml of warm medium was added slowly to the tube and mixed
by gentle repeat aspiration. Aliquots of cell suspension were transferred to flasks
containing additional medium and cultured under standard condition. Complete medium
changes were performed after 12 hours of culture and subsequently every 48 hours.
3.1.3: Cell number and viability
Medium from plates, wells or flasks was removed; adherent cells were washed twice
with (PBS) and released with 0.5% trypsin-EDTA solution. Cell number and viability were
determined by haemocytometer count and trypan blue exclusion according to accepted
conventions for cell counting in grids, namely, viable cells crossing the upper and right
hand grid lines are counted and those on the lower and left hand lines are excluded (Fig.
3.1)
Not
counted
Counted
Figure 3.1: Haemocytometer cell counting convention
3.2: Vital cell tracking
Cells difficult to visualise under bright field microscopy were treated with a vital,
intracellular, fluorescent dye to allow observation under ultra-violet light. Live cells were
labelled with CellTracker Green (CMFDA), according to the manufacturer’s instructions.
Cells were incubated at 37oC for 45min in labelling solution (1 μM CMFDA in prewarmed,
serum-free medium), followed by a 45 minutes incubation in normal medium (without
CellTracker). Cells were gently washed with PBS. Labelled cells were put back into the
incubator in normal medium for observations at 520 nm wavelength.
- 74 -
3.3: Cellular proliferation assay
One of the first steps in cell division is the replication of DNA during S-phase of the
cell cycle. Cellular proliferation in cultured cells can be assessed using various techniques.
Direct counting of mitotic cells in haematoxylin and eosin (H&E) stained sections can be a
difficult and time-consuming process. It is especially difficult to distinguish between cells in
prophase and cells undergoing pycnosis or apoptosis in H&E-stained samples. High
magnifications have to be used to distinguish the cycle phases and large numbers of cells
must be counted to obtain statistical validity. This has led to the development of specific
techniques and markers to immunologically identify cell division.
The anti-phosphorylated-H3 antibody is one such method, which recognises histone
H3 after it becomes phosphorylated when the chromosomes condense during cell division.
This technique has been shown to be a sensitive and reliable method for assessing cells
undergoing mitosis (Brenner et al., 2003).
This assay utilises the well established technique of immunohistochemistry, which
relies on the highly specific binding properties of mammalian antibodies to recognise
protein epitopes in fixed cell culture or tissue sections (Polack & van Noorden, 2003).
The indirect technique for detection of the targeted epitope was used (Fig. 3.2). This
method requires a primary and a secondary antibody as well as a visualisation marker to
allow counting of the proliferating cells.The primary antibody is usually an IgG raised
against the epitope of choice, in a mammalian species different from the sample species.
The secondary antibody is obtained from a different species to that of the primary antibody
and conjugated with peroxidase to allow signal detection (Fig 3.2A) in combination with an
avidin-biotin amplification complex and visualisation compound such as diaminobenzidine-
tetrahydrochloride (DAB) (Fig. 3.2B). Further important steps to block endogenous
peroxidase (Fig. 3.2C), charged proteins and non-specific antigens (Fig. 3.2D-E) are
carried out to reduce false positive detection and minimise background staining.
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Peroxidase enzyme (active) Biotin
Peroxidase enzyme (inactive) DAB
Tissue antigen Primary antibody
Non-specific antigen Secondary antibody
Avidin Tissue
C
ED
+
BA
Key
Figure 3.2: Indirect method of immunohistochemical antigen detection
A: The primary antibody binds the targeted epitope which in turn is bound by peroxidase
conjugated secondary antibody. The peroxidase activity is detected by colour development
by incubation with a substrate such as DAB. B: Amplification steps using avidin-biotin
complex can be included to strengthen the signal prior to DAB exposure. C: Hydrogen
peroxide is used to block endogenous peroxidase activity within the tissues. D: Charged
proteins and non-specific epitopes may react with primary antibody, leading to background
staining. E: Treatment with protein-rich serum blocks these non-specific epitopes to
provide a “clean” signal.
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3.3.1: Cellular Fixation
Cell cultures were washed once with PBS and fixed by cold 4% paraformaldehyde
(PFA) in PBS for 30 minutes at room temperature. The PFA was removed and the cells
washed with cold PBS for 10 minutes, 3 times by placing on a rocker-table agitator.
3.3.2: Blocking
Endogenous peroxidase activity was then quenched by incubation of the cells with
3% hydrogen peroxide (H2O2) in 10% methanol in PBS at room temperature for 20
minutes. The H2O2 was removed and the cells washed for 5 minutes, 3 times in PBS. Non-
specific proteins and charged compounds were then blocked by saturating the cells in a
10% solution of goat serum in PBS for 45 minutes at room temperature. The serum was
removed and the cells washed 3 times in PBS at room temperature.
3.3.3 Application of primary antibody
The cells were coated and incubated with a layer of anti-phosphorylated-H3 antibody
at a dilution of 1:400 in PBS overnight at 4oC. Negative controls were treated similarly
without the addition of primary antibody. The following day, samples were thoroughly
washed and agitated on a rocker-table 3 times with 0.5% Triton in PBS, to ensure only
specifically bound primary antibody remained, prior to application of the secondary
antibody. The cells were washed a further 3 times in PBS to remove traces of Triton.
3.3.4: Application of secondary antibody
The cells were then incubated for 45 minutes at room temperature with goat anti-
rabbit IgG diluted to 1:100 in PBS. They were then washed 3 times with PBS before
detection of the secondary antibody.
3.3.5: Antibody detection
Avidin-biotin-peroxidase complex was prepared from an ABC kit according to the
manufacturers instructions, diluted with PBS and allowed to stand for 30 minutes. It was
then added to the samples for 30 minutes before removal and washing with PBS. This
amplification kit confers a fourfold increase in the levels of peroxidase available for
development. Visualisation of the peroxidase tag was then detected by colorimetric
changes due to precipitation of its substrate diaminobenzidine-tetrahydrochloridehydrate
(DAB) which was made up into 5ml solutions with MilliQ water according to manufacturer’s
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instructions and filtered through a 0.4 µm pore filter. Half a mililiter of DAB was added to
each well and allowed to develop for a fixed period for all wells as ascertained by pre-
testing. The DAB solution was removed and wells washed for 5 minutes in PBS before
image capture.
3.3.6: Proliferation count
Once the plates had been processed, triplicates of four random areas per well were
captured digitally, downloaded and stored as TIFF image files onto a Mac G3. The total
number of cells per field and the number of H3 positive nuclei for that field were counted
using the Openlab software point counting option. Briefly, the computer mouse was used
to ‘click’ on each cell. Each ‘click’ labelled the cell with a mark and a number, so that the
user could see which cell, and how many, had been counted for any particular field of
view. To optimise objectivity of H3 counting, the gain/contrast control on the software was
then adjusted to exclude visualisation of cells not positive for H3 and the counting process
was repeated (Fig. 4.6A). This system was adopted to reduce counting error. The counts
were tabulated using Microsoft Excel software, where the H3 positive cells were expressed
as a percentage of the total cell count, using the following equation:
Mitotic Index = number of H3 positive nuclei
total number of cells in field
The data was separated into controls and FGF18 treated cells and transferred into SPSS
(10.0) for statistical analyisis. Proliferation rates were analysed for statistical significance
using analysis of variance between groups (ANOVA) and post hoc tests were carried out
using Bonferroni’s method.
3.4: Growth factor treatment
Human recombinant fibroblast growth factor (FGF) 18 was obtained from Sigma-
Aldrich (U.K.) and used for the treatment of cultured cell lines. Concentrations of FGF 18
between 10-10M and 10-8M were first prepared to ascertain a treatment range for
experimentation. The level of foetal calf serum (FCS) required to maintain viability of the
cells during experimentation was determined at 24 and 72 hours post treatment, using
FGF18 at a concentration of 10-9M.
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For experiments, triplicate samples of cell lines were seeded at 12,000 cell/cm2 in
normal culture medium. This was replaced after 12 hours following washing in PBS at
37oC, by experimental medium containing 2% FCS and FGF18 at differing concentrations.
Proliferation assays using anti-phosphorylated-H3 were carried out as described in
section 3.3 and a mitotic index calculated for each treatment condition
3.5: Bioabsorbable membranes
Bioabsorbable fixation plates or composite membranes provided by Bionx (Finland)
were removed from sterile packaging and manipulated under the tissue culture hood at all
times. Materials were divided for experimentation into equal portions, marked and cut with
a scalpel blade (Figure 3.3). The materials were placed in tissue culture wells and the
wells seeded with cells at the experimental concentration. For experiments lasting several
days, cells were allowed to attach for 12 hours before gently washing the materials with
PBS at 37oC to remove unattached cells and placed in a fresh well and medium to allow
only cells originally attached to the material to be included. Medium was changed every 48
hours. For measurement of seeding efficiency with membrane coatings, the material was
removed from its original well, gently washed in PBS at 37oC and cells detached with
warmed 0.5% trypsin-EDTA. Cells were counted as described in section 3.1.3. Staining for
markers of mineralisation was carried out as described in section 3.7.
Figure 3.3 : Commercially available resorbable bone fixation plates
A. BioSorbPDX, co-polymer, Polyglycolic(20%)/Polylactate(80%) plates supplied as sterile
packed implant. 800µm thick with 1.5mm screw holes.
B. Supplied plates were divided by sharp, sterile scalpel to provide single hole
fragments of 5mm diameter. Scale bar = 5mm
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3.6: Membrane coatings
Pre-treatment of culture dishes and bioabsorbable membranes with fibronectin or
laminin was performed by adding 0.5ml of 0.01% solutions of laminin or fibronectin to
tissue culture wells to allow total surface wetting, followed by removal of the excess.
Dishes were then allowed to air dry for 1 hour under the tissue culture hood, prior to
seeding of cells. PLGA bioabsorbable plates were coated by immersion into a solution of
either laminin or fibronectin at the above concentration, allowed to drip excess for 2
minutes then transferred to a culture plate to air dry before transferring to the centre of a
fresh culture well prior to the seeding of cells. Cells were released for collection or
counting as described in section 3.1.3.
3.7: Staining for mineralisation
3.7.1: Von Kossa
This method relies upon the principle that silver ions can be displaced from solution
by carbonate or phosphate ions due to their respective positions in the electrochemical
series. The argentaffin reaction is photochemical in nature and the activation energy is
supplied from strong visible light. Since the demonstrable forms of tissue carbonate or
phosphate ions are invariably associated with calcium ions, this method can be considered
as demonstrating sites of tissue calcium deposition. Cultures were washed 3 times in PBS
for 2 minutes on a rocker-table. Cells were then fixed with 4% PFA in PBS for 30 minutes
and washed 3 times with 10mM Tris-HCl, pH 7.2. Fixed cells were incubated with 5%
silver nitrate for 1 hour under a halogen lamp, washed 3 times in PBS and then treated
with 5% sodium thiosulphate. Cells were imaged using bright field microscopy and images
captured on colour reversal film.
3.7.2: Alizarin Red S
Following removal of medium, plates were gently washed with PBS 3 times and fixed
with 4% PFA for 30 minutes, The PFA was removed and the plates washed again 3 times
with PBS. Alizarin Red S stain was added at a concentration of 1% at pH 4.2 for 10
minutes at room temperature, then washed 3 times with distilled water and once with PBS
before visualisation with bright field microscopy and image capture with colour reversal
film.
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3.7.3: Alkaline phosphatase
Alkaline phosphatase activity was detected by NBT/BCIP staining. Plates were gently
washed once in PBS and then fixed with 4% PFA in PBS. They were then washed 3 times
for 5 minutes in PBS at room temperature on a rocker-table and incubated for 10–30
minutes at room temperature in 0.0375 μg/ml NBT + 0.0188 μg/ml BCIP dissolved in 100
mM Tris–HCl buffer, pH 9.5, containing 5 mM MgCl2. All plates were developed for the
same period of time. The reaction was stopped by washing 3 times in buffer followed by 3
times in distilled water. Plates were then imaged using bright field microscopy and
captured on colour reversal film
3.8: RNA analysis
All solutions for RNA work were made using diethylpyrocarbonate (DEPC) treated
water. DEPC is a potent inhibitor of ribonucleases (RNAse) which rapidly degrades RNA
molecules. 1ml DEPC was added to 1L MilliQ water. This was incubated at 37 °C
overnight to kill the RNAse. The DEPC in the treated water was finally degraded to ethanol
and carbon dioxide by autoclaving. All reagents used for RNA extraction were kept
separate from other laboratory agents to reduce the risk of RNAse contamination. RNAse-
free equipment was used throughout the procedure.
Total RNA was extracted from cultured cells using TRI-REAGENT. TRI-
REAGENT promoted the formation of RNA complexes with guanidinium and water
molecules, and inhibits hydrophilic interaction between the DNA and protein. The RNA
was isolated in the aqueous phase, which was subsequently removed and purified.
3.8.1: RNA extraction from cultured murine lines
All tissue culture media was removed from the culture flasks or plates. One mililiter of
0.5% trypsin-EDTA was added to each flask or plate and returned to a humidified tissue
culture incubator, at 37 C in 5% CO2 for 5 minutes. The samples were then gently
agitated to aid release of the intact cells which were then collected after the addition of 5
ml of PBS. This suspension was spun at 1000 G for 5 minutes. The supernatant was
discarded, and all traces of liquid removed from the cells using a fine glass pipette. 1 ml of
TRI REAGENT™ was added to the cellular pellet, and repeatedly pipetted for several
minutes and vortexed to promote complete cell lysis. The sample was either stored at -
80oC for later RNA extraction or left for 5 minutes at room temperature, treated with 200 l
chloroform, vortexed and centrifuged. Samples were left to stand at room temperature for
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15 minutes, in order to optimise the separation of RNA, DNA and proteins and then
centrifuged at 12,000 rpm for 10 minutes at 4C. The top aqueous layer containing the
RNA was removed carefully by pipette and put into a separate Eppendorf tube. Five
hundred microlitres of isopropanol was added to this in order to precipitate the RNA. The
extract was centrifuged at 12,000 rpm for 10 minutes at 4 C. The resultant RNA pellet
was visualised, and the supernatant removed. The pellet was washed gently in 1 ml of
75% ethanol in DEPC water and centrifuged at 12,000 rpm for 2 minutes. The supernatant
was removed completely, and the last traces of liquid were left to evaporate from the pellet
for several minutes before gently re-suspending the RNA in 20-50 l of DEPC water. The
concentration of RNA was then evaluated by measuring the absorbance at 260 nm
wavelength using a Genequant spectrophotometer. The quality of RNA extraction was
determined periodically throughout the study by running samples on agarose gel
electrophoresis. Intact total RNA run on a denaturing gel will have clear 28S and 18S
ribosomal RNA bands (Figure 3.4 A) whereas degraded RNA demonstrates smeared,
drawn-out bands. While crisp 28S and 18S RNA bands are indicative of intact RNA, visual
assessment of the 28S:18S rRNA ratio on agarose gels is somewhat subjective because
appearance of RNA bands is affected by electrophoresis conditions, amount of RNA
loaded, and saturation of ethidium bromide fluorescence. Hence, the RNA quality was
further determined periodically by a colleague testing samples in an Agilent Technologies
2100 Bioanalyzer (Figure 3.4 B). This uses a combination of microfluidics, capillary
electrophoresis, and fluorescence by the addition of an RNA specific dye, to evaluate both
RNA concentration and integrity.
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Figure 3.4 Determination of RNA quality
A: Extracted RNA was run on a denaturing gel. Characteristic 18S and 28S bands of
ribosomal RNA are clearly demonstrated.
B: 18S and 28S peaks are prominent and RNA concentration is determined by
spectrofluorescence.
MC3T3 WT C278F
d5 d d5d2 d20 d2L
28S
18
A
B
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3.8.2: Reverse transcription polymerase chain reaction
The reverse transcription polymerase chain reaction (RT-PCR) is a powerful
molecular technique that is widely used to assess gene transcription in whole embryos,
tissues, or isolated cells. The technique allowed for highly specific and sensitive
amplification of specific mRNA transcripts. RT-PCR was very useful in the detection of low
amounts of mRNA, that would not be detected using other methods such as Northern
blots. The RT-PCR method involved an initial reverse transcription (RT) step in which all
mRNA transcripts were reverse-transcribed by a retroviral enzyme using specific primers,
short random hexamers or oligo-dTs as primer templates (Fig.3.5). This process lead to
the formation of a set of double helices, each made up of the original mRNA template, and
its complementary strand of newly transcribed cDNA. Subsequently, the cDNA of interest
was separated from the mRNA and amplified exponentially using gene-specific primers
and a thermo-stable DNA polymerase enzyme (Fig.3.6).
3.8.2.1: Reverse transcription
Reverse transcription (RT) involved the synthesis of complementary DNA (cDNA)
using single stranded RNA as a template, as illustrated in Figure 3.4. The Maloney murine
leukaemia virus (M-MLV) reverse transcriptase was used for all RT reactions. Using
RNAse-free equipment, 1 g of RNA, made up to 10 l with DEPC water, was added to 1
l of 100 pmol random hexamer primers (pN6) in a 0.5 ml microfuge tube. The tube was
placed into a PCR thermal cycler and heated to 70 C for 10 minutes. This step removed
secondary mRNA structure. The reaction mix was cooled rapidly on ice. 9 l of a mix
containing 4 l of 5x first strand buffer, 2 l of 100 mM dithiothreitol (DTT), 1 l of 10 mM
deoxynucleoside triphosphates (dNTPs), 1 l of RNAse inhibitor and 1 l M-MLV RT (20
U) was added. This was incubated at 42C for an hour then heated to 95 C for 10 minutes
to destroy the RT enzyme. The RT products were stored at –20 C until use.
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Key
5’ AAAAAA3’
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3: Primers anneal, and reverse transcriptase transcribes cDNA
strands from the mRNA templates
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5’
AAAAA A3’5’
2: Add RT enzyme, primers, oligonucleotides and buffers
Figure 3.5: The reverse transcriptase reaction
1: Linearisation of extracted mRNA by denaturation. 2: Addition of reverse transcriptase,
random hexamer primers, oligonucleotides and buffer to the reaction mixture. The primers
become annealed to their complementary base pairs on the mRNA transcripts. 3:
Transcription of complementary strands of cDNA for each mRNA molecule present in the
extract.
(Adapted from Molecular Biology of the Cell, Alberts et al., 2002)
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Non linear cDNA
Linear cDNA
3’ - 5’ primer
5’ to 3’ primer
Key
Figure 3.6: The polymerase chain reaction.
A: The cDNA templates were heated to denature and separate the strands. B: Upon cooling
the reaction mix, primers corresponding to the cDNA of the gene being studied annealed to
the cDNA template. C: DNA polymerase then transcribed a complementary strand of DNA. D:
Re-heating the mixture separated the strands. Upon cooling, more primers annealed to the
newly transcribed strands, and the process of DNA replication began again (E). The process
was repeated many times (F,G,H) ranging from 24 - 36 cycles resulting in amplification of
cDNA strands transcribed. The process was finished with a ten minute polishing step.
Samples were stored at 4 °C prior to gel electrophoresis. Adapted from Molecular Biology of
the Cell, Alberts et al., (2002).
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3.8.2.2: Polymerase chain reaction
The Polymerase chain reaction (PCR) was used to amplify and detect specific cDNA
molecules from the many that had been reverse-transcribed from the mRNA template
during reverse transcription. This specificity was attained by the binding of primer pairs to
the cDNA template of interest (Fig.3.6). The integrity of RNA used in each RT reaction
was verified by amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a
house keeping gene believed to be expressed in all cells at constant levels.
3.8.3: Primer design
Primers were designed from cDNA records published in original papers, or from an
online ‘Pubmed Nucleotide Enquiry’ (Table 2.1). Primers consisted of 19-22 bases, and
flanked specific regions of the cDNA of interest, usually spanning a region of 350 to 650
bases. cDNA sites were chosen to cross intron/exon boundaries, in order to detect
potential contamination by genomic DNA. The expected product sizes for genomic DNA
and cDNA would be very different, allowing detection of genomic DNA contamination of
the sample. Primers were selected to have approximately 55% guanidine or cytosine
residues. Complementarity between primers was avoided to prevent the formation of
primer dimers, which could disrupt the efficiency of the polymerase chain reaction.
Generally, the primer concentration was 50 pM in a 50 l reaction.
The primer annealing temperature can affect the stringency of primer/cDNA
interaction. The optimal annealing temperature was calculated from the nucleotide
composition of the primer using the following formula:
Annealing temperature (°C) = 4 (G+C) + 2 (A+T) – 5.
The temperature calculated was not always that used for the primers in this study,
although it was a convenient starting point for optimising the temperature for each primer.
Annealing temperatures were optomised by running a PCR for each set of nucleotides at
1oC increments above and below the formulaic derived temperature. Annealing
temperatures of primer pairs were kept the same, thus permitting annealing (and therefore
transcription) at the same rate for each strand.
Having chosen the optimum annealing temperature for each primer pair, it was important
that visualisation of bands under U-V light should be within the linear intensity spectrum for
any particular gene being expressed. Therefore for every gene being studied, a linear
range diagram was drawn using 5-cycle PCR increments. The mid-point between
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non-detection and maximum intensity was chosen as the number of cycles (n) for each
individual gene being studied (Figure 3.6).
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Figure 3.6: Linear range of band intensity for Osteocalcin (OC)
A: PCRs products observed under U-V light at 5 cycle increments
B: Band intensities are measured using Alphaease software and a linear range diagram
constructed. The mid-linear point is chosen as the number of PCR cycles for this gene
(n = 33 for OC)
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A ‘master mix’ of PCR reagents was made up at 4 °C prior to dispensing into separate
tubes and the addition of cDNA. This was to ensure that all tubes had exactly the same
proportions of PCR reagents. The master mix for a typical 25 l reaction is given in Table
3.1. Four microlitres of cDNA (50 l reaction) or 2 l cDNA (25 l reaction) was then added
to each tube. These were placed into a thermal cycler with a heated base and lid for DNA
amplification. Table 3.2 illustrates a typical PCR cycle programme. Samples were kept at
4 °C prior to band separation and detection using agarose gel electrophoresis.
Reagent 1 X 25 l reaction
DEPC water 15.9 l
MgCl2 1.5 l
MgCl2 -free buffer 2.5 l
dNTPs 2.5 mM 2.0l
Forward primer 0.5 l
Reverse primer 0.5 l
Taq polymerase 0.1 l
Total per reaction 23 l
Table 3.1: PCR reagents
The reagents were first made up as a master mix, before addition to individual PCR
reaction tubes. This maximised consistency of reagents between reactions. 2 l cDNA was
added in a 25 l reaction mix and 4 l cDNA was added per 50 l reaction mix.
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Temperature Time Function
1) 95 °C 5 minutes (denatures secondary structures)
2) 95 °C 30 s (separates cDNA strands)
3) 55-56 °C 30 s (primer annealing)
4) 72 °C 40 s (Taq transcribes cDNA)
5) 72 °C 10 minutes (completion of all cDNA strands)
Table 3.2: Normal thermal cycling programme
The thermal cycler follows steps 1 to 6, cycling ‘n’ times between steps 2 and 4, before
advancing to the polishing step (5)
3.9: Mutation confirmation with restriction enzyme
Restriction enzymes, mostly purified from bacteria, recognise specific DNA
sequences and cleave the DNA either within the sequence or at a specific site flanking that
sequence. Therefore the number and size of the fragments produced by the digestion
depend on the frequency and position of the restriction sites.
The restriction enzyme BbsI was used periodically to confirm the presence and
absence of the mutation within the C278F and WT cell lines respectively. Following
amplification of the hFGFR2 gene, the RT-PCR products were then incubated with BbsI at
room temperature for 30 minutes. The products were run on agarose gel and imaged as
described in section 3.10 and 3.11.
3.10: Agarose gel electrophoresis
Agarose gels for electrophoresis of amplified cDNA were made by heating 1.2 g pure
agarose in 100ml tris-acetate-EDTA electrophoresis buffer (TAE) with 0.0025% ethidium
bromide (1 l /ml) for 1.5 minutes at full power in a 700 W microwave oven. The liquid gel
was allowed to cool slightly, and poured into a gel mould. Appropriate sized combs were
fitted, and the gel was left to set at room temperature for at least 1 hour. The finished gel
was placed into an electrophoresis tank, containing 800 ml TAE and 0.0025% ethidium
bromide. 2 l of orange G solution (10 g sucrose, 50mg orange G, 5mg sodium azide in 20
ml H2O) was added to 12 l PCR product.
Cycle
number
(n)
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This mix was carefully loaded into the wells in sequence. A 1kb DNA ladder was put
into the first well of each lane, so that the size of cDNA products could be determined. The
voltage was set to approximately 100mV, and the current applied. The cDNA was left to
migrate towards the anode through the agarose gel for an appropriate period
(approximately 1 hour), to allow adequate separation of the 100Kb bands of the
hyperladder.
3.11: Band detection and semi quantification
Ethidium bromide intercalates between molecules of DNA and is fluorescent under
long wave ultra violet (UV) light. This permitted visualisation of the DNA bands. Large gels
were divided into six to allow centralisation of groups within the UV imager. They were
then exposed to UV and captured digitally using the Alpha-Imager and Alphaease 3.3
software imaging system to allow measurement of band intensity and extrapolation as a
semi-quantification of PCR product.
3.12: Statistical analysis
Statistical analysis was performed by entering data initially into Microsoft™ Excel
spreadsheets and then uploading this data into SPSS (version 14.0) statistical package
software (SPSS inc., Chicago) with appropriate statistical tests applied such as analysis of
one way variance (ANOVA) with Bonferonnis’ post-tests for intergroup analysis.
Bonferonnis’ method was chosen as it is a simple method, valid for equal and unequal
sample sizes and is considered a powerful method for determining significant difference
when the number of groups being compared is small. A value for P < 0.05 was regarded
as statistically significant. All data are expressed as mean + standard error (SE).
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Chapter 4: Characterisation of osteoprogenitor cell lines
4.1: Introduction
Bone formation is a complex biological process which progresses through distinctive
developmental stages, from commitment of mesenchymal derived cells into the
osteoprogenitor lineage, followed by mitotic proliferation, through to expression of the
osteoblast phenotype and ultimately as terminally differentiated osteoblasts producing
mineralised extracellular matrix (Tonna, 1961; Owenm 1990; Aubin, 1995). Understanding
the processes of proliferation and differentiation, in tandem with further comprehension of
signalling pathways are fundamental to the understanding of normal osteogenisis and
pathological osteogenisis, such as that seen in craniosynostosis. This has been advanced
by the development of immortalised cell lines. These overcome the limitations of malignant
cell lines, which fail to display the normal coupling of differentiation and growth arrest and
of primary cell cultures in which data interpretation can be difficult, due to the presence of
various cell populations and tendency to lose osteoblast characteristics following repeated
subcultivation (Aronow et al., 1990). Furthermore, stable cell lines provide an unlimited
supply of material for study. This latter point is important, as the supply of primary bone
from patients suffering from craniosynostosis is limited by the small numerical chance that
any given individual mutation would present more than once for surgery to our institution,
within the research period.
The MC3T3-E1 cell line, derived from newborn murine calvaria is a well established,
stable cell line, which has been shown to display the osteoblast phenotype following
repeated passages (Kodama et al., 1981). They proliferate until confluent then differentiate
and can be induced to mineralise in a fashion which resembles membranous bone
formation (Sudo et al., 1983). This line has been well studied and characterised in terms of
phenotype and temporal pattern of expression of bone related proteins. Quarles et al.,
(1992), showed that sparcely seeded MC3T3-E1 cells undergo marked cell replication
without expression of alkaline phosphatase (ALP) or accumulation of significant
mineralised extracellular collagenous matrix during days 1-9 in culture. During days 9-16,
they undergo osteoblastic differentiation that is characterised by rising ALP activity and
osteocalcin (OC) secretion. After day 16, the mineralisation of extracellular matrix marks
the final phase of osteoblast phenotypic development (Fig. 4.1). This work has been
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largely confirmed by others, although the temporal stages and phases of marker
expression can be variable depending on seeding density, clonal selection drift and
numbers of passages (Choi et al., 1996; Beck et al., 1998; Wenstrup et al., 1996; Peterson
2004). Moreover, within our laboratory (Petoit A., PhD), we have generated an MC3T3-E1
cell line stably expressing the wild type human FGFR2 (WT) and to mimic the
craniosynostotic phenotype, FGFR-C278F (C278F), a mutated human FGFR2, found in
patients with Crouzon, Pfeiffer and Jackson-Weiss syndromes (Oldridge et al., 1995;
Steinberger et al., 1996; Passos-Bueno et al., 1998). In this mutation, the cysteine at
position 278 in the third immunoglobulin-like extracellular domain IIIa of FGFR2 is replaced
by a phenylalanine, causing constitutive activation of the receptor as described in chapter
1.
Days post induction
300 10
Matrix Deposition
Proliferation Mineralisation
Figure 4.1: Schematic representation of MC3T3-E1 development in culture
Plated osteoblasts initially undergo rapid proliferation with progressive deposition of
extracellular matrix, followed by a time dependent decrease in replication with a
concomitant increase in extracellular matrix deposition. Finally matrix mineralisation
predominates (time-line from Quarles et al., 1992; Choi et al., 1996)
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In the context of our long term aims of developing autologous, engineered scaffolds
for clinical use, the aim of the work described in this chapter was therefore to better
characterise the behaviour of osteoprogenitors carrying this mutation for craniosynostosis
and assess their viability as a model for studying the effect of FGFR2 mutations on cellular
behaviour and osteogenisis. This would ideally inform the development of potential
strategies to modify the behaviour of mutated cells if required.
4.2: Results
The three cell lines were grown under standard culture conditions or in the presence
of mineralisation medium. They were assessed morphologically, for their ability to form
ossification centres and mineralise and for the expression of cell-cell adhesion molecules,
markers of osteodifferentiation and a fibroblast growth factor.
4.2.1: hFGFR2 expression
Prior to assessing the expression of all molecules being investigated, it was
necessary to confirm that the cell lines were expressing the hFGFR receptors expected.
This was performed by adding a restriction enzyme to the PCR amplified products of
hFGFR2. The sequence 5’-GTCTGC-3’ is replaced by 5’-GTCTTC-3’ in the C278F cells.
This is recognised by the BbsI enzyme, creating two fragments. The results confirmed that
both the WT and C278F cells produce the hFGFR2 product which is absent in the MC3T3-
E1 cells. The restriction site enzyme cut the mutated hFGFR2, but not the wild type
receptor product, confirming there was no significant cross contamination of cell lines and
that the mutated hFGFR was expressing (Fig. 4.2).
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Figure 4.2: Confirmation of hFGFR2 receptor
RT-PCR for FGFR2 was performed on all three cell lines. Expression of hFGFR2 was
detected as amplification of a 630 bp product. This was treated with the restriction enzyme
BbsI, digesting the product to 420 bp and 210 bp fragments. The samples were run on a
2% agarose gel. L = DNA ladder to determine approximate length of amplified cDNA.
RE= Restriction enzyme BbsI. Negative control (–ve) consisted of DEPC water in place of
cDNA
4.2.2: Morphology
All cell lines were cultured in normal media as described until confluent and
supplemented with ascorbate and ß-glycerol-phoshate thereafter and monitored daily for
survival and growth. Initial cultures on plastic revealed that MC3T3-E1 and WT cells
appeared to grow well on a medium change regime of every 3rd or 4th day. However,
C278F cells did not thrive on this regime. There was notable early acidification of media
indicated by a change in media colour. This required a change to an alternate day feeding
regime, which was applied for all lines thereafter.
There were marked difference in the gross appearance and attachment behaviour
between the lines: C278F cells carrying the craniosynostotic mutation appeared to adhere
less well than either the untransfected MC3T3-E1 cells or the WT cells carrying the non-
mutated human FGFR2 receptor. MC3T3-E1 and WT cells attached evenly to plastic
L WT C278F MC3T3
Gap GapGaphFGF hFGF hFGF
WT C278F -ve
+RE +RE
630 bp
210 bp
420 bp
396 bp
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within 2-4 hours developing a fibroblastic, elongated morphology, typical of proliferating
osteoblasts (Fig. 4.3 A-B) In contrast, C278F cells (Fig. 4.3 C) attached poorly at first,
requiring 4-6 hours before significant attachment was observed. However, they
subsequently grew at a rate which appeared similar to the growth of the other lines. This
was confirmed by measures of plating efficiency (Fig. 4.4).
The mutated cells did not develop such an elongated or dendritic morphology and
unlike the evenly distributed MC3T3-E1 and WT cells (Fig. 4.3 D-E), they formed
aggregates (Fig. 4.3 F). Further proliferation demonstrated that MC3T3-E1 and WT cells
reached confluence after 4-5 days of culture, whereas C278F cells never became fully
confluent under normal conditions. There was an apparent high level of cellular death in
the C278F cultures, heralded by the vacuolated appearance of cells and subsequent
appearance of floating dead cells and cellular debris not seen in the MC3T3-E1 or WT
cultures.
C278F cells aggregated and proliferated in distinct condensations which progressed
to form multilayered nodules (Fig. 4.3 I). Nodular areas developed less obviously in the
MC3T3-E1 and WT cultures (Fig. 4.3 G-H). During all phases of growth, although more
prominently in the differentiating phase, the observed number of dead cells and cellular
debris was greatest in the C278F cultures.
When cells were released from plastic, MC3T3-E1 and WT cells detached similarly.
However, C278F cells detached more readily after approximately half the exposure period
to trypsin-EDTA. This raised the possibility that cell-cell and cell-substrate adhesion
molecules may be functioning differently in mutated cells. It was also noted that the
mutated cells appeared less tolerant to release from plastic by trypsinisation than the
MC3T3-E1 and WT lines, with a visibly higher proportion of cells not surviving the process.
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Figure 4.3: Morphology of MC3T3, WT and C278F cells
MC3T3-E1 (A,D,G) WT (B,E,H) and C278F (C,F,I) cells from a second passage post
plating were seeded at 12,000 cells/cm2 and grown in αMEM containing 10% FCS
until confluent (designated day 0). Medium was then supplemented with 50µg/ml (final
concentration) ascorbate and 10 mM ß-glycerophosphate. Cells were imaged by
phase contrast microscopy at 4 hours post plating (A-C), Pre-confluence(PC) (D-F)
and 21 days post confluence (G-I). Arrows (F, I) indicate areas of nodule formation.
Scale bars are 25µm in A-C and 200µm in D
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4.2.3: Plating efficiency
MC3T3-E1 cells showed the most efficient attachment. Mutated cells attached poorly
in comparison with MC3T3-E1 and WT cells. This was statistically significant at 1, 2 and 4
hours. However, mutated cells appeared to demonstrate “catch-up” growth when attached,
suggesting their proliferative rate may be greater than that of the MC3T3-E1 or WT cells.
At 4 and 8 hours for MC3T3-E1 cells and at 8 hours for WT cells, the number of cells
attached was greater than 100%, reflecting that these cultures had undergone mitotic
expansion beyond losses due to cell death and non attachment.
Figure 4.4: Plating efficiency of cell lines
Cells were plated at 12,000/cm2 in standard medium. Detached cells were counted at 1,2,4
and 8 hours following seeding. Data are expressed as the mean + SEM for each group.
Statistical differences among treatment groups were evaluated using analysis of variance
(ANOVA) and the significance of differences was determined by post hoc testing using
Bonferroni’s method. S = significant (p < 0.05 was considered significant)
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4.2.4: Cellular Proliferation
Initial observations of the behaviour of the cell lines and indications from measures of
plating efficiency, suggested that despite poor early attachment, mutated cells exhibited
“catchup” growth.
Studies have identified that FGF/FGFR signaling has profound effects on cellular
growth and differentiation and therefore it might be expected that the C278F cells would
exhibit altered proliferative characteristics compared to the wild-type.
To study proliferation in the C278 cells, the mitotic index was studied using anti-
Histone-H3 antibodies. Monoclonal antibodies directed against histone H3 phosphoserine
have been used to visualise mitotic chromosomal condensations to provide staining
indices that correlate well with simple mitotic indices (Chadee et al., 1999, Hirata et al.,
2004). The phospho-H3 antibody recognises histone H3 after it becomes phosphorylated
on serine 10 when the chromosomes condense during prophase, (Strahl & Allis, 2000).
Histone H3 remains phosphorylated until telophase, at which time it becomes
dephosphorylated by specific phosphatases (Cunningham, 2002).
This study revealed a greater mitotic index for C278F cells (Fig. 4.5) which became
statistically significant at day 2 (Fig. 4.6).
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Figure 4.5: Phosphorylated histone 3 (p-H3) immunostaining of osteoblasts
Histone staining of mitotic chromosomal condensations of cell lines at 24 and 48 hours
after plating in normal medium at 12,000 cells/cm2. Four random areas per well (triplicate
samples) were counted to give 12 counts for each cell line and time point. A negative
control (no primary antibody applied) for each time point was included (not shown). Images
obtained by phase contrast microscopy. Scale bars = 50 µm
Day 1 Day 2
MC3T3
WT
C278F
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Figure 4.6: Measurement of Mitotic Indices for MC3T3-E1, WT and C278F cell lines
A. Example (WT cells at 48hours) of method to count H3 positive cells. All cells (a) were
counted using Openlab software “click counting” facility. This was repeated (b) following
adjustment of gain and contrast levels to show only cells demonstrating H3 positivity.
Images obtained by phase contrast microscopy. Scale bars = 50µm
B. Mitotic index expressed as % of positive cells/total cell count. Data are expressed as the
mean + SEM for each group (n=12). Statistical differences among treatment groups was
evaluated using SPSS (version14.0) (SPSS inc., Chicago, USA) software by analysis of
variance (ANOVA) and the significance of differences was determined by post hoc testing
using Bonferroni’s method. S = significant (p < 0.05 was considered significant)
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4.2.5: Matrix mineralisation
The mineralisation of matrix proteins is of fundamental importance in osteogenisis as
would be the ability of any potential cell based biomaterials to remineralise in an
appropriate manner when implanted.
Quarles et al., (1992) and Choi et al., (1996), demonstrated that the MC3T3-E1 cell
line start to produce calcified nodules at approximately day 16 in differentiation culture
medium. Osteoblasts carrying mutations in FGFRs appear to mineralise matrix in a
manner which is dependent upon the specific mutation involved (Fragale et al., 1999).
Cell cultures were stained for Alizarin-S Red and von Kossa to attempt to reveal
areas of matrix mineralisation. In the case of Alizarin, a complex which displays a
red/orange birefringence is formed between calcium and Alizarin via its sulphonated and
hydroxyl groups. The reaction is not strictly specific for calcium, since magnesium,
manganese, barium, strontium, and iron may interfere, but these elements usually do not
occur in sufficient concentration to interfere with the staining. Furthermore, calcium-binding
proteins and proteoglycans are also detected by this stain.
The von Kossa technique which is widely used, relies on the binding of positively
charged silver ions with negatively charged phosphate and carbonate ions which act as a
surrogate for calcium. These are observed as black/brown deposits. However, caution
should be exercised in interpretation, as the presence of phosphate per se does not
necessarily imply the presence of calcium or hydroxyapatite.
At 21 days post confluence, C278F cells were observed showing well developed and
discrete calcified nodules (Fig. 4.7 C,F,I) whereas much more limited nodule formation
and calcification was seen in the MC3T3-E1 (Fig. 4.7 A,D,G) and WT (Fig. 4.7 B,E,H)
cells, which demonstrated a more homogenous pattern of staining. All attempts to show
mineralisation at 30 days were unsuccessful, due to detachment of the 30 day cultures
during the fixation and staining process.
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Fig 4.7: Alizarin S Red and von Kossa staining for mineralisation
MC3T3-E1 (A,D,G), WT (B,E,H) and C278F (C,F,I) Cells at 21 days post confluence,
unstained (A-C), stained with Alizarin (D-F) and von Kossa (G-I). The mutated cell cultures
(C,F,I) produced well developed nodules (Arrows) which stain for Alizarin S (AS) and von
Kossa (vK) within a background of cells which did not reached full confluence. The
MC3T3-E1 (A,D,G) and WT (B,E,H) cells exhibited very limited development of nodules
with a more homogenous pattern of mineralisation. Images obtained by phase contrast
microscopy. Scale bars = 200µm
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4.2.6: mRNA expression of osteodifferentiation markers
4.2.6.1: Collagen 1a1
All lines expressed collagen1a1 from the pre-confluent stage through to day 30 (Fig.
4.8). MC3T3-E1 cells expressed collagen at significantly higher levels from day 5-30. The
expression of type I collagen in the C278F cells was not raised in comparison to the WT
cells and both were significantly reduced in comparison to untransfected cells. Levels of
expression remained at a consistent level throughout the study period in the C278F and
WT lines with a tendency to decrease towards day 30 in the mutated cells, although this
was not statistically significant. In contrast, levels in the MC3T3-E1 cells increased towards
30 days, although again this was not statistically significant. The change from normal to
mineralising medium at day 0 made no obvious difference to levels of expression.
Figure 4.8: RT-PCR of Collagen 1a1 and GapDH expression in MC3T3-E1, WT and
C278F cells
Col1a1 (284 bp) and GapDH (396 bp) band detection following agarose gel
electrophoresis in buffer containing ethidium bromide. Samples were run from triplicated
culture plates on a single large gel. cDNA bands were detected under UV light and
intensity was determined with Alphaease (version3.3) (AlphaInnotech Corp., San
Leonardo, Ca, USA) software. L = DNA ladder. Negative control (-ve) consisted of DEPC
water in place of a cDNA sample
MC3T3 WT C278F
pc d5 d10 d30 pc d5 d10 d30 pc d5 d10 d30-ve -veL
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Figure 4.9: Semiquantitative analysis of collagen 1a1 mRNA expression
Band intensity upon UV fluorescence is proportional to the quantity of ethidium bromide
which intercalates with the cDNA. This should be proportional to the quantity of RNA at the
start of the RT-PCR reaction thereby giving an indication of the levels of cellular RNA
expression. However, gel electrophoresis is an end-product technique which cannot be
assumed to quantify the PCR product in the exponential phase of amplification. In addition,
ethidium bromide is an insensitive technique which is unable to resolve differences lower
than approximately 10-fold. Attempts to make the technique as sensitive as possible
include visualisation of the bands within the mid-linear range of band intensity as
described in section 3.8.3. Band intensity was detected using Alphaease software and
expressed as a ratio of Col1/GapDH for each sample point. (pc) = pre-confluent. The data
are expressed as the mean + SEM for each group (n=3). Statistical differences among
treatment groups were evaluated by analysis of variance (ANOVA) and the significance of
differences between the groups was determined by post hoc testing using Bonferroni’s
method. S = significant (p < 0.05 was considered significant)
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4.2.6.2 Osteocalcin
Osteocalcin expression was significantly higher in the C278F pre-confluent and
day 5 post-confluent cultures and decreased with time to levels similar to the MC3T3-E1
and WT lines in which osteoclacin levels showed a non significant tendency to increase
after confluence.
MC3T3-E1
214bp
396bp
A B CA B C A B C A B C
pc d5 d10 d30L
-ve
WT
C278F
Figure 4.10: RT-PCR of osteocalcin (OC) and GapDH mRNA expression
Osteocalcin (214 bp) and GapDH (396 bp) band detection following agarose gel
electrophoresis. Samples for each cell line were run on a single gel and divided for viewing
and band intensity reading. A,B,C represent separate samples for each line and timepoint.
pc = pre-confluent, L = DNA ladder. Negative control (-ve) consisted of DEPC water in
place of a cDNA sample
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Figure 4.11: Semiquantitative analysis of osteocalcin mRNA expression
RT-PCR analysis of pre-confluent, day 5 – day 30 post-confluent samples of all cell lines.
(pc) = pre-confluent. Data are expressed as the mean + SEM for each group (n=3).
Statistical differences among treatment groups were evaluated using analysis of variance
(ANOVA) and the significance of differences was determined by post hoc testing using
Bonferroni’s method. S = significant (p < 0.05 was considered significant)
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4.2.6.3 Alkaline phosphatase
Alkaline phosphatase was expressed in pre-confluent MC3T3-E1 cells and levels
rose towards day 30. Consistently lower levels were seen in WT cells which did not
express significantly until day 5. C278F cultures did not express until day 30 and at lower
levels than the MC3T3-E1 or WT cultures. Levels were significantly different between all
cell lines at days 5-30.
MC3T3
WT
C278F
pds
396 bp
A B CA B C A B C A B C
pc d5 d10 d30L
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-ve
Figure 4.12: RT-PCR of alkaline phosphatase (ALP) and GapDH mRNA expression
Alkaline phosphatase (386 bp) and GapDH (396 bp) band detection following agarose gel
electrophoresis. Cell lines were run on separate gels and divided for viewing and band
intensity reading. Faint expression observed at day 30 in C278F cells. pds = primer
dimers. L = DNA ladder for determining approximate size of RT-PCR products. Negative
control (-ve) consisted of DEPC water in place of a cDNA sample
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Figure 4.13: Semiquantitative analysis of alkaline phosphatase mRNA expression
RT-PCR analysis of pre-confluent, day 5 - 30 post-confluent samples of all lines. (pc) =
pre-confluent. Data are expressed as the mean + SEM for each group (n=3). Statistical
differences among treatment groups were evaluated using analysis of variance (ANOVA)
and the significance of differences was determined by post hoc testing using Bonferroni’s
method. S = significant (p < 0.05 was considered significant)
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4.2.7: N-Cadherin
MC3T3-E1 cultures showed significantly higher levels of N-Cadherin at all time
points. There was no significant difference in the levels of expression between WT and
C278F cultures.
A B CA B C A B C A B C
pc d5 d10 d30
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Figure 4.14: RT-PCR of NCadherin (NCad) and GapDH mRNA expression
NCadherin (306 bp) and GapDH (396 bp) band detection following agarose gel
electrophoresis. Cell lines run on separate gels and divided for viewing and band intensity
measurement. L = DNA ladder for determining approximate size of RT-PCR products.
Negative control (-ve) consisted of DEPC water in place of a cDNA sample
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Figure 4.15: Semiquantitative analysis of NCadherin mRNA expression
RT-PCR analysis of day 1 -8 post-plating samples of all lines (day1 – 4 cultures are pre-
confluent, day 8 cultures are confluent).
Data are expressed as the mean + SEM for each group (n=3). Statistical differences
among treatment groups were evaluated using analysis of variance (ANOVA) and the
significance of differences was determined by post hoc testing using Bonferroni’s method.
S = significant (p < 0.05 was considered significant)
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4.2.8: Connexin 43
Expression in all lines was highest immediately after plating and decreased as the
cells became confluent. C278F cultures expressed higher levels than WT at all time points
(not statistically significant).
MC3T3
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Figure 4.16: RT-PCR of connexin 43 (Cx43) and GapDH mRNA expression
CX43 (468 bp) and GapDH (396 bp) band detection following agarose gel electrophoresis.
Cell line samples run on single gels (note the changed well order) and divided for viewing
and band intensity measurement. A,B,C represent separate samples for each line and
timepoint L = DNA ladder. Negative control (-ve) consisted of DEPC water in place of a
cDNA sample
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Figure 4.17: Semiquantitative analysis of connexin43 mRNA expression
RT-PCR analysis of day 1 -8 post-plating samples of all lines and their GapDH (day 1 –
day 4 cultures are pre-confluent, day 8 cultures are confluent). Data are expressed as the
mean + SEM for each group (n=3). Statistical differences among treatment groups were
evaluated using analysis of variance (ANOVA) and the significance of differences was
determined by post hoc testing using Bonferroni’s method. S = significant (p < 0.05 was
considered significant)
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4.2.9: FGF18
All lines expressed FGF18 at all time points throughout the culture period. Levels
were significantly higher in pre-confluent and day 5 C278F cultures, dropping at day 10
and rising again on day 30. MC3T3-E1 and WT cultures expressed FGF18 at similar levels
from pre-confluent to day 10, with levels dropping in these cultures at day 30.
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Figure 4.18: RT-PCR of FGF18 and GapDH mRNA expression
FGF18 (267 bp) and GapDH (396 bp) band detection following agarose gel
electrophoresis. All samples run on single gel and divided for viewing and band intensity
measurement. L = DNA. Negative control (-ve) consisted of DEPC water in place of a
cDNA sample
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Figure 4.19 : Semiquantitative analysis of FGF18 mRNA expression
RT-PCR analysis of pre-confluent, day 5 - 30 post-confluent samples of all lines and their
GapDH. (pc) = pre-confluent. Data are expressed as the mean + SEM for each group
(n=3). Statistical differences among treatment groups were evaluated using analysis of
variance (ANOVA) and the significance of differences was determined by post hoc testing
using Bonferroni’s method. S = significant (p < 0.05 was considered significant)
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4.3: Discussion
4.3.1: Morphological development of cell lines
Initial observations of cellular growth in culture revealed the C278F cells required a
much more frequent feeding regime than non mutated cells. This might be explained by
the recent findings of Hatch et al., (2006), who observed significantly higher levels of
anaerobic metabolism within COS7 cells transfected with the FGFR-C278 mutation.
Importantly, an obvious difference in the morphology, attachment behaviour, growth
and levels of cellular death of the mutated C278F cells compared to the MC3T3-E1 and
WT cells was noted. C278F cells initially attached poorly compared to the MC3T3-E1 and
WT cells, as confirmed by measures of plating efficiency. When mutated cells attached
and began proliferating, their morphology consisted of a more rounded or cuboidal
appearance than the other cell lines. Mutated cells did not reach confluence, but formed
aggregates early, which developed into multilayered nodules with cultures taking on an
overall “woven” appearance. These observations were consistent with the findings of
Petiot et al., (2002), who studied the effect of the C278F mutation in premigratory quail
chick neural crest cells and in primary human cell cultures carrying different activating
mutations of FGFR2 (Lomri et al., 1998; Santos-Ruiz et al., 2007). When cultures were
treated with trypsin, mutated cells rounded and detached more quickly and demonstrated
a greater tendency to attach to each other.
In considering the possible mechanisms to explain these findings it is worth first
discussing the potential influences on cell shape. Two principle models of cellular shape
exist. In the first, the cell is a balloon type structure in which the cell membrane influenced
by external forces (e.g adjacent cells, matrix), contains a homogenous, viscous cytoplasm
(Evans and Yeung 1989; Dong et al., 1991). This fails to explain however, the influence of
internal microstructure. Hence, the “tensegrity” model popularised by Ingber, (1993), has
become the predominant view with respect to cell shape and movement. In this model,
cells generate their own internal tension or “prestress” in the actin filament and
intermediate filament cytoskeleton. This is counter-balanced by both internal microtubule
struts which withstand compression forces and by external ECM adhesions via cell surface
adhesion receptors such as the integrins.
Consistent with the model, it has been shown that forces from the exteracellular
environment acting through the cellular adhesion molecules, can be transmitted to the
nucleus via the cytoskeleton to influence gene expression (Wozniak et al., 2000; Chen et
al., 2001; Jalali et al., 2001; Wang et al., 2001). The mechanotransduction of these signals
occurs through focal adhesion proteins such as Vinculin which connect directly to
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microfilaments and indirectly to microtubules and intermediate filaments (Alenghat et al.,
2000). This in turn activates integrin-associated signaling cascades such as focal adhesion
kinase (FAK), extracellular signal-regulated protein kinase (ERK), and G-proteins.
(Janmey et al., 1998)
The link between FGFRs and cytoskeletal transduction of signals has not been fully
defined. However, Mehta et al., (2001), have documented the p-38(MAPK) dependant
formation of actin plaques and cell membrane retraction upon treatment of prostate-DU145
cells with FGF2. More recently, Sandilands et al., (2007), have shown in foetal mouse
fibroblasts that ligand-induced activation of FGFRs is dependant on intact actin filaments
to allow function of the Src/RhoB endosome shuttle which transfers FGFR from the
cytoplasm to the cell membrane. More specifically with relation to craniosynostosis, micro-
array studies of pericranial fibroblasts from patients with Crouzon syndrome have
demonstrated the down-regulation of Cofilin and Profilin (Carinci et al., 2002). Cofilin is an
actin-modulating protein that binds and depolymerises filamentous actin and inhibits the
polymerisation of monomeric actin and is involved in the translocation of the actin-cofilin
complex from cytoplasm to the nucleus, while Profilin is important for spatially and
temporally controlled growth of actin microfilaments. These reports describe important
interactions between FGFR signaling and the cytoskeleton to affect cellular shape and
function and give further insight into the morphology and behaviour of the C278F cells,
suggesting that potential down regulation of these proteins in the mutated cells leads to a
decrease in prestress and subsequent rounding of the cells.
The tensegrity model also goes some way to explaining that cellular behaviours,
including differentiation, motility, and contractility, can be altered by changing cell shape or
ECM rigidity (Ben-Ze’ev et al., 1988; Opas, 1989; Mochitate et al., 1995; Lee et al., 1997;
Parker et al., 2002). In general, spread cells grow, retracted cells differentiate and fully
round or detached cells undergo apoptosis (Weaver et al., 2002), even when stimulated
with optimal levels of growth factors and ECM attachment (Dike et al., 1999). Therefore,
these findings may help to explain the observation that the more rounded, less well
attached C278F cells had an apparently higher rate of cellular death suggesting that they
maybe further down the differentiative path than MC3T3-E1 and WT cells.
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4.3.2: Cellular proliferation
Although C278F cells initially attached poorly, they appeared to undergo “catchup”
growth upon measures of plating efficiency. This was confirmed by H3 proliferation studies
which revealed a greater mitotic index for C278F cells, which became statistically
significant at day 2. The finding of differential proliferation between the lines was not
altogether surprising as Li et al., (1994), demonstrated that fibroblast proliferation is
mediated through FGFR1 and FGFR2. Mansukhani et al., (2000), transfected the OB1
osteoblast cell line with an FGFR2 mutation for Apert syndrome (S252W) and Crouzon
syndrome (C342Y) and found that both mutations conferred a two-fold increase in
proliferation. Other authors however have reported differently. Lomri et al., (1998), found
that osteoblast culture from patients carrying the S252W mutation for Apert syndrome
have no alteration in their proliferation rate compared with aged matched controls. Fragale
et al., (1999), reported decreased osteoblast proliferation in a patient with Apert syndrome
(FGFR2/P253R) and Pfeiffer syndrome (FGFR2/C342R). However, Ratisoontorn et al.,
(2003), have found that chicken calvarial osteoblasts transfected with the C278F mutation,
exhibited significantly increased proliferation.
Ohbayashi et al., (2002), have shown that FGF18 is implicated in the control of
osteoblasts proliferation/differentiation and hence the finding in this study that FGF18 is
expressed at significantly higher levels within the C278F cells during early proliferation,
may further explain the increased levels of proliferation within these cells.
Mutated cells failed to reach confluence prior to developing nodular condensations
and despite the apparently higher levels of proliferation in the first two days post-plating,
upon prolonged culture, there was no obvious increase in the total biomass of C278F cells
when pelleted for splitting or freezing. This would suggest one of two phenomenons:
Either, proliferation in this cell line was down-regulated to a greater degree by cellular
communication as the cells became more confluent. Alternatively or in addition, C278F
cells may have been undergoing a higher level of apoptosis which would have been
consistent with the cellular morphology. Indeed, significantly raised levels of TUNEL (a
marker of apoptosis) expression in C278F cells were confirmed by a co-worker in our
laboratory (Dr Santos-Ruiz, unpublished data). This is consistent with papers in which
osteoblasts carrying FGFR2 mutations exhibit increased apoptosis compared to wild type
or control populations (Mansukhani et al., 2000; Lemmonier et al., 2001)
Another explanation of this apparently higher level of proliferation relates to the levels
of confluence during the study: Despite seeding at the same cellular concentration and
because of the previously described attachment behaviour and higher levels of cell death,
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the C278F cells were less confluent than the MC3T3-E1 and WT cells at both time points
(Fig. 4.5). This gives rise to the possibility that measured differences in proliferation may
have been due to a relatively lower level of proliferation within the non mutated lines,
secondary to the phenomenon of contact inhibition. This may have become apparent by
proliferation studies carried out beyond day 2 once C278F cells were denser. An
alternative approach would have been to seed at different densities allowing for plating
efficiency and early cell death, to provide cell cultures displaying equal confluence for each
time point.
4.3.3: Expression of markers of osteodifferentiation and mineralisation
Although pathologically increased levels of type 1 collagen by calvarial osteoblasts
has been demonstrated in craniosynostosis associated with mutations of the FGFRs
(Bodo et al., 1996; Lomri et al., 2000; Baroni et al., 2002), the expression of type I collagen
in the C278F cells was not raised in comparison to the wild type receptor and significantly
reduced in comparison to untransfected cells.
Alkaline phosphatase was not expressed in the mutated cells until day 30 and then at
significantly lower levels than the untransfected and WT cells, which first expressed in the
pre-confluent and day 5 cultures respectively.
Franceschi et al., (1992, 1994), demonstrated that MC3T3-E1 cells expressing low
levels of normal type I collagen, expressed lower levels of ALP and OC. In addition,
Wenstrup et al., (1996), found that MC3T3-E1 osteoblasts require a normally structured
collagen rich matrix for up regulation of ALP activity and that cells with disrupted collagen
structure had down-regulation of ALP but up-regulation of OC, a pattern of expression
demonstrated in early cultures of C278F cells, possibly suggesting the presence of an
abnormal collagen matrix in the mutated cells.
The finding that Col1 and ALP were expressed at generally lower levels in the
mutated cells was seemingly inconsistent with previous reports that type1 collagen and
ALP are upregulated in FGFR2 mutations in osteoblasts from patients with
craniosynostosis, (Lomri et al., 1998; Fragale et al., 1999), although interestingly, the
same authors noted that mineralisation was blocked in osteoblasts from patients carrying
Crouzon/Pfeiffer mutations, yet accelerated in osteoblasts from patients with Apert
mutations (P253R and S252W). It should be recognised however, that interpretation of the
effects of FGFR mutations in patients with craniosynostosis are limited by the varying ages
of patients and controls. Nevertheless, these findings are largely corroborated by
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osteoblast transfection studies; Mansukhani et al., (2000), reported that mutations
producing constitutive activation of FGFR2, block ALP expression and mineralisation.
The fact that the C278F cells were forming prominent nodules and mineralising
also seemed at odds with poor expression of ALP. However, during the course of this
study, Ratisoontorn et al., (2003), reported the downregulation of type 1 collagen and ALP
in chick calvarial osteoblasts transfected with the C278F mutation. Furthermore, Wang et
al., (1999), who have shown that there is good correlation between mRNA expression and
protein transcription of ALP and OC in the MC3T3-E1 cell line, have questioned the
correlation between osteodifferentiation markers and mineralisation, with the finding that
MC3T3-E1 cells exhibit clonal subpopulations with widely different expression patterns;
some subclones mineralised without expressing ALP or OC, while other clonal populations
expressed ALP and OC but did not mineralise. In addition, Beck et al., (1998), showed that
ALP expression could be dissociated from OC expression and mineralisation in MC3T3-E1
cells by targeting with adenovirus E1A protein.
Osteocalcin is generally reported as the last marker of differentiation to express,
typically appearing not before day 7 in MC3T3-E1 cultures and increasing as differentiation
advances (Choi et al., 1996; Quarles et al., 1997). The finding that all cells expressed OC
from the preconfluent stage with the mutated cells expressing OC maximally at this stage
and decreasing with confluence and nodule formation was surprising. However, this was
not an isolated finding, as Ratisoontorn et al., (2003), have also reported their osteoblast
lines expressing OC from the outset.
Whilst the differences in levels of expression of ALP and OC between the WT and
mutated cells are likely, given the differing morphology and adhesion behaviour, to be due
directly to downstream effects of the FGFR2 mutation, it is worth considering that they may
be affected by one or a combination of factors not directly attributable to the mutation. The
cell lines may be at different levels of maturation for a number of reasons including clonal
drift into a phenotypically more differentiated cell line (Leis et al., 1997), selection of
particular subclones (Wang et al., 1999) or the effects of multiple passaging, an effect
which may be under emphasised in osteoblast research according to Chung et al., (1999)
and Peterson et al., (2004).
A further consideration which makes comparisons with the findings of other authors
difficult, is possibly the effect which different serum concentrations was having on the
cultures: The presence and concentration of the numerous inductive, permissive or
inhibitory hormones or cytokines will likely influence osteoblast specific gene expression
and cell-matrix interactions. Both the qualitative and quantitative size of these effects
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cannot be known and true comparison and interpretation would only be possible by the
omission of serum from the experiments.
4.3.4: Expression of markers of cell adhesion
The expression of cell-cell adhesion and gap junction molecules was examined
based on the difference in morphology and attachment behaviour of the cell lines as
previously described. The expression of Cx43 in all lines was highest immediately after
plating and decreased as the cells became confluent. C278F cultures expressed
consistently higher levels than WT at all time points although this was not statistically
significant. This tendency however, may start to explain the clumping and cell-cell
attachment behaviour observed in the mutated cells, as cellular coupling has been directly
correlated with Cx43 expression in MC3T3-E1 cells (Yamaguchi et al., 1994).
To date, there are no reports of Cx43 expression in either primary or cell line
osteoblasts carrying FGFR mutations. The finding by Gramsch et al., (2001), that there is
a correlation between Cx43 expression and increased levels of proliferation in the UMR
osteosarcoma cell line would also be consistent with Cx43 expression and increased
proliferation of the C278F cells, although extrapolation of findings in an osteosarcoma line
to an osteoblast line may be problematic.
When N-cadherin expression was looked at, there appeared to be little difference in
the expression levels between the wild type and mutated cells which both consistently and
significantly expressed N-cadherin at a lower level than the untransfected cells. This is
difficult to explain given the inter-cellular clumping behaviour of the cell lines. Moreover,
Lemonnier et al., (2001), have reported the up-regulation of N-cadherin in human primary
osteoblasts carrying the S252W mutation for Apert syndrome, although, as previously
discussed with reference to osteodifferentiation markers, discordant findings for different
mutations within the FGFR2 receptors may be anticipated (Lomri et al., 1998). This is not
altogether surprising as the mechanism of receptor activation for the C278F Crouzon
mutation involves ligand independent constitutive activation whereas the Apert mutations
do not induce ligand independent dimerisation.
4.3.5: Expression of FGF18
FGF18 was expressed in all lines from pre-confluent culture until late differentiation
at day 30. Levels of expression were similar in the MC3T3-E1 and WT cells at all time
points, decreasing marginally towards day 30. However, the level of expression in the
mutated cells was significantly raised by a factor of almost two in preconfluent cultures.
- 123 -
These levels subsequently declined at day 5 although remained raised with respect to the
WT and MC3T3-E1. At day 10, levels had fallen to those seen in the MC3T3-E1 and WT
cultures. Interestingly, transcript levels rose again in the late differentiated phase.
These findings would suggest that C278F cells were producing raised levels of
FGF18 in the proliferative phase, creating an autocrine enhanced proliferative drive. As
previously alluded to, Ohbayashi et al., (2002), have shown that FGF18 is implicated in
stimulation of osteoblast proliferation via ERK activation. It can therefore be postulated that
this up-regulation of the expression of FGF18 may be an attempt to regain functionality by
a feedback response to down-regulation of the FGFRs, brought about by the constitutively
active FGFR2-C278F. This would be consistent with work published after the completion
of this study by Hatch et al., (2006), in which MC3T3-E1 cells transfected with the FGFR2-
C278F receptor mutation showed increased receptor internalisation and degradation within
the Golgi-ER-Complex and decreased surface expression.
The rise in levels at day 30 is more difficult to explain based on our knowledge to
date of FGF18 interactions and effects. Possibly a higher level of cellular death within the
C278F cells at late maturation, created a phase in which pockets of unoccupied matrix
exist, allowing cells to resume proliferation.
Where statistical significance has been demonstrated, this should be read in the
context that a Gaussian distribution was assumed for the distribution of data and sample
sizes consisted of triplicates. This is small and indeed the smallest sample size which
allows an analysis of variance (ANOVA) and intergroup post-hoc testing. This produces
large standard errors which may prevent the identification of real as opposed to statistically
significant differences. Furthermore, while the Bonferonni method was chosen for
measures of significance because it is considered to be a simple method, good for
comparing groups of less than approximately five, it should be recognised that it provides
conservative measures of p-value which again may fail to demonstrate significant
differences.
4.3.6: Summary
The basic morphological development of the three cell lines and the differences due
to the mutation in the FGFR2 receptor has been highlighted. I have demonstrated altered
adhesion, cell shape and enhanced early proliferation within the mutated cells. The
differential expression of osteodifferentiation markers has been semi-quantified as has the
expression of the functionally important cell adhesion molecules Connexin-43 and N-
cadherin.
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The expression of Cx43 and FGF18, a ligand recently implicated in the control of the
proliferative-differentiative balance in osteogenisis has been studied for the first time in
FGFR2 mutated cells. It is interesting to speculate as to the molecular causes of the
altered cellular morphology and why expression of a mutated FGFR2 receptor should
affect the shape and attachments of cells both to themselves and tissue culture plastic. As
alluded to, there is probably a complex interplay between cellular adhesion molecules,
cytoskeleton, and the nucleus which affects cellular integration and function as predicted
by the tensegrity model. This may become increasingly obvious and important when
investigating the surface form of scaffolds for bioengineering. The obvious difference in
attachment behaviour and shape of the mutated cells would justify further analysis of the
nature of adhesion interactions between the cells, the ECM and the expression of
cytoskeletal structures. This would facilitate the determination of the fundamental
relationship between cell adhesion and function and would have been a focus for future
work on this cell model.
What these findings in conjunction with a review of the relevant literature highlights,
is that it seems difficult to make broad inferences and apply them to specific cell types or
mutations. The interaction of cell type, cell age, the multitude of signaling pathways along
with the individual culture and experimental conditions, allow for only limited conclusions to
be drawn from any particular set of findings. For example, the precise role which each
single component of the extracellular matrix plays in determining the phenotype of any
particular craniofacial syndrome is not at all clear.
Having described qualitatively and semi-quantitatively the difference in morphology
and behaviour which the FGFR2-C278F(C278F) mutation was eliciting, It seemed relevant
to attempt to modify or “rescue” the phenotype of the mutated cell line, to one which more
resembled cells not carrying the mutation, with particular emphasis on facilitating maximal
proliferative expansion. This would be a potential strategy for utilising mutated, autologous
osteoprogenitors for bone engineering. Specifically, it would be informative to explore the
effect of FGF18 treatment given the significantly raised levels of mRNA expression within
the C278F cell line and the potential importance of this FGF raised in the recent literature.
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Chapter 5: Modulation of osteoblast behaviour
5.1: Introduction
In chapter 4, phenotypic study of the cell lines, revealed that in comparison to WT
and untransfected MC3T3-E1 cells, FGFR2-C278F(C278F) mutated cells appeared
morphologically and behaviourally different. They demonstrated a more rounded/cuboidal
appearance when attached to plastic with less well developed filopodia. Attachment
behaviour was also markedly different, with C278F cells taking longer to attach to culture
plastic and attaching in a manner which allowed a more rapid release by trypsin. Upon
attachment mutated cells attached in clusters which subsequently took on a nodular
appearance before they were able to reach full confluence. Proliferation studies revealed
that once attached the mutated cells demonstrated an initially higher mitotic rate in the
early pre-confluent stages of growth. Throughout all culture periods and conditions, the
mutated cells subjectively demonstrated a higher proportion of cell death, which was
consistent with unpublished data from our laboratory (Dr. Santos-Ruiz), confirming this
mutation exhibited increased levels of apoptosis in standard culture conditions. While the
expression of mRNA for osteodifferentiation proteins revealed that the appropriate markers
were expressed, the temporo-spacial expression was different from that which would have
been expected in cells expressing in the accepted progression along the osteoblast
lineage. Specifically, the expression of high levels of osteocalcin in pre confluent cultures
before the development of significant nodules and the subsequent falling levels were
contrary to what was anticipated in osteoblasts (Aubin et al., 1995; Liu et al., 2003).
In considering development of bio-composites for bone engineering, the use of
osteoprogenitors from patients with syndromic craniosynostosis and the ability to optimally
expand them on a scaffold prior to terminal differentiation and mineralisation would
theoretically be an ideal manipulation.
Fibroblast growth factor signalling plays an important role in cranial bone
development and osteoblast function as alluded to in chapter 1. The biological effects of
FGFs depend on stage of growth, and in vitro studies have shown that FGF1, FGF2, FGF4
and FGF18 can potentiate the growth of proliferating calvarial osteoblasts (Canalis et al.,
1988; Tang et al., 1996; Hurley et al., 1995; Shimoaka et al., 2002) but not mature or
differentiated osteoblasts (Mansukhani et al., 2000).
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Studies within our laboratory have confirmed that endogenous levels of FGF2 may
constitute a mechanism to control proliferation in a concentration dependent manner
(Moore et al., 2002) and analysis of FGF18 null mice has revealed a decrease in
proliferation of osteogenic mesenchymal cells associated with delayed suture closure
(Ohbayashi et al., 2002).
Differentiation also seems to be under the control of FGFs, as prolonged treatment
with FGF2 promotes osteocalcin transcription and mineralisation in rodent and human
osteoblasts (Newberry et al., 1998; Debiais et al., 1998). FGF18 inhibited differentiation
and matrix synthesis in MC3T3 cells (Shimoaka et al., 2002). Proliferation and terminal
differentiation of calvarial osteoblasts was decreased in FGF18 null mice (Ohbayashi et
al., 2002) with a reduction in osteocalcin and osteopontin expression (Liu et al., 2002). In
addition, apoptosis is influenced by FGF signalling, which again seems dependent on the
stage of osteoblast differentiation. This is important as apoptosis is known to be a
fundamental controller of osteoblast longevity and osteogenisis (Manolagas, 2000).
FGF2 treatment of neonatal mouse calvarial osteoblasts protected cells from
apoptosis when starved of serum (Hill et al., 1997), whereas FGF1 treatment induced
apoptosis in more differentiated osteoblasts and over-expression of FGF2 signalling in
transgenic mice led to increased apoptosis in mouse calvaria (Mansukhani et al., 2000;
Lemmonier et al., 2001). Mansukhani et al., (2000), also noted similar patterns of
proliferation and apoptosis in osteoblasts constitutively activated by FGFR mutations.
Interestingly, the effect of exogenous FGF treatment on cells carrying activating mutations
for FGFRs has not been studied to a large extent, with only one report by Mansukhani et
al., (2000), finding that OB1 osteoblasts transfected with an Apert FGFR2/S252W
mutation, demonstrated a 22-54% increase in proliferation upon FGF1 treatment. Crouzon
FGFR2/C342Y cells demonstrated only a minimal increase in proliferation upon treatment.
FGF1 treatment inhibited osteodifferentiation in these osteoblasts with no quantifiable
difference between the groups. Treatment of differentiating, non-mutated OB1 cells with
FGF1 induced apoptosis to levels seen in untreated mutated cells.
Thus, FGF signaling of immature osteoblasts appears to reduce apoptosis and
increase proliferation and cell numbers, whereas later stage signaling promotes apoptosis.
Hence this apparently opposing effect is likely to be an important control mechanism in
osteogenisis.
Taken together, along with the findings of Shimoaka et al., (2002), who reported that
the mitogenic effects of FGF18 on osteoblasts were as strong as FGF2; the finding in
chapter 4 that FGF18 was expressed at significantly higher levels in early and late cultures
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of C278F cells, combined with the recent literature suggesting an important role for FGF18
in the control of proliferation/differentiation, directed the study towards examination of the
effect of FGF18 treatment on the cell lines.
5.2: Foetal calf serum (FCS)
As seen in chapter 4, the growth of the C278F mutated cells relied on culture
medium change more frequently than that required for the WT and untransfected cells.
Likewise, the literature reviewed suggests that the concentration of serum in which cells
are cultured, influences the response to growth factor treatment (Sachs et al., 1982; Allen
et al., 1983). Foetal calf serum contains a variety of polypeptides that may "attach" to cells,
inducing significant metabolic/morphologic changes. For example, bone marrow derived
mesenchymal progenitor cells show a different behaviour in culture performed in the
presence of FCS with or without heat inactivation (Bruinink et al., 2004). It is known that
deprivation of serum or growth factors from the medium causes apoptotic death of cultured
cells. Myc and p53 appear to be involved in the mechanism underlying such apoptotic cell
death, but the precise mechanism is still unknown (Packham et al., 1995; Elliott et al.,
1995). Components of serum, such as growth factors other than FGFs highlighted
previously, can cause attenuation of apoptosis in cell cultures, for example, epidermal
growth factor (EGF) has been shown to protect cultured cells against apoptosis induced by
serum deprivation (Tong et al.,, 1999). In addition, increasing MC3T3-E1 cell number has
been shown to be linearly proportional to serum concentration up-to 4 days in culture
(Masayuki et al., 2000) and the effect of exogenous FGF2 treatment on MC3T3-E1 cells is
dependant on serum concentration. It was necessary therefore, to ascertain the lowest
concentration of FCS which would sustain the cells during the treatment period and avoid
the masking of effects solely due to FGF18.
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5.3: Results
5.3.1: Assessment of FGF18 concentration effect
In the first instance, the study observed the effects of FGF18 treatment on the cell
lines and established that the concentrations used, were in the correct range to observe an
effect. These initial doses were chosen based on the findings of Shimoaka et al., (2002).
Initial studies were carried out in 10% serum in keeping with the experiments in chapter 4,
in order that any observed differences could be attributed to the FGF18 treatment.
Cellular behaviour observed in culture is shown in figure 5.1. MC3T3-E1 cells and
WT cells just reached monolayer confluence at 48 hours post plating without treatment
(Fig. 5.1 A,B), whereas C278F cells displayed their typical non confluent appearance (Fig.
5.1 C) as observed in chapter 4. Cells treated for 36 hours with FGF18 at [10-10 M],
particularly when observed directly through the microscope, appeared more densely
packed in the case of the MC3T3-E1 and WT lines (Fig. 5.1 D,E).
The mutated cells took on a different morphology to that seen in standard culture
when treated with FGF18 at [10-10 M]: Whilst still not fully confluent there were fewer and
smaller voids on the culture dish (Fig. 5.1 F), indicating that the treatment had probably
increased the cell population and/or altered cellular motility and attachment. When treated
with a ten fold higher concentration of FGF18 [10-9 M], there was a multilayered
appearance and increase in cellular density in the MC3T3-E1 and WT lines (Fig. 5.1 G,H),
compared to cells treated with FGF18 [10-10 M].
Treatment of the mutated cell line with FGF18 [10-9 M] (Fig. 5.1 I), produced a
surprising result in that the appearance of the cultures was indistinguishable from the
untransfected and wild-type cell lines. Full confluence had been achieved and there was
no evidence of clustering behaviour.
These initial observations appeared to be consistent with the findings of Shimoaka et
al., (2002), with respect to the MC3T3-E1 cells. Thus, treatment of the mutated C278F
cells with FGF18 altered the characteristics of the line to one which took on the
appearance more in keeping with the behaviour of the untransfected and WT cells. This
observation suggested that FGF18 treatment might be a candidate for “rescuing” the
behaviour of mutated cells in any potential bone engineering application.
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Figure 5.1: Treatment of osteoprogenitor lines with FGF18 for 2 Days
Cultures were plated at 12,000 cells/cm2 in standard medium containing 10% FCS.
Medium was replaced after 12 hours with standard medium (A-C), standard medium
supplemented with FGF18[10-10M] (D-F) or standard medium supplemented with
FGF18[10-9 M] (G-I). Cultures were imaged at 48 hours following the commencement of
treatment. Medium was changed every 24 hours. MC3T3-E1 (A,D,G) and WT (B,E,H)
cells have just reached confluence without treatment(A,B) . Treated cells are more
densely packed and start to appear multilayered (D,G and E,H). C278F cells(C,F,I) are
partially confluent in clusters without treatment (C), almost fully confluent with
FGF18 [10-10 M] (F) and fully confluent when treated with FGF18 [10-9] (I). Images
obtained by phase contrast microscopy. Scale bar = 200 µm
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5.3.2: Effects of foetal calf serum
The effect of foetal calf serum (FCS) concentration on the cell lines prior to
quantification of the FGF18 effects was studied. The concentration of FGF18 chosen was
[10-9 M] as this had appeared to “normalise” the proliferation of the mutated cells in section
5.3.1.
MC3T3-E1, WT and C278F cells were observed at 24 and 72 hours with or without
the addition of FGF18 [10-9 M] in the presence of 10%, 1% or no FCS. The results are
shown in Figure 5.2.- 5.7. At 24 hours post treatment the MC3T3-E1 cells grown without
FGF18 supplementation (Fig. 5.2 B,D,F) looked unstressed and showing progressive
confluence from no FCS (Fig. 5.2 B) to the 10% FCS (Fig. 5.2 F) which were near full
confluence. When cells were treated with FGF18 (Fig. 5.2 A,C,E), the cells growing
without FCS (Fig. 5.2 A) appeared to be more confluent than the equivalent cells without
FGF18. However, they also appeared more “stressed” with a greater number of dead cells
suggested by the pattern of light diffraction. The cells growing in 1% FCS (Fig. 5.2 C) were
fully confluent although once again there was a suggestion that a greater degree of cell
death had occurred. Cells grown in 10% FCS (Fig. 5.2 E) were fully confluent and looked
healthy.
When observed at 72 hours, the MC3T3-E1 cells growing in 1% and 10% FCS were
fully confluent with (Fig. 5.3 c,e) and without (Fig. 5.3 d,f) FGF18 supplementation. Cells
grown without FCS and without FGF18 (Fig. 5.3 b) looked healthy but still not fully
confluent. Whereas cells grown without FCS but with FGF18 (Fig. 5.3 a) had changed
very little from the 24 hour appearance, looking non confluent and demonstrating signs of
stress and cellular death.
WT cells at 24 hours post treatment grown without FGF18 supplementation (Fig. 5.4
B,D,F) looked unstressed and showed progressive confluence from no FCS (Fig. 5.4 B) to
just fully confluent in the 10% FCS condition. When cells were treated with FGF18 (Fig.
5.4 A,C,E), cells growing without FCS (Fig. 5.4 A) appeared to be undergoing a high level
of cell death and appeared much less healthy than in the equivalent group without FGF18.
This appearance was significantly improved when grown in 1% (Fig. 5.4 C) and 10% (Fig.
5.4 E) FCS which were near confluence and confluent respectively. At 72 hours without
FCS or growth factor (Fig. 5.5 b), WT cells appeared healthy but had not reached
confluence, in contrast cells without FCS and treated with FGF18 (Fig. 5.5 a) were
surviving poorly with high levels of cellular death and few viable cells remained. Cells
growing in 1% and 10% FCS with or without growth factor supplementation (Fig. 5.5 d,f
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and c,e) were all confluent, although cells growing in 1% FCS with FGF18 added (e)
demonstrated a higher level of cell death.
When mutated cells were observed at both time points, it was apparent that they
tolerated the absence of FCS poorly. At 24 hours without FGF18 (Fig. 5.6 B,D,F)
approximately half of the visible cells were dead if no FCS was present (Fig. 5.6 B). When
FGF18 was added, no viable cells were seen (Fig. 5.6 A). Cell survival was improved in
the presence of 1% FCS (Fig. 5.6 D,C), however, the presence of FGF18, again conferred
a high level of cell death (Fig. 5.6 C). With 10% FCS similar cell numbers were observed
although cells treated with FGF18 (Fig. 5.6 E) appeared more stressed. At 72 hours only a
few viable cells were seen in the cultures without FCS or growth factor (Fig. 5.7 b), when
growth factor had been added only cellular debris was seen (Fig. 5.7 a). When 1% FCS
was added (Fig. 5.7 d) cell survival was greatly enhanced. When FGF18 was also added
(Fig. 5.7 c) a greater number of cells were observed, although a higher level of cellular
stress was also noted. In the presence of 10% serum without FGF18 (Fig. 5.7 f) C278F
cells took on their subconfluent appearance, whereas when treated with FGF18 (Fig.
5.7,e) they became fully confluent, although multiple dead cells were apparent.
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Figure 5.2: Effects of foetal calf serum and FGF18 on MC3T3-E1 cell growth at 24 h
Cells at 24 hours with FGF18[10-9] (A,C,E) or without treatment (B,D F), without serum (A,B),
with 1% (C,D) or 10% (E,F) serum.
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours with
the treatment medium. Cultures were imaged by phase contrast after 24 of treatment. Scale
bar = 200 µm
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Figure 5.3: Effects of foetal calf serum and FGF18 on MC3T3-E1 cell growth at 72 h
Cells at 72 hours with FGF18[10-9] (a,c,e) or without treatment (b,d,f), without serum (a,b),
with 1% (c,d) or 10% (e,f) serum.
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours
with the treatment medium and every 24 hours thereafter. Cultures were imaged by phase
contrast after 72 of treatment. Scale bar = 200 µm
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Figure 5.4: Effects of foetal calf serum and FGF18 on WT cell growth at 24 h
Cells at 24 hours with FGF18[10-9] (A,C,E) or without treatment (B,D F), without serum (A,B),
with 1% (C,D) or 10% (E,F) serum.
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours with
the treatment medium. Cultures were imaged by phase contrast after 24 of treatment. Scale
bar = 200 µm
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Figure 5.5: Effects of foetal calf serum and FGF18 on WT cell growth at 72 h
Cells at 72 hours with FGF18[10-9] (a,c,e) or without treatment (b,d,f), without serum (a,b),
with 1% (c,d) or 10% (e,f) serum.
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours
with the treatment medium and every 24 hours thereafter. Cultures were imaged by phase
contrast after 72 of treatment. Scale bar = 200 µm
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Figure 5.6: Effects of foetal calf serum and FGF18 on C278F cell growth at 24 h
Cells at 24 hours with FGF18[10-9] (A,C,E) or without treatment (B,D F), without serum (A,B),
with 1% (C,D) or 10% (E,F) serum.
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours with
the treatment medium. Cultures were imaged by phase contrast after 24 of treatment. Scale
bar = 200 µm
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Figure 5.7: Effects of foetal calf serum and FGF18 on C278F cell growth at 72 h
Cells at 72 hours with FGF18[10-9] (a,c,e) or without treatment (b,d,f), without serum (a,b),
with 1% (c,d) or 10% (e,f) serum.
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours
with the treatment medium and every 24 hours thereafter. Cultures were imaged by phase
contrast after 72 of treatment. Scale bar = 200 µm
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5.3.3: Proliferation effects of FGF18 treatment
Treatment with FGF18 produced an obvious increase in cell numbers amongst all
cell lines, but most strikingly in the mutated cells, allowing them to grow to full confluence
which until this stage, had not been observed. This apparent proliferative enhancement
was quantified using anti-phosphohistone3 (pH3) as described in chapter 4.
Observations from the previous section revealed that the mutated cells required FCS
to survive. While the addition of 1 % FCS obviously improved the survival of mutated cells,
they continued to show a high degree of cellular stress, particularly in the presence of
growth factor. Therefore further observations of cellular growth with different
concentrations of FCS in the presence of FGF18 were performed and it was elected to
carry out the experiment with all cultures growing in 2% FCS. This concentration allowed
all lines to grow, without showing excessive signs of cellular stress.
Treatment with FGF18 increased the proliferation of all cell lines. This effect was
greatest in the first 24 hours of treatment and a visual impression of this is gained by
comparison of day 1 and day 2 staining in Figures 5.8 and 5.9. This was confirmed by
analysis of the mitotic indices, calculated for each line and time point as shown in Figure
5.10. Proliferation was significantly enhanced in a concentration dependent manner most
notably for the WT and C278F lines. On day 1 this effect was greatest for mutated cells,
producing a 2.4 fold increase in proliferation at [10-8M] compared to a 1.9 fold increase for
both MC3T3-E1 and WT cells. At day 2 the effect was less obvious and there was no
statistically significant difference in the increase between lines.
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Figure 5.8: Effect of FGF18 on proliferation using anti-pH3. Day 1
Cells were seeded in triplicate at 5000/cm2 in normal medium. Medium was replaced after 12
hours with treatment medium containing 2% FCS in the absence (A-C) of FGF18 or
supplemented with FGF18[10-9 M] (D-F) or FGF18[10-8 M] (G-I). Cultures were
immunostained for anti-pH3 after 24 hours of treatment and imaged by phase contrast for
measurement of mitotic index using Openlab software “click counting” facility. (gain/contrast
adjusted images not shown). Scale bar = 50 µm
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Figure 5.9: Effect of FGF18 on proliferation using anti-pH3. Day 2
Cells were seeded in triplicate at 5000/cm2 in normal medium. Medium was replaced after 12
hours with treatment medium containing 2% FCS in the absence (a-c) of FGF18 or
supplemented with FGF18[10-9 M] (d-f) or FGF18[10-8 M] (g-i) which was changed after 24
hours. Cultures were immunostained for anti-pH3 after 48 hours of treatment and imaged by
phase contrast as before. Scale bar = 50 µm
- 142 -
A.
B.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
MC3T3 WT C278F
H
3/
N
R
at
io
-ve
FGF18 [10-9]
FGF18 [10-8]
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
MC3T3 WT C278F
H
3/
N
R
at
io
-ve
FGF18 [10-9]
FGF18 [10-8]
s
s
s
s
s
H
3/
N
R
at
io
H
3/
N
R
at
io
H
3/
N
R
at
io
H
3/
N
R
at
io
H
3/
N
R
at
io
H
3/
N
R
at
io
Figure 5.10: Effect of FGF18 on mitotic index.
Graphic representation of mitotic index, assessed by anti-pH3 staining
A. Day 1. Ratio of anti-pH3 positive cells as proportion of total cell count for MC3T3-E1,
WT and C278F cells.
B. Day 2.
Data are expressed as the mean + SEM for each group (n=12). Statistical differences
among treatment groups were evaluated using analysis of variance (ANOVA) and the
significance of differences between groups was determined by post hoc testing using
Bonferroni’s method. S = significant (p<0.05 was considered significant)
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5.4: Discussion
5.4.1: Effect of FCS
During initial observations of cell culture in chapter 4, it was observed that the
mutated cells seemed more dependent on serum supplementation than did the MC3T3-E1
or WT cells. This was further emphasised whilst optimising culture conditions before
quantifying the effects of FGF18 treatment. MC3T3-E1 cells tolerated serum starvation
well as did WT cells in the absence of FGF18, whereas C278F cells did not tolerate serum
starvation. The addition of FGF18 in the absence of serum had a severely deleterious
effect on WT and C278F cell survival, in contrast to reports by Hill et al., (1998) and
Debiais et al., (2004), that FGF2 rescues serum starved mouse primary calvarial
osteoblasts and human primary osteoblasts respectively.
The addition of 1% FCS rescued the behaviour of WT cells. However 2% FCS was
required in order to normalise the appearance of C278F cells. It became apparent that in
conditions of low or absent FCS, FGF18 treatment was causing cell death, whereas the
addition of FGF18 at higher concentrations of FCS, enhanced cell numbers. This was
seen most obviously during the preliminary finding that C278F cells reached full
confluence in the presence of 10% FCS and FGF 18 [10-9M]. This had not previously been
observed in the C278F cells. In addition there was no evidence that the cells were forming
nodules early. The effect also appeared to be dependent on FGF18 concentration, as the
addition of FGF at [10-10M] modified the appearance of C278F cells towards confluence.
Taken together, these observations suggested that FGF18 acting alone was driving
cell death, but that in the presence of other growth factors and serum components, was
enhancing cell survival either by increasing proliferation, reducing apoptosis or a
combination of both. In addition, the absence of clustering and early nodule formation
suggested that cell function was being affected. These observations might be explained in
part and would be consistent with the tensegrity model. Such that low serum
concentrations provided suboptimal levels of absorbed extracellular matrix proteins
including fibronectin for example, for integrin associated attachment. The mutated cells
therefore attach poorly, remain round and undergo apoptosis.
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5.4.2: Effects of FGF18
Quantification of the proliferative effect of FGF18 in 2% FCS, revealed a
concentration dependent increase in cellular mitosis for all cell lines. This was significantly
greater at day 1 for the mutated cells than for the MC3T3-E1 and WT cells. However, the
overall magnitude of increase was not seen to the same degree as Shimoaka et al.,
(2002), who carried out treatment in 10%FCS. This suggests that other growth factors
present in the serum work in synergy with the FGF18 to influence proliferation.
Furthermore, when cells were serum starved or at very low concentrations of FCS, the
degree of cell death, possibly apoptotic in nature, was visually much greater in the mutated
cells. It can be postulated that this response of the C278F cells suggests that the lack of
cellular attachment and spreading via the ECM, in combination with a substance which
under different conditions is mitogenic, is causing cellular death. This observation is
consistent with both the more rounded appearance of the mutated cells in this study as
predicted by the tensegrity model and the findings by Mansukhani et al., (2000), who
observed that more mature cells respond to FGF treatment by undergoing apoptosis.
The observed concentration effect on proliferation differs from previous findings for
FGFs, particularly FGF2, where it has been found that at low concentrations, FGF2
promotes proliferation and at higher concentration proliferative arrest and differentiation is
observed (Iseki et al., 1999; Moore et al., 2001; Sarkar et al., 2001). This study was unable
to examine the effect of concentrations higher than 10-8 Molar. Had this been possible it
would have been interesting to assess whether cells switched from proliferation to
differentiation upon treatment with FGF18 at higher concentrations.
The mutation carried by the C278F cells causes ligand independent constitutive
activation of the receptor (Robertson et al., 1998) and should therefore not respond to
exogenous FGF. Moreover, it is possible that the constitutively activated FGFR2 creates a
negative feedback, causing down-regulation of the receptor, a theory which has
subsequently been supported by the recent findings of Hatch et al., (2006), as discussed
in Chapter 4. It is therefore likely that the early increase in proliferation by FGF18 in the
mutated cells is caused by the activation of other endogenous wild type FGF receptors,
which may have differentially up-regulated expression secondary to the autocrine influence
of the mutated FGFR2 receptor. It would therefore have been informative to look at the
expression profiles of the FGFRs following FGF18 treatment.
In addition to increased proliferation, the full confluence of mutated cells without the
tendency to form nodules prematurely was observed and it is tempting to speculate that
treatment with FGF18 is affecting cell-cell interaction and adhesion. Further studies
- 145 -
examining the expression of some of the likely candidates should be considered in future
work.
5.4.3: Summary
In this chapter, it was observed that at low serum concentrations or in the absence of
serum, FGF18 treatment was associated with cell death and that this was seen to the
greatest degree in cells carrying the C278F mutation. When serum concentration was
increased to a level which supported normal cell survival, treatment with FGF18 increased
proliferation and this effect was greatest in pre-confluent cultures of C278F cells. In
addition, treatment with FGF18 at concentrations at or above [10-10M] “normalised” the
appearance of the C278F cultures by allowing the cells to become fully confluent without
early clustering. The effect of FGF18 treatment on the expression of osteodifferentiation
and cellular attachment proteins would have been a natural further extension of this study.
Having observed that behaviour of the mutated cells could be influenced by
modification of the culture environment, in a manner which seemed beneficial to the
expansion of the cellular population, it was also necessary as part of an integrated
approach, to look for substances which might act as an appropriate scaffold, on which to
transfer osteoprogenitors to surgical sites requiring bony regeneration.
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Chapter 6: Bioabsorbable Membranes
& Substrate Attachment
6.1: Introduction
The development and widespread introduction of internal metallic bone fixation over
the past 25 years has been one of the most significant advances in craniomaxillofacial
surgery since the basic concepts of secure bone fixation and primary bone healing were
introduced several decades previously. With the extensive use of fixation technology in
paediatric craniofacial surgery in particular, it is now apparent that there are several
potential postoperative complications that may occur as discussed in chapter 1. Given the
young age at which the paediatric craniofacial procedures are performed, some patients
will require device removal in their lifetime (Rubin & Yaremchuck, 1997). More
significantly, the development and bone apposition/resorptive pattern of skull growth,
creates the potential for growth restriction and eventual translocation of metal fixation
devices to the endocranial surface (Munro et al., 1993). The tips of screws against the
dura or juxtaposed to the cerebral cortex impose a risk of creating an injury to the brain
surface and seizure focus, (Fearon et al., 1995). The use therefore, of resorbable devices
in an attempt to prevent the associated complications, has been the subject of much study
and clinical evaluation.
The first published clinical use of resorbable devices was in 1972 by Cutright and
Hunsuck, who used non load-bearing polylactide sheets for orbital floor repair.
Subsequently, more complex patterns including screws and fixation plates were introduced
into clinical practice in the late 1970s and early 1980s. (Sedel et al., 1978; Rokkanen et al.,
1985). Resorbable devices are now commonly used for procedures requiring bone fixation
and having been used successfully and safely in this context, there has been a natural
endeavour to extend their application to one of tissue engineering.
Whilst many workers have studied the interaction of osteoprogenitor cells on
numerous potential scaffolds, there remains a scarcity of work investigating the interaction
of these scaffolds with osteoprogenitors carrying mutations affecting osteogenisis. It was
therefore important to firstly discover whether osteoprogenitors carrying the FGFR2-C278F
- 147 -
mutation would be attracted to and attach to bioresorbable scaffolds which might be
candidates for a bone engineering application.
In the absence of a novel material which had been pledged for study, a commercially
available co-polymer plate (BioSorbPDX ) which was already being widely used for bone
fixation in the clinical setting was chosen.
Having also observed (Chapter 4) that cells carrying the C278F mutation did not
attach to culture plastic so readily and detached more easily than the wild type and
untransfected cells, it was envisaged that it maybe possible to optimise the attachment,
growth and differentiation of these cells on scaffolds by surface modification with the use
of coating agents. For this purpose, the matrix proteins fibronectin and laminin were
chosen having previously been studied and shown to affect attachment of several cell
types to different materials (Cargill et al., 1999; Rezania & Healy, 1999; Yang et al., 2001;
Stephansson et al., 2002).
In order to combine the attributes of the PLGA co-polymer and bioactive glasses
which have been shown to be osteoconductive or even osteoinductive (Yuan et al., 2001)
but which have poor tensile strength and are brittle, a novel composite scaffold made of
bioactive glass fibres and the biodegradable PLGA co-polymer was also assessed for its
ability to attach and sustain osteoblasts.
6.2: Results
6.2.1: Early attachment to untreated co-polymer plates
Initial attempts to grow the osteoblast cell lines on the BioSorbPDX plate (Figure 6.1)
revealed that cells were slow to attach compared to tissue culture wells. Whereas MC3T3-
E1 cells showed no sign of attachment to BioSorbPDX plates (A), cells were well attached
on culture plastic at 24 hours post plating (B). However, cells eventually attached and at 4
days post plating, several cells could be seen with pre-confluent morphology on the
BioSorbPDX surface (C). In contrast cells grown on culture plastic had a typical confluent
or near-confluent morphology with visibly greater numbers (D).
The poor early attachment of cells to co-polymer plates led to the seeding of cells at
significantly higher densities for subsequent experiments involving the plates and coating
agents. This took into consideration the ultimate target of achieving efficient cellular
expansion upon the scaffolds prior to normal differentiation and in addition allowed for the
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finite availability of the plates and coating agents. There was also recognition of the time
constraints upon the study. For similar reasons, experiments were subsequently confined
to the WT and C278F cell lines.
Fig 6.1: MC3T3-E1 cells growth on co-polymer plate (BioSorbPDX) and culture well
Non-attached cells on copolymer plate at 24h (A). Cells attached to culture plastic at 24h
(B). Cells attached to copolymer plate at 4d (C). Near confluent cells on culture plastic at
4d (D). The parallel line pattern seen in (A) represents the surface profile markings created
during manufacture of the plates. Arrows represent the edge of the bevelled screw hole.
Cells seeded at 20,000/cm2. Images obtained by phase contrast microscopy.
Scale bars = 200 µm in (A); 50 µm in (B-D)
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6.2.2: Effect of laminin and fibronectin treatment on cellular attachment
Before attempting to enhance attachment of cells to the BioSorbPDX plates, the
effect of the two commercially available substrates, laminin and fibronectin on wild type
and mutated osteoblast growth on tissue culture plastic was quantified. High magnification,
phase contrast images of mutated cells (Figure 6.2) demonstrated that after two hours
there is was observable enhancement of cellular attachment, manifest by more highly
developed filopodia and visible nucleoli in wells coated with fibronectin and laminin (not
shown).
Figure 6.2: The effect of fibronectin on early attachment of C278F cells
Cells grown on untreated culture wells two hours after seeding (A), and cells on
fibronectin coated wells at two hours (B). Cells were seeded at 30,000cells/cm2.
Images obtained by phase contrast microscopy. Scale bars = 25 µm
Wild type and C278F cells were seeded on 12-well plates coated with fibronectin or
laminin or on untreated wells (-ve control). Wells were imaged at 1, 4 & 24 hours (Fig. 6.3
and 6.4) and triplicated samples for each condition and time point were released for
counting at 1, 2, 4 and 48 hours post plating (Fig. 6.5). Approximately half of the WT cells
appeared to show early signs of attachment one hour after seeding in unprepared culture
wells (Fig 6.3 A), whereas virtually all cells seeded on wells coated with fibronectin and
laminin had attached (Fig 6.3 B,C). After 4 hours in culture, most cells in unprepared
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wells demonstrated signs of early attachment (Fig 6.3 D), compared to the visible
attachment of all viable cells in the fibronectin and laminin coated wells (Fig 6.3 E,F). After
1 day in culture without coating, all viable cells had attached (Fig 6.3 G). However, cells
growing on fibronectin (Fig 6.3 H) had undergone considerable proliferative expansion and
those grown on laminin were near confluent (Fig 6.3 I). Two days after plating (not shown)
cells on fibronectin and laminin were fully confluent whereas negative controls were
approximately 70-80% confluent.
Mutated cells (Fig. 6.4) one hour after seeding in uncoated wells, demonstrated
minimal signs of attachment (Fig 6.4 A). Approximately half of the cells seeded on wells
coated with fibronectin (Fig 6.4 B) were attached and nearly all cells on laminin (Fig 6.4 C)
showed signs of attachment. After 4 hours in culture there were progressive signs of
attachment, with fibronectin and laminin coated wells (Fig 6.4 E,F) showing the more
typical morphology of well attached osteoblasts. After 1 day in culture without coating,
most cells had attached and undergone a limited degree of expansion (Fig 6.4 G). Cells
growing on both fibronectin and laminin were near confluent (Fig 6.4 H,I).
Quantification of cell numbers as described previously, are represented graphically in
figure 6.5. Attachment of WT cells was significantly enhanced by both laminin and
fibronectin at all time points although this effect was greatest for early cultures. Laminin
and fibronectin had an equal effect on cell numbers in cultures of four hours or less. In
later cultures at 48 hours, laminin had a statistically significant advantage on wild type cells
compared to fibronectin which also significantly increased cellular attachment. Laminin and
fibronectin significantly increased C278F cell numbers for time points up to 4 hours. There
was no significant difference between laminin and fibronectin at 1 hour. However laminin
had a significantly greater effect than fibronectin at 2 and 4 hours. Both substrates
significantly increased cell numbers at 48 hours, although interestingly, the increase at this
time point was significantly greater with fibronectin.
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Figure 6.3: Effect of fibronectin & laminin coating on WT adhesion
Wild type cells were imaged at 1 hour (A-C), 4 (D-F) or 24 hours(G-I) after seeding in
untreated wells(A,D,G), or in wells coated with fibronectin (FN) (B,E,H) or laminin (C,F,I).
Approximately half the cells were attached at 1 hour on uncoated wells (A) compared to
almost all cells on coated wells (B,C). After 4 hours, most cells showed early attachment on
uncoated wells (D), whereas all viable cells were well attached on coated wells (E,F). At one
day, all viable cells on uncoated wells had attached and appeared to have undergone some
expansion (G), whereas cells grown on FN had undergone greater expansion (H) and cells
grown on laminin were confluent (I). Cells were seeded at 30,000cells/cm2. Images obtained
by phase contrast microscopy. Scale bars = 200 µm
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Figure 6.4: Effect of fibronectin & laminin coating on C278F adhesion
Cells carrying the C278F mutation were imaged at 1 hour (A-C), 4 (D-F) or 24 hours(G-I)
after seeding in untreated wells (A,D,G), or in wells coated with fibronectin (FN) (B,E,H) or
laminin (C,F,I). After 1 hour, cells grown on uncoated wells showed minimal attachment (A).
Approximately half of the cells grown on FN (B) showed attachment and nearly all cells
seeded on laminin (C) appeared to be attached. After 4 hours in culture cells in FN (E) and
laminin (F) coated wells appeared well attached compared to non coated wells (D). After 1
day in the uncoated wells (G), cells were mostly attached, whereas cells grown on FN and
laminin were near confluent (H,I) Cells were seeded at 30,000cells/cm2. Images obtained by
phase contrast microscopy. Scale bars = 200 µm
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Figure 6.5: Effect of fibronectin & laminin coating on adhesion and growth of
WTand C278F cells
Analysis of effect of fibronectin and laminin on wild type (A) and C278F (B) cells.
Cells were seeded as triplicates at 30,000/cm2 in standard medium. Data are expressed as
the mean + SEM. Statistical difference amongst treatment groups (n=3) were evaluated
using analysis of variance (ANOVA). Significance was determined by post hoc testing
using Bonferronis’s method. S=significant (p < 0.05 was taken as significant)
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6.2.3: Effect of laminin and fibronectin treatment on cellular attachment to
BioSorbPDX plates
Having shown significant attachment enhancement of both wild type and mutated
cells to tissue culture plastic with laminin and fibronectin, the next step, having also
observed the poor early attachment of osteoblasts to the BioSorbPDX plate, was to assess
the potential of these two substrates to optimise the attachment, growth and mineralisation
on the plates.
Observation of the BioSorbPDX plates within the first 1-6 hours (not shown), after
seeding with C278F cells, revealed that early attachment had been enhanced by both
fibronectin and laminin in a similar fashion to that observed when cells were seeded on
treated culture dishes as shown in figure 6.4. Five days after seeding, cells were fully
confluent on the fibronectin (Fig. 6.6 C) and laminin (Fig. 6.6 E) coated membranes, while
some non-confluent areas remained on the untreated plate (Fig. 6.6 A). After 20 days of
culture, multilayered nodules had developed in all conditions (Fig. 6.6 B,D,F) with nodules
on the fibronectin coated plates appearing more developed (Fig. 6.6 D).
When compared with non coated plates, both substrates produced a significant
increase in cell numbers at days 1 and 5 and this effect was significantly greater for
laminin than fibronectin at both time points (Fig. 6.7). Surprisingly, at day 20, BioSorbPDX
plates which had not been treated showed significantly greater cell numbers than either of
the treatment groups. Of the two coating agents, fibronectin appeared to produce the
greatest increase in cell numbers although this did not reach statistical significance.
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Figure 6.6: C278F cells on BioSorbPDX plate with fibronectin or laminin coatings.
Five days after seeding, cells were fully confluent on the fibronectin (C) and laminin (E)
coated plates. Non-confluent areas remained on the untreated plate (yellow arrows) (A).
After 20 days of culture, multilayered nodules had developed in all conditions (B,D,F),
as indicated by the white arrows. Scale bars = 200 µm
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Figure 6.7: Quantitative effect of substrate coating of BioSorbPDX plates on C278F
adhesion
Cells were seeded at 75,000/cm2 in normal medium (replaced daily) onto untreated
BioSorbPDX plates or plates coated with fibronectin or laminin. Cells were harvested and
counted at days 1, 5 and 20. Data are expressed as the mean + SEM for each group
(n=3). Statistical differences among treatment groups were evaluated using analysis of
variance (ANOVA) and the significance of differences was determined by post hoc testing
using Bonferroni’s method. S = significant (p < 0.05 was considered significant).
6.2.4: Alkaline phosphatase activity of C278F cells on treated BioSorbPDX plates.
Having observed and quantified the ability of cells carrying the C278F activating
mutation to attach and expand on BioSorbPDX plates in the presence or absence of ECM
coating, assessment of the cells ability to mineralise on the plates was undertaken.
Observed at day 20, ALP activity was greatest within the multilayered, nodular
structures and appeared similar in cells growing on untreated membranes (Fig. 6.8 B) and
those treated with fibronectin (Fig. 6.8 D) and laminin (Fig. 6.8 F). Interestingly, areas of
cellular detachment were observed most obviously on plates treated with laminin,
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Figure 6.8: Alkaline phosphatase staining of C278F cells on treated BioSorbPDX plates.
Day 20, C278F cells on BioSorbPDX plates in differentiating medium, demonstrated
multilayered structures in unstained (A,C,E) and stained (B,D,F) wells. Staining for alkaline
phosphatase was maximal in the nodular regions. White arrows indicate examples of
multilayer, nodular structures. Areas of cellular detachment are indicated by red arrows.
Cells were seeded at 75,000 cells/cm2. Images obtained by plain backlit microscopy.
Scale bars = 500 µm
- 158 -
6.2.5: Copolymer-bioactive glass composite membrane
This composite material consisted of bioactive glass fibres embedded onto an
amorphous matrix of PLGA copolymer. The surface characteristics and microscopic
appearance of the copolymer in this composite differed from the BiosorbPDX® studied
previously in this chapter and did not allow the cells to be distinguished when viewed by
microscopy (Fig. 6.9 A). Therefore, a vital cell tracker (CMFDA) was incorporated into the
cells to allow observation under fluorescent microscopy (Fig. 6.9 B).
Initial observations of C278F cells 20 hours after seeding, revealed that attachment
to both the co-polymer (Fig. 6.9 A, B) and bioactive glass fibre (Fig. 6.9 C) components of
the composite was poor; they appeared rounded in shape with little evidence of
development of pseudopodia or the typical elongated morphology of attached cells.
Clumps of cells did however appear to be attracted towards the bioactive glass fibres (Fig.
6.9 C). Five days after seeding, cells were arranged longitudinally along the glass fibres
suggesting that attachment had occurred (Fig. 6.9 D).
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Figure. 6.9: Attachment of C278F cells onto copolymer-bioactive glass composite membrane
At 20 hours after seeding in normal medium, cells were difficult to observe on the copolymer
component (A). Cells stained with CMFDA were visualised under fluorescent microscopy
and the image digitally superimposed on the phase contrast image (B). When bioactive
glass fibres were brought into focus, cells could be seen (arrow) clustering adjacent to the
fibres (C). After 5 days, cells were attached (arrow) to the bioactive glass fibres (D). Cells
seeded at 20,000 cells/cm2. Scale bars = 200 µm (A,B) and 100 µm (C,D)
(See Appendix for note on published data)
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6.3: Discussion
6.3.1: Effect of coating agents on cellular attachment
Initial observations revealed that the cell lines did not readily attach to the
BioSorbPDX plate. This was an expected finding and consistent with the reports, using
various cell types, of other authors who have demonstrated that polyester materials are
only weakly hydrophilic and initially attach cells less efficiently than tissue culture plastic
(Quirk et al., 2001; Moran et al., 2003; Lim et al., 2004). Furthermore, there are no cell
recognition sites on the surfaces of PLGA scaffolds, leading to less than optimal cell
affinity. It was therefore attempted to optimise cellular attachment to the BioSorbPDX
plates as this appeared intuitively, to be a beneficial manipulation to enhance what would
ultimately be an autograft, tissue engineering application. This study aimed to determine if
there was a quantifiable benefit in coating potential scaffolds with ECM proteins and if
there was any relative advantage between the ECM proteins.
Fibronectin and laminin coating of tissue culture plastic significantly enhanced the
attachment of the cell lines which was demonstrated by the early morphological change in
appearance of the WT and C278F cells. The visual impact of the enhanced attachment
was obvious at early time points and appeared to have facilitated enhancement of cell
numbers and growth at the later time points. This appearance was confirmed by
quantification of the effect. Interestingly, at time points upto 4 hours, fibronectin and
laminin similarly enhanced WT cell attachment with laminin having a significantly greater
effect over fibronectin at 48 hours. However, attachment of cells carrying the mutation was
enhanced to a greater degree by laminin, although at 48 hours this differential effect had
been reversed to show fibronectin having the largest effect. The fact that laminin had a
significantly greater affect on C278F cells soon after seeding, suggests that the mutation
conferred on the cell an early selective receptor affinity for the different ECMs.
Whilst the RGD peptide is the single most important binding domain, other domains
on the fibronectin and laminin molecules may be differentially bound by receptors
expressed by the different cell lines. Moreover, passive adsorption could induce the
competitive adsorption of other factors in the system and change the configuration of the
adsorbed fibronectin or laminin molecules. As a result, its cell-binding activity would be
influenced. For this reason it would have been informative to have also studied the effect
of plates coated with the solitary RGD peptide.
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It is more difficult to explain why there should have been switching between an early
attachment advantage for laminin and a later advantage for fibronectin in the C278F cells.
This effect is more likely to have been due to a cellular-ECM interaction than due to the
chemico-physical interaction between the ECM protein and the culture plate surface, as
laminin had produced increased attachment at 48 hours in the WT cells.
Culture dishes and BioSorbPDX plates were coated at the manufacturers
recommended concentration and no attempt was made to study the concentration effect of
laminin and fibronectin. However, it has been shown that attachment, proliferation and
mineralisation of human osteoblasts is dose dependant for fibronectin or RGD peptide.
(Yang et al., 2001; Behravesh et al., 2003).
Further studies of the cellular-ECM interaction would have been informative, both
in quantifying the differential effect of extracellular proteins for enhancing attachment to
scaffold materials and with respect to the differences in adhesion characteristics between
the mutated and WT cells. These studies which could have involved such techniques as
microcantilever (Bowen et al., 1997) micropipette (Athanassiou & Deligiannil 2001) or jet
impingement (Gilberti et al., 2002) could have been linked with expression assays of
cytoskeletal structures to facilitate the determination of the fundamental relationships
between cell adhesion and function within these cells .
6.3.2: Attachment and growth on copolymer (BioSorbPDX) plates
Having demonstrated a clear attachment advantage for both fibronectin and laminin
coated culture plastic, it was important to demonstrate if this advantage was transferable
to the BioSorbPDX plates and whether this might influence mineralisation.
Fibronectin and laminin significantly increased C278F cell numbers on the
BioSorbPDX plate at days 1 and 5. As with the study on tissue culture plastic, laminin had
the greatest effect at the earlier time points. However at some point between day 5 and
day 20 this advantage was lost, such that day 20 plates which were untreated, surprisingly
had significantly greater cell numbers attached than those treated with either of the coating
agents. This may have been due to the influence of the adsorbed proteins on cellular
proliferation or apoptosis or both, as the cells moved from a proliferative to a differentiative
phase. However, it is possible that the biomass of attached cells combined with even the
minimalist agitation of the culture fluid when changing medium, may have caused shearing
of cells from the plates and indeed voids can be seen on the plates where areas of cells
have become detached (Figure 6.8). This would be consistent with the fact that polyesters
lack chemical reactivity due to the absence of functional groups to support covalent
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attachment. There may in fact come a point at which the mechanical attachment of cells to
irregularities on the plate surface (see parallel grooves in Figure 6.1) is stronger than the
surface-ECM interface, a concept supported by the findings of Matsuzaka et al., (1999).
The pattern of C278F growth was different on BioSorbPDX plates and culture
dishes. Cells grown on BioSorbPDX appeared to reach confluence compared to their
inability to reach full confluence (in the absence of growth factor) on tissue culture plastic.
This might be explained by the recognition that nuclear shape which in turn may be
influenced by overall cell shape has been shown to significantly affect cell function and
regulatory pathways (Folkman & Mosconal 1978; Meyle et al., 1993; Lampin et al., 1997;
Huang & Ingberl, 2000). This is also consistent with the finding that MC3T3-E1
differentiation and mineralisation is dependant upon the 3D conformation of the FN
molecule which is itself dependant on the surface characteristics of the material upon
which it is adsorbed (Stephansson et al., 2002).
A morphological feature which appears to be necessary across the spectrum of
osteogenerative cells if functional bone is to be produced, is the development of
mineralised nodules. Cellular growth on all of the plates in this study, supported the ability
to form multilayered nodules. The nodules appeared to be more highly developed in the
fibronectin coated plates, although this was not obvious when plates were stained for ALP
expression. It should be noted however, that cells intended for ALP staining were grown in
differentiating medium which may have influenced the growth and functionality of the cells.
6.3.3: Cellular alkaline phosphatase activity on BioSorbPDX plates
Successful mineralisation of matrix is one of the ultimate requirements for
engineered bone tissues. It is recognised that potential materials for bone engineering are
highly variable in their ability to support mineralisation (Calvert et al., 2005) and even the
polylactic-polyglycolic (PLGA) co-polymer has been shown to greatly affect the ability of
osteoblasts to mineralise matrix, depending upon the particular formulation of the material
(Meredith et al., 2003). It was important therefore to establish whether the formulation
being used in this study supported mineralisation.
The C278F cells at 20 days, stained for ALP in all conditions. The appearances
suggested that staining was strongest on the plates not pre-coated. However this may
have been due simply to more cells per unit area on the uncoated plates rather than an
ability of these cells to express ALP more readily. There did not appear to be any obvious
differential expression of ALP between the fibronectin and laminin coated plates.
- 163 -
The strong expression of ALP in all test conditions was interesting, in light of the
finding in chapter 4, that C278F cells grown on tissue culture plastic did not express
significant levels of ALP mRNA until day 30. While direct correlation of ALP mRNA
expression and ALP protein activity cannot be made, Wang et al., (1999), have shown
good correlation between mRNA expression and protein transcription for ALP in MC3T3-
E1 cells. It can therefore be postulated that this apparent enhancement of ALP activity
might be due to the influence of the co-polymer plate or its acidic breakdown products.
Indeed this is supported by Ikarashi et al., (2000), who observed that poly-L-lactide (80%
of the polyester in the BiosorbPDX plates) can stimulate ALP activity in MC3T3-E1 cells.
Attempts to stain for mineralisation using von Kossas’ technique proved
unsuccessful as the process caused almost total detachment of the cells from the plates.
6.3.4: Copolymer-Bioactive glass composite
A novel composite formulation of PLGA-bioactive glass became available towards
the end of the project which allowed only limited investigation of the material.
Consistent with the previous findings of cellular growth on the BiosorbPDX plates,
C278F cells did not attach readily to the amorphous co-polymer component of the material
or the glass fibres. At 5 days however, cells were aligned longitudinally along the fibres.
Further work within our laboratory has demonstrated the ability of another
formulation of this PLGA-bioactive glass composite to attract and allow proliferation and
osteo-differentiation of the C278F line (Santos-Ruiz et al., 2007).
6.3.5: Summary
The findings in this chapter confirm that preosteoblasts carrying the C278F mutation
attached poorly in the first instance to the co-polymer plates used in this study. It was
shown that this early attachment can be enhanced by pre-coating with the extra-cellular
matrix proteins, fibronectin and laminin and those cells carrying the mutation attach
preferentially to laminin coated tissue culture plastic and co-polymer plates. Whilst early
attachment is enhanced this seems to confer no later advantage in terms of cellular
expansion. Indeed, when cells were in the late stages of osteodifferentiation there
appeared to be a depletion of cell mass compared to untreated plates, which may have
been due to detachment of cells at the material-ECM interface.
Co-polymer plates supported the formation of multilayered nodules and the
expression of alkaline phosphatase, and may have demonstrated foci of mineralisation
had the staining technique chosen not prevented the assay.
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The limited analysis of cellular interaction with a novel composite material
consisting of bioactive glass and co-polymer revealed that whilst early attachment of cells
was poor, subsequent cellular attachment provides encouragement to proceed with further
evaluation of this material.
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Chapter 7: Final discussion
This study aimed to assess the feasibility of the MC3T3-E1 cell line carrying a
craniosynostotic mutation, as a model for studying osteogenisis in craniosynostosis. It
further sought to study the potential use of craniosynostotic osteoprogenitors in
combination with bioresorbable materials and to identify potential modifiers to optimally
manipulate these interactions.
Although transformed murine cells are inappropriate for therapeutic applications,
MC3T3-E1 cells stably transfected with the human FGFR-C278F mutation coding for
craniosynostosis, enabled studies on the growth and differentiation of craniosynostotic
osteoprogenitor cells. These cells retained several properties of primary osteoblast
cultures, including the ability to form a mineralised, collagenous, extracellular matrix and
express gene products consistent with the osteoblast phenotype, thereby allowing the
study of the functional effects of an FGFR2 mutation.
Cells carrying the FGFR2-C278F mutation appeared morphologically distinct from
the MC3T3-E1 and WT cells. They required more frequent feeding and demonstrated
higher levels of cell death suggesting a fundamental difference in phenotype and
metabolic demands. When attached, they appeared more rounded implying lower levels of
cellular prestress and possibly greater differentiation. Their attachment and clumping
behaviour confirmed these differences although increased levels of Cx43 did not reach
statistical significance. Hence, further studies directed at the mechanisms of cellular
attachment in craniosynostotic cells, paying particular emphasis to the functional
interaction between the extracellular matrix and the integrin linked cytoskeleton would be
warranted.
The temporal expression of mRNA markers of osteodifferentiation did not wholly
conform to expected findings. High early levels of osteocalcin in all cell lines and
mineralisation of the C278F cells despite the delayed expression of alkaline phosphatase
gives support to the findings of others that mineralisation can be dissociated from
expression of osteocalcin and alkaline phosphatase (Beck et al., 1998; Ratisoontorn et al.,
2003). This may also suggest that the well defined temporal relationships reported by the
early workers with the MC3T3-E1 cell line, may have shifted due to significant clonal drift
and subpopulation transformation, in keeping with the findings of Wang et al., (1999). In
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this respect, the model studied could be questioned as to its suitability to represent and
predict the effect of an in vivo mutation on progression of osteoprogenitors through the
osteoblast lineage.
The study of growth factor manipulation and scaffold modification has been facilitated
by these cells and should continue to allow the investigation and comparison between
other mutations involved in pathological osteogenisis. This should allow further studies
aimed at “reverting” the craniosynostotic phenotype without the need for genetic
modification. In conclusion, the FGFR2-C278F cell line has been a useful osteoprogenitor
model throughout this study and central to its findings. This model, compared with primary
human craniosynostotic cultures for bio-scaffold engineering, has been further investigated
in subsequent work carried out in our laboratory, (Santos-Ruiz et al., 2007).
The observation that FGF18 was expressed at higher levels in the early proliferative
phase of C278F cell growth, suggested an important role for this growth factor in
osteogenisis and in particular proliferative expansion. Therefore, for the first time the effect
of exogenous FGF18 treatment on cells carrying a mutation for craniosynostosis was
studied. In the presence of adequate serum concentrations, treatment with FGF18
enhanced proliferation of the cells in a dose dependant manner and allowed them to reach
confluence, whereas C278F cells underwent cell death in low serum concentrations. This
implied that these cells were more dependent on serum factors for cell survival and
proliferation and as discussed in chapter 4, this may have been linked to levels of
prestress within the cells and their dependence on adequate ECM attachments. Moreover,
the levels of endogenous FGF18 produced by the cells were already raised and further
treatment with exogenous mitogenic factors may have been additively detrimental when
the cells were poorly attached. These findings suggest that FGF18, under the right
conditions, may be a useful growth factor for the enhanced expansion of cell numbers.
Since the completion of this study the importance of FGF18 in osteogenisis has been
further elucidated. Reinhold and Naski (2007), have shown that the transcription factors,
Runx2 and TCF/Lef which are transducers of Wnt signals and considered essential for
osteogenisis, converge on the FGF18 promotor and suggest that expansion of an early
osteoblast population through stimulation of cell proliferation will almost certainly be a key
attribute of FGF18.
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In further considering the possible clinical translation of FGF18 function, Haque et al.,
(2007), have recently found that chondrocytes within fracture callus of long bones
undergoing distraction osteogenisis in a rabbit model, express FGF18 at high and
persisting levels. It may be a significant observation that in children undergoing
craniofacial distraction osteogenisis, the areas of bone which demonstrates regeneration
are not those forming in membranous bone, but those at the skull base formed by
endochondral ossification (Fig. 1.5B).
Taken together, these findings and observations suggest that FGF18 is a worthy
candidate for further study in future developments of osteogenisis and bone engineering.
There are many different interacting and complex factors which will ultimately affect
the progress of osteogenesis on bio-composite scaffolds. It has been shown that
osteoprogenitor cells carrying this particular FGFR2-C278F mutation, attach, grow and
express an osteoblast like phenotype on PLGA (Biosorb PDX) fixation plates and that the
ECM molecules, fibronectin and laminin, support early attachment and growth of these
cells. However, a non-activating FGFR mutation such as those found in Aperts syndrome
may respond differently to the same proteins. Likewise, the optimum concentration of
growth factors for any particular culture system on any particular scaffold formulation or
architecture may be very different. This study has hence demonstrated that these
complexities overwhelm the conventional “one-sample/one-measurement” approach to the
evaluation of bioactive systems.
In recognition of these multifactorial and complex interactions, superior bioactive
systems must be designed by taking into account the synergisms of the most important of
these factors. To this end, attempts are being made to approach this problem by the
development of combinatorial libraries using such techniques as micro-array gene
analysis, chromatographic gradient libraries and high-throughput polymer concentration
and surface libraries (Chicurel, 2001; Meredith et al., 2003). Ultimately, this approach
might lead to the customised engineering of bone for any individual patient, dependant
upon the genotype/phenotype of the autologous osteoprogenitors
Overall, this study has found the transfected MC3T3-E1 cell lines to be a useful
model for studying the molecular basis of craniosynostoses and the response of mutated
osteoprogenitors to different materials, extracellular matrix molecules and growth factors.
Fibronectin and laminin supported cellular attachment and growth to facilitate the early
expansion of mutated osteoprogenitors on a commercially available bioresorbable
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scaffold. FGF18 expression and its exogenous effects on osteoprogenitor behaviour,
suggest that this is an important growth factor in osteogenisis. This study provides the
basis for further investigation aimed at using these molecules to develop bio-composites
for autologous cell therapy, without the medical and ethical hazards of genetic
manipulation, in the management of these challenging surgical reconstructions.

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Appendix :
Publication Note
The contribution of the author to the referenced publication Santos-Ruiz et al.,
(2007), involved reviews and revisions of the original manuscript and contribution of the
following data:
p202, Figure 1, Osteocalcin expression data
p203, Figure 2 (G,H,I), MC3T3/WT/C278F von Kossa staining at 21 days
p208 Figure 9 (A,B,C), MC3T3 on culture wells, BiosorbPDX with and without alizarin
The copolymer-bioglass membrane which appears in Figure 6.9 of this thesis was
material which became available towards the end of this study and is an earlier formulation
than that which appears in the published paper.
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